

Request

Noble, J  
SEARCH REQUEST FORM

Access DB#

150340

Scientific and Technical Information Center

Requester's Full Name: Sabela Ogi Examiner #: 74141 Date: 4/9/05  
Art Unit: 1616 Phone Number: 20630 Serial Number: 10/642, 194  
Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

4670. Law, 4445  
If more than one search is submitted, please prioritize searches in order of need. MEJ

\*\*\*\*\*  
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched.  
Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or  
utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if  
known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: Sustain Release Pharmaceutical Composition  
of a Cephalosporin AntibioticInventors (please provide full names): KSHIRSAGAR et alEarliest Priority Filing Date: 8/18/03

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the  
appropriate serial number.

Please search for a composition  
containing cephalosporin antibiotic  
as in Cls 1-16. Specific cephalosporin  
are listed in Cl6

Please see attached sheet

Thank you

## STAFF USE ONLY

Searcher: <u>Noble</u>	Type of Search	Vendors and cost where applicable
Searcher Phone #: _____	NA Sequence (//) _____	STN <u>\$1649</u>
Searcher Location: _____	AA Sequence (//) _____	Dialog _____
Date Searcher Picked Up: <u>4/14/05</u>	Structure (//) <u>14</u>	Questel/Orbit _____
Date Completed: <u>4/19/05</u>	Bibliographic _____	Dr. Link _____
Searcher Prep. Review Time <u>30</u>	Litigation _____	Lexis/Nexis _____
Clerical Prep. Time: _____	Patent Family _____	Sequence Systems _____
Offline Time <u>170</u>	Other _____	WWW/Internet _____
		Other (specify) _____

Request Noble, J  
150340

=&gt; d his

(FILE 'HOME' ENTERED AT 15:07:39 ON 15 APR 2005)

FILE 'HCAPLUS' ENTERED AT 15:07:47 ON 15 APR 2005

L1 3 (US20040096496 OR US20040033262)/PN  
 L2 3 IN2002-MA601#/AP, PRN  
 L3 0 IN2002-MAS601#/AP, PRN  
 L4 3 L1-2

FILE 'REGISTRY' ENTERED AT 15:10:23 ON 15 APR 2005

L5 FILE 'HCAPLUS' ENTERED AT 15:10:26 ON 15 APR 2005  
 TRA L4 1- RN : 47 TERMS

L6 FILE 'REGISTRY' ENTERED AT 15:10:26 ON 15 APR 2005  
 47 SEA L5

L7 FILE 'WPIX' ENTERED AT 15:10:29 ON 15 APR 2005  
 1 (US20040096496 OR US20040033262)/PN OR IN2002-MA601#/AP, PRN  
 L8 0 IN2002-MAS601#/AP, PRN

=&gt; b hcap

FILE 'HCAPLUS' ENTERED AT 15:11:54 ON 15 APR 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Apr 2005 VOL 142 ISS 17  
 FILE LAST UPDATED: 14 Apr 2005 (20050414/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; d all 14 tot

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:412577 HCAPLUS  
 DN 140:395542  
 ED Entered STN: 21 May 2004  
 TI Sustained release pharmaceutical composition of a cephalosporin antibiotic  
 IN Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao; Jindal, Kour Chand  
 PA Orchid Chemicals & Pharmaceuticals Limited, India  
 SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 222,930.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-545  
 ICS A61K009-20; A61K031-736  
 NCL 424465000; 514200000; 514054000  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004096496	A1	20040520	US 2003-642194	20030818 <--
	US 2004033262	A1	20040219	US 2002-222930	20020819 <--
	WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

Search done by Noble Jarrell

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI IN 2002-MA601 A 20020816 <--  
 US 2002-222930 A2 20020819  
 WO 2002-1B3320 A 20020819

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

US 2004096496	ICM	A61K031-545
	ICS	A61K009-20; A61K031-736
	NCL	424465000; 514200000; 514054000
US 2004096496	ECLA	A61K031/545; A61K031/546 <--
US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736 <--

- AB Sustained release pharmaceutical compns. comprising at least a cephalosporin antibiotic, a mixture of polymers comprising of galactomannans and neutral swellable polymers, and other pharmaceutically acceptable excipients are described. The composition comprises about 30% to about 90% by weight of a cephalosporin antibiotic; about 1% to about 30% by weight of said mixture of polymers comprising from about 0.1% to about 15% by weight of galactomannans, and about 0.1% to about 15% of neutral swellable polymer by weight of sustained release composition
- ST cephalosporin antibiotic sustained release tablet
- IT Drug delivery systems  
 (carriers; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Lubricants  
 (pharmaceutical; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Swelling agents  
 (polymers; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Antibiotics  
 Binders  
 Drying  
 Mixing  
 Plasticizers  
 Sieving  
 (sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Gelatins, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Polyesters, biological studies  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Drug delivery systems  
 (sustained-release; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Polymers, biological studies  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (swellable; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Drug delivery systems  
 (tablets, coated; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Drug delivery systems  
 (tablets; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Fats and Glyceridic oils, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL

- (Biological study); USES (Uses)  
(vegetable, hydrogenated; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 7631-86-9, Silicon dioxide, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(colloidal; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 9004-34-6, Cellulose, biological studies  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(microcryst.; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 9005-25-8, Starch, biological studies  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pregelatinized; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 9003-39-8, Polyvinylpyrrolidone 9004-62-0, Hydroxyethylcellulose  
9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose  
RL: MOA (Modifier or additive use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 557-04-0, Magnesium stearate 557-05-1, Zinc stearate 1592-23-0, Calcium stearate 9000-30-0, Guar gum 11138-66-2, Xanthan gum 14807-96-6, Talc, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 153-61-7, Cephalothin 11078-30-1, Galactomannan 11111-12-9D, Cephalosporins, derivs. 15686-71-2, Cephalexin 21593-23-7, Cephapirin 34444-01-4, Cefamandole 35607-66-0, Cefoxitin 50370-12-2, Cefadroxil 53994-73-3, Cefaclor 61270-58-4, Cefonicid 64544-07-6, Cefuroxime axetil 68401-81-0, Ceftizoxime 87239-81-4, Cefpodoxime proxetil 92665-29-7, Cefprozil 117467-28-4, Cefditoren pivoxil  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 9004-32-4 9010-88-2, Ethyl acrylate-methyl methacrylate copolymer 9050-04-8, Calcium carboxymethyl cellulose 25086-89-9, Plasdene S-630  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 9004-53-9, Dextrin 66828-18-0, Dextrate 74811-65-7, Croscarmellose sodium  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:162583 HCAPLUS

DN 140:205146

ED Entered STN: 29 Feb 2004

TI Sustained release pharmaceutical compositions of a cephalosporin

IN Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao; Jindal, Kour Chand

PA Orchid Health Care, A Division of Orchid Chemicals & Pharmaceuticals Ltd., India

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-22

ICS A61K031-545; A61K031-546

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN. CNT 3



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016251	A1	20040226	WO 2003-IB3340	20030818 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004033262	A1	20040219	US 2002-222930	20020819 <--
	WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	IN 2002-MA601	A	20020816	<--	
	US 2002-222930	A	20020819		
	WO 2002-IB3320	A	20020819		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004016251	ICM	A61K009-22
	ICS	A61K031-545; A61K031-546
US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736 <--

AB Sustained release pharmaceutical compns. comprising at least a cephalosporin, a mixture of polymers comprising of galactomannans and neutral swellable polymers, and other pharmaceutically acceptable excipients are described. The composition comprises 30-90% of a cephalosporin antibiotic, 1-30% mixture of polymers comprising 0.1-15% galactomannans, and 0.1-15% by weight of a neutral swellable polymer. Thus, tablets contained cephalixin monohydrate 75.73, lactose 6.27, xanthan gum 7.0, Eudragit NE 30D 7.0, HPMC E5 31.5, Mg stearate 1.0 and water qs to 100%.

ST sustained release cephalosporin polymer

IT Drug delivery systems

(granules, sustained release; sustained release pharmaceutical compns. of cephalosporins)

IT Binders

Dissolution

Drug bioavailability

Human

Lubricants

Plasticizers

(sustained release pharmaceutical compns. of cephalosporins)

IT Carbohydrates, biological studies

Gelatins, biological studies

Polymers, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained release pharmaceutical compns. of cephalosporins)

IT Drug delivery systems

(sustained-release; sustained release pharmaceutical compns. of cephalosporins)

IT Drug delivery systems

(tablets, sustained-release; sustained release pharmaceutical compns. of cephalosporins)

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(vegetable, hydrogenated; sustained release pharmaceutical compns. of cephalosporins)

IT 9004-34-6, Cellulose, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(microcryst.; sustained release pharmaceutical compns. of  
cephalosporins)

IT 15686-71-2, Cephalexin 50370-12-2, Cefadroxil  
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological  
study); USES (Uses)  
(sustained release pharmaceutical compns. of cephalosporins)  
IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological  
studies 57-11-4, Stearic acid, biological studies 63-42-3, Lactose  
69-65-8, Mannitol 69-79-4, Maltose 153-61-7, Cephalothin 557-04-0  
557-05-1, Zinc stearate 1592-23-0, Calcium stearate 7631-86-9, Silica,  
biological studies 9000-30-0, Guar gum 9000-40-2, Locust bean gum  
9003-39-8, Polyvinylpyrrolidone 9004-53-9, Dextrin 9004-62-0,  
Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3,  
Hydroxypropyl methyl cellulose 9005-25-8, Starch, biological studies  
9010-88-2, Eudragit NE 30D 9050-04-8, Calcium carboxymethyl cellulose  
9063-38-1, Sodium starch glycolate 11078-30-1, Galactomannan  
1111-12-9, Cephalosporin 11138-66-2, Xanthan gum 14807-96-6, Talc,  
biological studies 21593-23-7, Cephapirin 23325-78-2, Cephalexin  
monohydrate 25086-89-9, Plasdone S-630 34444-01-4, Cefamandole  
35607-66-0, Cefoxitin 53994-73-3, Cefaclor 61270-58-4, Cefonicid  
64544-07-6, Cefuroxime axetil 68401-81-0, Ceftizoxime 74811-65-7,  
Croscarmellose sodium 87239-81-4, Cefpodoxime proxetil 92665-29-7,  
Cefprozil 104145-95-1, Cefditoren 117467-28-4, Cefditoren pivoxil  
121123-17-9, Cefprozil monohydrate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained release pharmaceutical compns. of cephalosporins)

RE. CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Lupin Lab Ltd; WO 0241876 A 2002 HCAPLUS
- (2) Shankar, M; WO 02067943 A 2002 HCAPLUS
- (3) Squibb Bristol Myers Co; WO 9846213 A 1998 HCAPLUS

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:142610 HCAPLUS

DN 140:187392

ED Entered STN: 22 Feb 2004

TI Sustained-release pharmaceutical composition of a cephalosporin antibiotic

IN Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao; Jindal, Kour Chand

PA Orchid Health Care, India

SO U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-545

ICS A61K031-736; A61K009-20; A61K009-22

NCL 424468000; 514054000; 514200000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN. CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004033262	A1	20040219	US 2002-222930	20020819 <--
WO 2004016250	A1	20040226	WO 2002-1B3320	20020819
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004016251	A1	20040226	WO 2003-1B3340	20030818 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,			

TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 2004096496 A1 20040520 US 2003-642194 20030818 <—  
 PRAI IN 2002-MA601 A 20020816 <—  
 US 2002-222930 A 20020819  
 WO 2002-IB3320 A 20020819

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004033262	ICM	A61K031-545
	ICS	A61K031-736; A61K009-20; A61K009-22
	NCL	424468000; 514054000; 514200000
US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736 <—
US 2004096496	ECLA	A61K031/545; A61K031/546 <—
AB	A sustained release pharmaceutical composition comprising at least a cephalosporin antibiotic and a mixture of polymers and other pharmaceutically acceptable excipients is described. Polymers are selected from mixture of galactomannans and neutral swellable polymers, which releases the active ingredient in a predetd. manner. For example, a sustained-release tablet composition contained cephalexin 795.32 mg, lactose 107.68 mg, xanthan gum 31.5 mg, Eudragit NE 30D 52.5 mg, HPMC E5 52.5 mg, and magnesium stearate 10.5 mg. Cephalexin release from the tablets was 25.21%, 50.84%, 73.18%, and 84.17% after 1h, 6 h, 10 h and 14 h, resp.	
ST	cephalosporin polymer mixt sustained release tablet	
IT	Dissolution	
	Drug bioavailability	
	Granulation (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)	
IT	Polymers, biological studies RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)	
IT	Drug delivery systems (sustained-release; sustained-release composition of cephalosporin antibiotic containing mixture of polymers)	
IT	Drug delivery systems (tablets, sustained-release; sustained-release composition of cephalosporin antibiotic containing mixture of polymers)	
IT	9000-30-0, Guar gum 9000-40-2, Locust bean gum 9010-88-2, Eudragit NE 30D 11078-30-1, Galactomannan 11138-66-2, Xanthan gum RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)	
IT	153-61-7, Cephalothin 11111-12-9, Cephalosporin 15686-71-2, Cephalexin 21593-23-7, Cefaprin 34444-01-4, Cefamandole 35607-66-0, Cefoxitin 50370-12-2, Cefadroxil 53994-73-3, Cefaclor 61270-58-4, Cefonicid 64544-07-6, Cefuroxime axetil 68401-81-0, Ceftizoxime 87239-81-4, Cefpodoxime proxetil 92665-29-7, Cefprozil 117467-28-4, Cefditoren pivoxil RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)	

=&gt; b wpix

FILE 'WPIX' ENTERED AT 15:12:08 ON 15 APR 2005  
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 14 APR 2005 <20050414/UP>  
 MOST RECENT DERWENT UPDATE: 200524 <200524/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

Search done by Noble Jarrell

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV.  
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>  
FOR DETAILS. <<<

=> d all 17 tot

L7 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-257150 [24] WPIX

CR 2004-257149 [24]

DNC C2004-100402

TI Sustained release composition useful for treating bacterial and microbial  
infection comprises cephalosporin antibiotic, and a mixture of polymers  
containing galactomannans and neutral swellable polymers.

DC A96 B02 B07

IN BOLDHANE, S P; JINDAL, K C; KSHIRSAGAR, R S

PA (ORCH-N) ORCHID HEALTH CARE; (ORCH-N) ORCHID CHEM & PHARM LTD; (ORCH-N)  
ORCHID HEALTH CARE DIV ORCHID CHEM & PHA

CYC 103

PI WO 2004016251 A1 20040226 (200424)\* EN 55 A61K009-22

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS

LU MC MW MZ NL OA PT SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK

DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR

KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL

PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU

ZA ZM ZW

US 2004033262 A1 20040219 (200424) A61K031-545 <---

US 2004096496 A1 20040520 (200434) A61K031-545 <---

AU 2003255874 A1 20040303 (200457) A61K009-22

ADT WO 2004016251 A1 WO 2003-IB3340 20030818; US 2004033262 A1 US 2002-222930  
20020819; US 2004096496 A1 CIP of US 2002-222930 20020819, US 2003-642194  
20030818; AU 2003255874 A1 AU 2003-255874 20030818

FDT AU 2003255874 A1 Based on WO 2004016251

PRAI WO 2002-IB3320 20020819; IN 2002-CH601 20020816;

US 2002-222930 20020819

IC ICM A61K009-22 A61K031-545

ICS A61K009-20; A61K031-546; A61K031-736

AB WO2004016251 A UPAB: 20040907

NOVELTY - A composition (C1) comprises cephalosporin antibiotic, a mixture  
of polymers containing galactomannans and neutral swellable polymers, and  
an excipient.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for the  
preparation of (C1) involving:

(1) mixing the active ingredient, excipients and galactomannans in a  
mixer;

(2) optionally compacting the mixture and sizing it by passing  
through sieve;

(3) granulating the mixture with neutral swellable polymer;

(4) drying the granules by either tray drier or fluid bed drier;

(5) milling the dried granules followed by addition and blending of  
dry binder and lubricant(s);

(6) compressing the lubricated granules into tablets using a tablet press; and

(7) optionally coating the tablets.

ACTIVITY - Antibacterial; Antimicrobial.

MECHANISM OF ACTION - Microbial growth inhibitor.

USE - For the treatment of bacterial and microbial infections.

ADVANTAGE - The composition reduces the administration frequency by maintaining a constant plasma concentration of drug over an extended period of time to ensure sustained effect of active ingredient. The release of active ingredient from the delivery system is controlled by the specific polymers present in the matrix and in specific concentrations, thus allowing blood levels above MIC over extended period of time such that the frequency of the dosage form is released at a rate suitable for once or twice daily administration.

Dwg. 0/5

FS CPI

FA AB; DCN

MC CPI: A03-A00A; A12-V01; B02-C02; B04-B01C1; B04-C02A; B04-C02B; B04-C02D;  
B04-C03; B04-N02; B05-B02C; B07-A02; B10-A07; B10-C04E; B12-M10A;  
B14-A01

=> b home

FILE 'HOME' ENTERED AT 15:12:12 ON 15 APR 2005

=>

=> d his full

(FILE 'HOME' ENTERED AT 15:07:39 ON 15 APR 2005)

FILE 'HCAPLUS' ENTERED AT 15:07:47 ON 15 APR 2005

L1 3 SEA ABB=ON PLU=ON (US20040096496 OR US20040033262)/PN  
D BIB TOT  
L2 3 SEA ABB=ON PLU=ON IN2002-MA601#/AP, PRN  
L3 0 SEA ABB=ON PLU=ON IN2002-MAS601#/AP, PRN  
L4 3 SEA ABB=ON PLU=ON (L1 OR L2)

FILE 'REGISTRY' ENTERED AT 15:10:23 ON 15 APR 2005

FILE 'HCAPLUS' ENTERED AT 15:10:26 ON 15 APR 2005  
L5 TRA L4 1- RN : 47 TERMS

FILE 'REGISTRY' ENTERED AT 15:10:26 ON 15 APR 2005  
L6 47 SEA ABB=ON PLU=ON L5

FILE 'WPIX' ENTERED AT 15:10:29 ON 15 APR 2005

L7 1 SEA ABB=ON PLU=ON (US20040096496 OR US20040033262)/PN OR  
IN2002-MA601#/AP, PRN  
L8 0 SEA ABB=ON PLU=ON IN2002-MAS601#/AP, PRN

FILE 'REGISTRY' ENTERED AT 15:35:55 ON 15 APR 2005

L9 1 SEA ABB=ON PLU=ON 11111-12-9  
L10 446 SEA ABB=ON PLU=ON CEPHALOSPORIN#  
E CEPHALOSPORIN/CN

FILE 'HCAPLUS' ENTERED AT 15:38:29 ON 15 APR 2005

L11 3972 SEA ABB=ON PLU=ON L9/D OR L10/D OR (CEPHALOSPORIN# OR  
CEPHALOTINUM#) (L) DERIV?  
E SWELLING AGENTS/CT  
E E 3+ALL  
E SWELLING AGENTS/CT  
E E3+ALL  
L12 105 SEA ABB=ON PLU=ON SWELLING AGENTS/CT (L) POLYMER?  
E POLYMERS/CT  
E E3+OLD, NT1  
L13 5204 SEA ABB=ON PLU=ON (POLYMER?/CW OR POLYMERS+OLD, NT1/CT) (L)  
SWELL?  
E CEPHALOSPORIN/CT  
E E6+ALL  
E E2+ALL  
L14 23935 SEA ABB=ON PLU=ON CEPHALOSPORIN+OLD, NT/CT

FILE 'REGISTRY' ENTERED AT 16:02:25 ON 15 APR 2005

E GALACTOMANNAN/CN  
L15 1 SEA ABB=ON PLU=ON GALACTOMANNAN/CN  
D SCA  
D IDE L15  
L16 32 SEA ABB=ON PLU=ON GALACTOMANNAN?

FILE 'HCAPLUS' ENTERED AT 16:03:08 ON 15 APR 2005

L17 3314 SEA ABB=ON PLU=ON L15 OR L16 OR GALACTOMANNAN? OR GALACTO  
(1A) MANNAN? OR DAIKOL? OR FAIBARON? OR GUAPACK? OR MANNOGALACT  
AN? OR MEYPROID? OR MOLVENIN? OR SUNFIBER? OR SUN (W) FIBER?  
E GALACTOMANNAN/CT  
E E4+ALL  
E E2+ALL  
L18 2077 SEA ABB=ON PLU=ON GALACTOMANNAN+OLD/CT  
L19 5 SEA ABB=ON PLU=ON (L11 OR L14) AND (L12 OR L13)  
E KSHIRSAGAR R/AU  
L20 10 SEA ABB=ON PLU=ON ("KSHIRSAGAR R"/AU OR "KSHIRSAGAR RAJESH  
S"/AU OR "KSHIRSAGAR RAJESH SURESH"/AU)  
E BOLDHANE S/AU  
L21 3 SEA ABB=ON PLU=ON "BOLDHANE SANJAY PARBHATRAO"/AU  
E JINDAL K/AU  
L22 34 SEA ABB=ON PLU=ON ("JINDAL K"/AU OR "JINDAL K C"/AU OR  
"JINDAL KOUR CHAND"/AU)

```

L23      63 SEA ABB=ON  PLU=ON  (ORCHID AND CHEM? AND PHARM?)/CS, PA
L24      1 SEA ABB=ON  PLU=ON  L19 AND (L20 OR L21 OR L22 OR L23)
L25      4 SEA ABB=ON  PLU=ON  L19 NOT L24
          D BIB TOT
          D SCA
          D TI L25 TOT
          SEL AN 1-2 4 L25
L26      3 SEA ABB=ON  PLU=ON  ("129:207213"/AN OR "131:262650"/AN OR
          "1977:411647"/AN OR "1998:580026"/AN OR "1999:640708"/AN OR
          "87:11647"/AN) AND L25
L27      0 SEA ABB=ON  PLU=ON  L26 AND (L17 OR L18)
L28      13 SEA ABB=ON  PLU=ON  (L11 OR L14) AND (L17 OR L18)
L29      3 SEA ABB=ON  PLU=ON  L28 AND (L20 OR L21 OR L22 OR L23)
L30      10 SEA ABB=ON  PLU=ON  L28 NOT L29
          SEL AN 3-9 L30
L31      7 SEA ABB=ON  PLU=ON  ("125:185914"/AN OR "128:184696"/AN OR
          "130:105323"/AN OR "130:17234"/AN OR "135:348920"/AN OR
          "138:61315"/AN OR "140:309365"/AN OR "1996:544057"/AN OR
          "1998:123996"/AN OR "1998:742255"/AN OR "1999:42584"/AN OR
          "2001:814019"/AN OR "2003:1215"/AN OR "2004:267168"/AN) AND
          L30
L32      3 SEA ABB=ON  PLU=ON  (L12 OR L13) AND (L17 OR L18)
L33      1 SEA ABB=ON  PLU=ON  L32 AND (L20 OR L21 OR L22 OR L23)
L34      2 SEA ABB=ON  PLU=ON  L32 NOT L33
          D SCA
L35      3 SEA ABB=ON  PLU=ON  L24 OR L29 OR L33
L36      12 SEA ABB=ON  PLU=ON  L26 OR L31 OR L34
          D QUE L11
L37      1 SEA ABB=ON  PLU=ON  (CEPHALOSPORIN# OR CEPHALOTINUM#) AND (L12
          OR L13)
L38      1 SEA ABB=ON  PLU=ON  L37 AND (L20 OR L21 OR L22 OR L23)
L39      7 SEA ABB=ON  PLU=ON  (CEPHALOSPORIN# OR CEPHALOTINUM#) AND (L17
          OR L18)
L40      3 SEA ABB=ON  PLU=ON  L39 AND (L20 OR L21 OR L22 OR L23)
L41      4 SEA ABB=ON  PLU=ON  L39 NOT L40
          D SCA L41
          D TI TOT
          SEL AN 1-3 L41
L42      3 SEA ABB=ON  PLU=ON  ("130:105323"/AN OR "135:348920"/AN OR
          "140:309365"/AN OR "1999:42584"/AN OR "2001:814019"/AN OR
          "2004:267168"/AN) AND L41
L43      3 SEA ABB=ON  PLU=ON  L35 OR L40
L44      12 SEA ABB=ON  PLU=ON  L36 OR L42

```

=> b reg

FILE 'REGISTRY' ENTERED AT 16:29:26 ON 15 APR 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 14 APR 2005 HIGHEST RN 848555-82-8  
 DICTIONARY FILE UPDATES: 14 APR 2005 HIGHEST RN 848555-82-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

```

*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****

```

Search done by Noble Jarrell

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide 19 tot

L9 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 11111-12-9 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Cephalosporin (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Ceflin  
CN Cephalosporins  
CN Cephalotinum  
MF Unspecified  
CI COM, MAN  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CEN, CHEMLIST, CIN, CSCHM, CSNB, DIOGENES, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, MEDLINE, NAPRALERT, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL  
Other Sources: EINECS\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4817 REFERENCES IN FILE CA (1907 TO DATE)  
862 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
4821 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d ide 115 tot

L15 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 11078-30-1 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Daikol U 2  
CN Faibaron S  
CN Galactomannan  
CN Guapack PM 1  
CN Mannan, galacto  
CN Mannogalactan  
CN Meyproid 7700  
CN Molvenin 848  
CN Sunfiber R  
DR 74505-30-9, 76688-81-8  
MF Unspecified  
CI PMS, COM, MAN  
PCT Manual registration  
LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, PIRA, PROMT, TOXCENTER, TULSA, USPAT2, USPATFULL  
Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1963 REFERENCES IN FILE CA (1907 TO DATE)  
263 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1963 REFERENCES IN FILE CAPLUS (1907 TO DATE)



=&gt; b hcap

FILE 'HCAPLUS' ENTERED AT 16:30:12 ON 15 APR 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Apr 2005 VOL 142 ISS 17  
 FILE LAST UPDATED: 14 Apr 2005 (20050414/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; d all fhitr 143 tot

L43 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:412577 HCAPLUS  
 DN 140:395542  
 ED Entered STN: 21 May 2004  
 TI Sustained release pharmaceutical composition of a cephalosporin antibiotic  
 IN Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao; Jindal, Kour Chand  
 PA Orchid Chemicals & Pharmaceuticals Limited, India  
 SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 222,930. CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-545  
 ICS A61K009-20; A61K031-736  
 NCL 424465000; 514200000; 514054000  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004096496	A1	20040520	US 2003-642194	20030818
	US 2004033262	A1	20040219	US 2002-222930	20020819
	WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	IN 2002-MA601	A	20020816		
	US 2002-222930	A2	20020819		
	WO 2002-IB3320	A	20020819		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004096496	ICM	A61K031-545
	ICS	A61K009-20; A61K031-736

NCL 424465000; 514200000; 514054000  
 US 2004096496 ECLA A61K031/545; A61K031/546  
 US 2004033262 ECLA A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546;  
 A61K031/736

AB Sustained release pharmaceutical compns. comprising at least a **cephalosporin** antibiotic, a mixture of polymers comprising of **galactomannans** and neutral swellable polymers, and other pharmaceutically acceptable excipients are described. The composition comprises about 30% to about 90% by weight of a **cephalosporin** antibiotic; about 1% to about 30% by weight of said mixture of polymers comprising from about 0.1% to about 15% by weight of **galactomannans**, and about 0.1% to about 15% of neutral swellable polymer by weight of sustained release composition

ST cephalosporin antibiotic sustained release tablet .

IT Drug delivery systems  
 (carriers; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Lubricants  
 (pharmaceutical; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Swelling agents  
 (polymers; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Antibiotics  
 Binders  
 Drying  
 Mixing  
 Plasticizers  
 Sieving  
 (sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Gelatins, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Polyesters, biological studies  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Drug delivery systems  
 (sustained-release; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Polymers, biological studies  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (swellable; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Drug delivery systems  
 (tablets, coated; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT Drug delivery systems  
 (tablets; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)


IT Fats and Glyceridic oils, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (vegetable, hydrogenated; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT 7631-86-9, Silicon dioxide, biological studies  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (colloidal; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

IT 9004-34-6, Cellulose, biological studies  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)

- IT 9005-25-8, Starch, biological studies  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pregelatinized; sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)
- IT 9003-39-8, Polyvinylpyrrolidone 9004-62-0, Hydroxyethylcellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose  
RL: MOA (Modifier or additive use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)
- IT 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 557-04-0, Magnesium stearate 557-05-1, Zinc stearate 1592-23-0, Calcium stearate 9000-30-0, Guar gum 11138-66-2, Xanthan gum 14807-96-6, Talc, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)
- IT 153-61-7, Cephalothin 11078-30-1, Galactomannan 11111-12-9D, **Cephalosporins, derivs.**  
15686-71-2, Cephalexin 21593-23-7, Cephapirin 34444-01-4, Cefamandole 35607-66-0, Cefoxitin 50370-12-2, Cefadroxil 53994-73-3, Cefaclor 61270-58-4, Cefonicid 64544-07-6, Cefuroxime axetil 68401-81-0, Ceftizoxime 87239-81-4, Cefpodoxime proxetil 92665-29-7, Cefprozil 117467-28-4, Cefditoren pivoxil  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)
- IT 9004-32-4 9010-88-2, Ethyl acrylate-methyl methacrylate copolymer 9050-04-8, Calcium carboxymethyl cellulose 25086-89-9, Plasdone S-630  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)
- IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 9004-53-9, Dextrin 66828-18-0, Dextrate 74811-65-7, Croscarmellose sodium  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)
- IT 153-61-7, Cephalothin  
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(sustained-release pharmaceutical composition of a **cephalosporin** antibiotic)
- RN 153-61-7 HCAPLUS  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R, 7R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



AN 2004:162583 HCAPLUS  
 DN 140:205146  
 ED Entered STN: 29 Feb 2004  
 TI Sustained release pharmaceutical compositions of a **cephalosporin**  
 IN **Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao**  
**; Jindal, Kour Chand**  
 PA **Orchid Health Care, A Division of Orchid**  
**Chemicals & Pharmaceuticals Ltd., India**  
 SO PCT Int. Appl., 55 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-22  
 ICS A61K031-545; A61K031-546  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1  
 FAN. CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016251	A1	20040226	WO 2003-IB3340	20030818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004033262	A1	20040219	US 2002-222930	20020819
	WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	IN 2002-MA601	A	20020816		
	US 2002-222930	A	20020819		
	WO 2002-IB3320	A	20020819		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004016251	ICM	A61K009-22
	ICS	A61K031-545; A61K031-546
US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736

AB Sustained release pharmaceutical compns. comprising at least a **cephalosporin**, a mixture of polymers comprising of **galactomannans** and neutral swellable polymers, and other pharmaceutically acceptable excipients are described. The composition comprises 30-90% of a **cephalosporin** antibiotic, 1-30% mixture of polymers comprising 0.1-15% **galactomannans**, and 0.1-15% by weight of a neutral swellable polymer. Thus, tablets contained cephalixin monohydrate 75.73, lactose 6.27, xanthan gum 7.0, Eudragit NE 30D 7.0, HPMC E5 31.5, Mg stearate 1.0 and water qs to 100%.


ST sustained release **cephalosporin** polymer

IT Drug delivery systems  
 (granules, sustained release; sustained release pharmaceutical compns. of **cephalosporins**)

IT Binders  
 Dissolution  
 Drug bioavailability  
 Human  
 Lubricants

- Plasticizers  
(sustained release pharmaceutical compns. of **cephalosporins**)
- IT Carbohydrates, biological studies  
Gelatins, biological studies  
Polymers, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained release pharmaceutical compns. of **cephalosporins**)
- IT Drug delivery systems  
(sustained-release; sustained release pharmaceutical compns. of **cephalosporins**)
- IT Drug delivery systems  
(tablets, sustained-release; sustained release pharmaceutical compns. of **cephalosporins**)
- IT Fats and Glyceridic oils, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated; sustained release pharmaceutical compns. of **cephalosporins**)
- IT 9004-34-6, Cellulose, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(microcryst.; sustained release pharmaceutical compns. of **cephalosporins**)
- IT **15686-71-2**, Cephalexin **50370-12-2**, Cefadroxil  
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained release pharmaceutical compns. of **cephalosporins**)
- IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 57-11-4, Stearic acid, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose **153-61-7**, Cephalothin 557-04-0 557-05-1, Zinc stearate 1592-23-0, Calcium stearate 7631-86-9, Silica, biological studies 9000-30-0, Guar gum 9000-40-2, Locust bean gum 9003-39-8, Polyvinylpyrrolidone 9004-53-9, Dextrin 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Starch, biological studies 9010-88-2, Eudragit NE 30D 9050-04-8, Calcium carboxymethyl cellulose 9063-38-1, Sodium starch glycolate **11078-30-1**, Galactomannan **11111-12-9**, Cephalosporin 11138-66-2, Xanthan gum 14807-96-6, Talc, biological studies **21593-23-7**, Cephapirin 23325-78-2, Cephalexin monohydrate 25086-89-9, Plasdane S-630 **34444-01-4**, Cefamandole 35607-66-0, Cefoxitin **53994-73-3**, Cefaclor 61270-58-4, Cefonicid 64544-07-6, Cefuroxime axetil **68401-81-0**, Cefprozil 74811-65-7, Croscarmellose sodium 87239-81-4, Cefpodoxime proxetil 92665-29-7, Cefprozil 104145-95-1, Cefditoren 117467-28-4, Cefditoren pivoxil 121123-17-9, Cefprozil monohydrate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained release pharmaceutical compns. of **cephalosporins**)
- RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE  
(1) Lupin Lab Ltd; WO 0241876 A 2002 HCAPLUS  
(2) Shankar, M; WO 02067943 A 2002 HCAPLUS  
(3) Squibb Bristol Myers Co; WO 9846213 A 1998 HCAPLUS
- IT **15686-71-2**, Cephalexin  
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained release pharmaceutical compns. of **cephalosporins**)
- RN **15686-71-2** HCAPLUS
- CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L43 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:142610 HCAPLUS  
 DN 140:187392  
 ED Entered STN: 22 Feb 2004  
 TI Sustained-release pharmaceutical composition of a cephalosporin antibiotic  
 IN Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao  
 ; Jindal, Kour Chand  
 PA Orchid Health Care, India  
 SO U.S. Pat. Appl. Publ., 10 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K031-545  
 ICS A61K031-736; A61K009-20; A61K009-22  
 NCL 424468000; 514054000; 514200000  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004033262	A1	20040219	US 2002-222930	20020819
WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004016251	A1	20040226	WO 2003-IB3340	20030818
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004096496	A1	20040520	US 2003-642194	20030818
PRAI IN 2002-MA601	A	20020816		
US 2002-222930	A	20020819		
WO 2002-IB3320	A	20020819		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004033262	ICM	A61K031-545
	ICS	A61K031-736; A61K009-20; A61K009-22
	NCL	424468000; 514054000; 514200000
US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736
US 2004096496	ECLA	A61K031/545; A61K031/546
AB		A sustained release pharmaceutical composition comprising at least a

**cephalosporin** antibiotic and a mixture of polymers and other pharmaceutically acceptable excipients is described. Polymers are selected from mixture of **galactomannans** and neutral swellable polymers, which releases the active ingredient in a predetd. manner. For example, a sustained-release tablet composition contained cephalexin 795.32 mg, lactose 107.68 mg, xanthan gum 31.5 mg, Eudragit NE 30D 52.5 mg, HPMC E5 52.5 mg, and magnesium stearate 10.5 mg. Cephalexin release from the tablets was 25.21%, 50.84%, 73.18%, and 84.17% after 1h, 6 h, 10 h and 14 h, resp.

ST **cephalosporin** polymer mixt sustained release tablet  
 IT Dissolution  
 Drug bioavailability  
 Granulation  
 (sustained-release composition of **cephalosporin** antibiotic containing mixture of polymers)  
 IT Polymers, biological studies  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release composition of **cephalosporin** antibiotic containing mixture of polymers)  
 IT Drug delivery systems  
 (sustained-release; sustained-release composition of **cephalosporin** antibiotic containing mixture of polymers)  
 IT Drug delivery systems  
 (tablets, sustained-release; sustained-release composition of **cephalosporin** antibiotic containing mixture of polymers)  
 IT 9000-30-0, Guar gum 9000-40-2, Locust bean gum 9010-88-2, Eudragit NE 30D **11078-30-1**, **Galactomannan** 11138-66-2, Xanthan gum  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release composition of **cephalosporin** antibiotic containing mixture of polymers)  
 IT **153-61-7**, Cephalothin **11111-12-9**, **Cephalosporin** **15686-71-2**, Cephalexin **21593-23-7**, Cefaprin **34444-01-4**, Cefamandole 35607-66-0, Cefoxitin **50370-12-2**, Cefadroxil **53994-73-3**, Cefaclor 61270-58-4, Cefonicid 64544-07-6, Cefuroxime axetil **68401-81-0**, Cefprozil 87239-81-4, Cefpodoxime proxetil 92665-29-7, Cefprozil 117467-28-4, Cefditoren pivoxil  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release composition of **cephalosporin** antibiotic containing mixture of polymers)  
 IT **11078-30-1**, **Galactomannan**  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release composition of **cephalosporin** antibiotic containing mixture of polymers)  
 RN **11078-30-1** HCAPLUS  
 CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

=> d all hitstr 144 tot

L44 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN **2004:267168** HCAPLUS  
 DN 140:309365  
 ED Entered STN: 01 Apr 2004  
 TI Surface dissolution and/or bulk erosion controlled release pharmaceutical compositions  
 IN Shefer, Adi; Shefer, Samuel David  
 PA USA  
 SO U.S. Pat. Appl. Publ., 21 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K009-00

ICS A61K009-127  
 NCL 424400000  
 CC 63-6 (Pharmaceuticals)  
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004062778	A1	20040401	US 2002-255289	20020926
	WO 2004043513	A2	20040527	WO 2003-US29401	20030917
	WO 2004043513	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2002-255289	A	20020926		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

US 2004062778	ICM	A61K009-00
	ICS	A61K009-127
	NCL	424400000

AB The present invention relates to a controlled release system comprising matrix compns. which control the lag time and release rate of the composition, as well as pharmaceutical and other active ingredients included in the composition, through surface dissoln. and/or bulk erosion of the system. The controlled release system can be used to target and control the release of active ingredients onto certain regions of the gastrointestinal tract including the stomach and the small intestine. The matrix compns. of the present invention can be comprised of the following components: a wax material, fat material, water sensitive material and surface active material. Thus, a composition contained carnauba wax 30.0, beeswax 5.0, glyceryl monostearate 10.0, Tween-20 15.0, lactitol 30.0, and BaSO4 10.0%.

ST controlled release pharmaceutical bulk erosion

IT Fats and Glyceridic oils, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Japan wax; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Imaging agents

(NMR contrast; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Imaging agents

(acoustic imaging contrast agents; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Positron-emission tomography

Tomography

(agents for; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Carboxylic acids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alkyl esters; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Quaternary ammonium compounds, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(alkylbenzylidimethyl, chlorides; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Surfactants

(amphoteric; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Heart, disease

(angina pectoris; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Waxes

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(animal; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)



- IT Surfactants  
(anionic; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Heart, disease  
(arrhythmia; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Infection  
(bacterial; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Prostate gland, disease  
(benign hyperplasia; surface dissoln. and/or bulk erosion controlled  
release pharmaceutical compns.)
- IT Hyperplasia  
(benign prostatic; surface dissoln. and/or bulk erosion controlled  
release pharmaceutical compns.)
- IT Surfactants  
(cationic; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Inflammation  
Intestine, disease  
(colitis; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Intestine  
(colon; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Nose, disease  
(congestion; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Drug delivery systems  
(controlled-release; surface dissoln. and/or bulk erosion controlled  
release pharmaceutical compns.)
- IT Monoglycerides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cottonseed-oil, hydrogenated; surface dissoln. and/or bulk erosion  
controlled release pharmaceutical compns.)
- IT Mental disorder  
(depression; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Castor oil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(derivs.; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Diglycerides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(digalactosyl; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Waxes  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(emulsifying; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(essential; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Fatty acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(esters; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Alcohols, biological studies  
Amides, biological studies  
Esters, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Heart, disease  
(failure; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)
- IT Vein, disease  
(hemorrhoid; surface dissoln. and/or bulk erosion controlled release  
pharmaceutical compns.)

IT Castor oil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated, ethoxylated; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Castor oil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrogenated; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Syrups (sweetening agents)  
 (hydrolyzed starch; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Dental materials and appliances  
 Prosthetic materials and Prosthetics  
 (implants; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Sexual behavior  
 (impotence; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Thyroid gland  
 (inhibitors; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Alcohols, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lanolin; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Hydrocarbon waxes, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst.; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Drug delivery systems  
 (microspheres; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Antibodies and Immunoglobulins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (monoclonal; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Drug delivery systems  
 (nanospheres; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Surfactants  
 (nonionic; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Anti-inflammatory agents  
 (nonsteroidal; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Alcohols, biological studies  
 Esters, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (propoxylated; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Infection  
 (protozoal; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Intestine  
 (small; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Muscle, disease  
 (spasm; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Brain, disease  
 (stroke; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT Analgesics  
 Anthelmintics  
 Anti-inflammatory agents  
 Antianginal agents  
 Antiarrhythmics  
 Antibacterial agents  
 Anticoagulants  
 Anticonvulsants

Antidepressants  
Antidiabetic agents  
Antiemetics  
Antihistamines  
Antihypotensives  
Antimalarials  
Antimigraine agents  
Antiobesity agents  
Antiparkinsonian agents  
Antitussives  
Antiviral agents  
Anxiety  
Anxiolytics  
Appetite depressants  
Beeswax  
Blood coagulation  
Bronchodilators  
Cognition  
Cognition enhancers  
Contraceptives  
Cosmetics  
Cough  
Decongestants  
Diabetes mellitus  
Digestive tract  
Dissolution  
Diuresis  
Diuretics  
Epilepsy  
Expectorants  
Fungicides  
Gout  
Granulation  
Gums and Mucilages  
Hydrocolloids  
Hydrophile-lipophile balance value  
Hypertension  
Hypnotics and Sedatives  
Hypotension  
Imaging agents  
Immunomodulators  
Immunosuppressants  
Immunosuppression  
Inflammation  
Inotropics  
Laxatives  
Leukotriene antagonists  
Malaria  
Medical goods  
Mental disorder  
Muscarinic antagonists  
Muscle relaxants  
Mycosis  
Neoplasm  
Nutrition, animal  
Osteoporosis  
Ozocerite  
Pain  
Parkinson's disease  
Particle size distribution  
Protozoacides  
Psychotropics  
Sleep  
Spheronization  
Stomach  
Surfactants  
Tranquilizers  
Vaccines  
Vasoconstriction  
Vasoconstrictors

- Vasodilation
- Vasodilators
- Vomiting
  - (surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT Amine oxides
- Candelilla wax
- Carbohydrates, biological studies
- Cardiolipins
- Carnauba wax
- Corticosteroids, biological studies
- Cytokines
- Diglycerides
- Fats and Glyceridic oils, biological studies
- Fatty acids, biological studies
- Gelatins, biological studies
- Glutens
- Glycerides, biological studies
- Hormones, animal, biological studies
- Hydrocarbon waxes, biological studies
- Interferons
- Isoprenoids
- Keratins
- Lecithins
- Lipids, biological studies
- Macrolides
- Monoglycerides
- Oligomers
- Oligonucleotides
- Oligosaccharides, biological studies
- Opioids
- Peptides, biological studies
- Phosphatidic acids
- Phosphatidylcholines, biological studies
- Phosphatidylethanolamines, biological studies
- Phosphatidylglycerols
- Phosphatidylinositols
- Phosphatidylserines
- Phospholipids, biological studies
- Polyamides, biological studies
- Polyesters, biological studies
- Polymers, biological studies
- Polyoxyalkylenes, biological studies
- Polysaccharides, biological studies
- Prostaglandins
- Proteins
- Sex hormones
- Shellac
- Sphingolipids
- Steroids, biological studies
- Terpenes, biological studies
- Tocopherols
- Tumor necrosis factors
- Vitamins
- Waxes
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT Drug delivery systems
  - (tablets, controlled-release; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT Fats and Glyceridic oils, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (vegetable, hydrogenated; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT Infection
  - (viral; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT Surfactants
  - (zwitterionic; surface dissoln. and/or bulk erosion controlled release

- pharmaceutical compns.)
- IT Adrenoceptor antagonists  
( $\beta$ -; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT Lactams  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\beta$ -; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT 9015-94-5, Renin, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitor; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT 9001-92-7, Protease  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(inhibitor; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT 329900-75-6, COX-2  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(inhibitors; surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)
- IT 50-69-1, Ribose 50-70-4, Sorbitol, biological studies 50-78-2, Aspirin 50-99-7, Glucose, biological studies 50-99-7D, Glucose, esters 56-86-0D, Glutamic acid, acyl derivs. 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-50-1D, Sucrose, esters 57-55-6D, Propylene glycol, esters 57-88-5, Cholesterol, biological studies 58-86-6, Xylose, biological studies 59-23-4, Galactose, biological studies 69-65-8, Mannitol 69-72-7D, derivs. 69-79-4, Maltose 79-10-7D, Acrylic acid, polymers 79-41-4D, Methacrylic acid, esters, polymers 87-99-0, Xylitol 88-99-3D, Phthalic acid, derivs. 89-78-1, Menthol 107-21-1D, Ethylene glycol, esters 107-97-1D, Sarcosinic acid, acyl derivs. 111-46-6D, Diethylene glycol, esters 112-80-1, Oleic acid, biological studies 124-30-1, Stearylamine 143-07-7, Lauric acid, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 373-49-9, Palmitoleic acid 544-64-9, Myristoleic acid 544-66-1, Physeteric acid 555-43-1, Glycerol tristearate 585-86-4, Lactitol 585-88-6, Maltitol 593-39-5, Petroselinic acid 1256-86-6, Cholesterol sulfate 1510-21-0, Cholesterol hemisuccinate 2462-63-7, Dioleoylphosphatidylethanolamine 2644-64-6, Dipalmitoylphosphatidylcholine 3458-28-4, Mannose 4539-70-2, Distearoylphosphatidylcholine 7664-93-9D, Sulfuric acid, esters 7727-43-7, Barium sulfate 7778-18-9, Calcium sulfate 8050-81-5, Simethicone 9000-01-5, Acacia gum 9000-65-1, Tragacanth 9002-72-6, Growth hormone 9002-79-3, Melanocyte-stimulating hormone 9002-89-5, Polyvinyl alcohol 9003-01-4D, Polyacrylic acid, derivs. 9003-05-8, Polyacrylamide 9003-39-8, Polyvinylpyrrolidone 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, derivs. 9004-38-0, Cellulose acetate phthalate 9004-62-0, Hydroxyethyl cellulose 9005-25-8, Starch, biological studies 9005-25-8D, Starch, derivs. 9005-64-5, Tween 20 9006-26-2, Ethylene-maleic anhydride copolymer 9007-12-9, Calcitonin 9011-16-9, Maleic anhydride-methylvinyl ether copolymer 9026-81-7, Nuclease 9032-50-2, Methyl cellulose phthalate 9050-31-1, Hydroxypropyl methyl cellulose phthalate 9050-36-6, Maltrin M 180 9054-89-1, Superoxide dismutase 9062-05-9, Hydroxypropyl carboxymethyl cellulose 9083-87-8 **11078-30-1**, **Galactomannan** 11096-26-7, Erythropoietin **11111-12-9**, **Cephalosporin** 11138-66-2, Xanthan 12441-09-7D, Sorbitan, esters 15687-27-1, Ibuprofen 18656-38-7, Dimyristoylphosphatidylcholine 18656-40-1, Dilauroylphosphatidylcholine 24529-88-2 25322-68-3, Polyethylene oxide 25322-69-4 25618-55-7D, Polyglycerol, esters with fatty acids 29385-00-0, Isolauric acid 30399-84-9, Isostearic acid 31566-31-1, Glyceryl monostearate 32844-67-0, Isopalmitic acid 37324-30-4, Hydroxypropyl cellulose phthalate 37353-59-6, Hydroxymethyl cellulose 51110-01-1, Somatostatin 52907-01-4, Cellulose acetate trimellitate 53237-50-6 53714-56-0, Leuprolide 56509-23-0, Sodium cellulose acetate phthalate 59865-13-3, Cyclosporin 62571-86-2, Captopril 62683-29-8, Colony stimulating factor 64519-82-0, Palatinin 64792-89-8, Dibehenoylphosphatidylcholine 65437-21-0, Isomyristic acid 66829-29-6, Hi-Cap 100 67896-63-3, Dipentadecanoylphosphatidylcholine 68354-99-4 68424-04-4, Polydextrose 68737-67-7,

Dioleoylphosphatidylcholine 71138-97-1, Hydroxypropylmethyl cellulose acetate succinate 71259-34-2 76822-97-4 78543-25-6, 1-Hexadecyl-2-palmitoylglycerophosphoethanolamine 82196-85-8 83172-32-1, Ditricosanoylphosphatidylcholine 83554-62-5 88527-84-8, Amylose acetate phthalate 96299-42-2 96299-43-3 96352-13-5, Hydroxypropyl ethyl cellulose phthalate 97782-02-0 99614-02-5, Ondansetron 106392-12-5, Poloxamer 108032-13-9 127512-30-5 129385-16-6 129385-17-7 143475-87-0 154897-15-1, Dilignoceroylphosphatidylcholine 252856-84-1, Polyvinyl acetate hydrogen phthalate 676259-03-3 676270-47-6  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

IT 11078-30-1, Galactomannan 11111-12-9, Cephalosporin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (surface dissoln. and/or bulk erosion controlled release pharmaceutical compns.)

RN 11078-30-1 HCAPLUS

CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 11111-12-9 HCAPLUS

CN Cephalosporin (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L44 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:1006735 HCAPLUS

DN 140:31525

ED Entered STN: 26 Dec 2003

TI Film-shaped mucoadhesive administration form for administering cannabis active ingredients

IN Wessling, Werner

PA LTS Lohmann Therapie-Systeme A.-G., Germany

SO PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K009-00

ICS A61K009-70; A61K035-78

CC 63-6 (Pharmaceuticals)

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003105800	A2	20031224	WO 2003-EP4807	20030508
	WO 2003105800	A3	20041209		
	W: AU, BR, CA, CN, IL, IN, JP, KR, MX, NZ, PH, PL, RU, US, ZA				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	DE 10226494	A1	20040108	DE 2002-10226494	20020614
	BR 2003011867	A	20050315	BR 2003-11867	20030508
	EP 1513494	A2	20050316	EP 2003-725174	20030508
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
PRAI	DE 2002-10226494	A	20020614		
	WO 2003-EP4807	W	20030508		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003105800	ICM	A61K009-00
	ICS	A61K009-70; A61K035-78
WO 2003105800	ECLA	A61K009/00M18D; A61K009/70B
DE 10226494	ECLA	A61K009/00M18D; A61K009/70B

AB The invention relates to a film-shaped, mucoadhesive administration form containing at least one active ingredient from the group of cannabis active ingredients. Sublingual or buccal films are prepared that also contain swellable polymers, flavoring substances, fillers, dyes, emulsifiers, softeners, permeation enhancers, antioxidants, buffers, and preservatives. Active ingredient content is 0.1-20 weight/weight%; preferably 0.5-10 %; the

- thickness of the films is 0.05-0.5 mm. The compns. are applied as pain killers for cancer and AIDS patients and to alleviate other diseases.
- ST cannabis tetrahydrocannabinol drug mucoadhesive film buccal sublingual
- IT Drug delivery systems  
(buccal; film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chamomile; film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Mental disorder  
(dementia; film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Opioids  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(dependence; film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Nervous system, disease  
(dystonia; film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(eucalyptus; film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT AIDS (disease)  
Alcoholism  
Alzheimer's disease  
Analgesics  
Anorexia  
Anticonvulsants  
Antiemetics  
Antimigraine agents  
Antioxidants  
Arthritis  
Asthma  
Buffers  
Cachexia  
Chemotherapy  
Drug dependence  
Drug withdrawal  
Dyes  
Dysmenorrhea  
Emulsifying agents  
Epilepsy  
Fillers  
Flavor  
Glaucoma (disease)  
Hepatitis  
Human  
Multiple sclerosis  
Neoplasm  
Parkinson's disease  
Permeation enhancers  
Plasticizers  
Preservatives  
Sweetening agents  
Swelling, physical  
(film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Collagens, biological studies  
Gelatins, biological studies  
Polyoxyalkylenes, biological studies  
Turpentine oil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Drug delivery systems  
(films; film-shaped mucoadhesive administration form for administering cannabis active ingredients)
- IT Cannabis sativa

(marijuana, exts. or oils of; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT Headache  
(migraine; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT Pain  
(neuropathic; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT Thickness  
(of drug film; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT Drug delivery systems  
(sublingual; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT **Polymers, biological studies**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(swellable; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT Essential oils  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thyme, Thymus vulgaris; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT Injury  
(trauma; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT Disease, animal  
(wasting; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT 12794-10-4, Benzodiazepine  
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)  
(dependence; film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT 60-12-8, Phenylethanol 79-10-7D, Acrylic acid, esters, polymers  
79-92-5, Camphene 89-78-1, Menthol 92-48-8, 6-Methyl coumarin  
106-22-9, Citronellol 119-36-8, Methylsalicylate 121-32-4,  
Ethylvanillin 123-86-4, Acetic acid-n-butyl ester 138-86-3, Limonene  
470-82-6, Eucalyptol 521-35-7, Cannabinol 1330-16-1, Pinene  
1972-08-3, Tetrahydrocannabinol 6066-49-5, Butylphthalide 9000-07-1,  
Carrageenan gum 9000-65-1, Tragacanth gum 9000-69-5, Pectins  
9002-18-0, Agar 9003-01-4, Polyacrylic acid 9003-05-8, Polyacrylamide  
9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethyl cellulose  
9004-57-3, Ethyl cellulose 9004-62-0, Hydroxyethyl cellulose  
9004-64-2, Hydroxypropyl cellulose 9005-18-9, Propyl cellulose  
9005-25-8, Starch, biological studies 9005-25-8D, Starch, derivs.  
9005-32-7, Alginic acid 9012-36-6, Agarose 9012-76-4, Chitosan  
9036-66-2, Arabinogalactan 9057-02-7, Pullulan **11078-30-1**,  
**Galactomannan** 13956-29-1, Cannabidiol 20675-51-8,  
Cannabichromene 25322-68-3, Polyethylene oxide 37353-59-6,  
Hydroxymethyl cellulose  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(film-shaped mucoadhesive administration form for administering cannabis active ingredients)

IT **11078-30-1, Galactomannan**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(film-shaped mucoadhesive administration form for administering cannabis active ingredients)

RN 11078-30-1 HCAPLUS

CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L44 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN **2003:1215** HCAPLUS  
DN 138:61315  
ED Entered STN: 02 Jan 2003  
TI Controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers  
IN Chhabra, Harinderpal; Sarkar, Shyamal K.  
PA USA  
SO U. S., 23 pp.



CODEN: USXXAM  
 DT Patent  
 LA English  
 IC ICM A61K009-22  
 ICS A61K009-24; A61K009-30  
 NCL 424474000; 424468000; 424470000; 424472000; 424475000; 514770000;  
 514772300; 514777000; 514778000; 514779000  
 CC 63-6 (Pharmaceuticals)

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6500459	B1	20021231	US 1999-358732	19990721
	CA 2314298	AA	20010121	CA 2000-2314298	20000721
PRAI	US 1999-358732	A	19990721		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6500459	ICM	A61K009-22
	ICS	A61K009-24; A61K009-30
	NCL	424474000; 424468000; 424470000; 424472000; 424475000; 514770000; 514772300; 514777000; 514778000; 514779000
US 6500459	ECLA	A61K009/00L4; A61K009/28K

AB A pharmaceutical composition for controlled onset and sustained release of an active ingredient, comprises: (i) a core comprising: (a) an active ingredient; (b) a hydrophilic carrier; (c) a hydrodynamic diffusion enhancer; and optionally (d) conventional excipients selected from the group consisting of binders, fillers and lubricants and combinations thereof; and (ii) a functional coating membrane surrounding the core. Thus, 240 g verapamil-HCl was sieved through a mesh sieve and blended with 150 g E50 premium HPMC. To this blend was added 270.0 g croscarmellose sodium and mixed for 15 min. This blend was granulated with PVP K-29/32 solution in iso-PROH (30% weight/weight). The wet mass obtained in the above step was dried at 60° for 3 h. After drying, the granules were passed a mesh sieve. The granules were then mixed with 2.5 g of Magnesium Stearate and 15 g of Stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. The granules were then mixed with 2.5 g of Mg stearate and 15 g of stearic acid in a V blender. This granule blend was compressed in a tablet press by using appropriate size tooling. These tablets were then coated by using a perforated coating pan. A seal coating membrane was applied on the surface of tablets to achieve a weight gain of 1.66% of the weight of the core. The seal coating dispersion of Opadry Clear in water at 10% was sprayed on to the surface of the tablets by using a perforated coating pan.

ST controlled release drug hydrophilic carrier diffusion enhancer; sustained release drug hydrophilic carrier diffusion enhancer

IT Erythropoiesis  
 (agents for; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)

IT Antacids  
 Anti-infective agents  
 Anti-inflammatory agents  
 Antianginal agents  
 Antiarrhythmics  
 Antiasthmatics  
 Antibacterial agents  
 Anticholesteremic agents  
 Anticonvulsants  
 Antidiabetic agents  
 Antidiarrheals  
 Antiemetics  
 Antihistamines  
 Antihypertensives  
 Antitussives  
 Anxiolytics  
 Appetite depressants  
 Binders  
 Coating materials  
 Decongestants  
 Diuretics

- Expectorants
- Human
- Hypnotics and Sedatives
- Hypolipemic agents
- Laxatives
- Lubricants
- Molecular weight distribution
- Nervous system stimulants
- Plasticizers
- Psychotropics
- Thyroid gland, disease
- Vasoconstrictors
- Vasodilators
- Viscosity
  - (controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Vitamins
  - Waxes
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Drug delivery systems
  - (controlled-release; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Vasodilators
  - (coronary; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Clays, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (diffusion enhancer; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Diffusion
  - (enhancers for; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Drug delivery systems
  - (granules; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Polyoxyalkylenes, biological studies
  - Polysaccharides, biological studies
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (hydrophilic carrier; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Protamines
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (sulfates; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Drug delivery systems
  - (sustained-release; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Drug delivery systems
  - (tablets, controlled-release; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT Drug delivery systems
  - (tablets, sustained-release; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT 9003-39-8D, crosslinked
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (Crospovidone, diffusion enhancer; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT 50-70-4, Sorbitol, biological studies 50-99-7, Dextrose, biological studies 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 9004-34-6, Cellulose, biological studies 9005-25-8D, Starch, derivs. 9050-36-6, Maltodextrin
  - RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
  - (binder; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)
- IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-47-5, Desmethylinipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies

50-54-4, Quinidine sulfate 50-81-7, Ascorbic acid, biological studies  
 51-06-9, Procainamide 51-48-9, Thyroxine, biological studies 51-52-5,  
 Propylthiouracil 52-01-7, Spironolactone 52-28-8, Codeine phosphate  
 52-53-9, Verapamil 52-86-8, Haloperidol 53-03-2, Prednisone 53-86-1,  
 Indomethacin 54-31-9, Furosemide 55-56-1, Chlorhexidine 55-63-0,  
 Glyceryl trinitrate 57-66-9, Probenecid 57-96-5, Sulphinpyrazone  
 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine  
 58-74-2, Papaverine 58-93-5, Hydrochlorthiazide 59-02-9,  
 $\alpha$ -Tocopherol 59-30-3, Folic acid, biological studies 59-43-8,  
 Thiamin, biological studies 59-67-6, Nicotinic acid, biological studies  
 60-13-9, Amphetamine sulphate 60-32-2,  $\epsilon$ -Aminocaproic acid  
 61-75-6, Bretylium tosylate 65-23-6, Pyridoxine 69-23-8, Fluphenazine  
 76-42-6, Oxycodone 77-36-1, Chlorthalidone 78-11-5, Pentaerythritol  
 tetranitrate 86-22-6, Brompheniramine 86-54-4, Hydralazine 87-33-2,  
 Sorbide dinitrate 90-82-4, Pseudoephedrine 93-14-1, Guaiphenesin  
 94-20-2, Diabenese 113-15-5, Ergotamine 113-45-1, Methylphenidate  
 113-92-8, Erythromycin 117-89-5, Trifluoperazine 123-03-5,  
 Cetylpyridinium chloride 125-71-3, Dextromethorphan 128-62-1,  
 Noscapine 134-80-5, Diethylpropion hydrochloride 146-22-5, Nitrazepam  
 152-11-4, Verapamil hydrochloride 298-46-4, Carbamazepine 299-28-5,  
 Calcium gluconate 315-30-0, Allopurinol 317-34-0, Aminophylline  
 364-62-5, Metoclopramide 389-08-2, Nalidixic acid 396-01-0,  
 Triamterene 404-82-0, Fenfluramine hydrochloride 439-14-5, Diazepam  
 456-59-7, Cyclandelate 480-30-8, Dichloral phenazone 525-66-6,  
 Propranolol 554-13-2, Lithium carbonate 555-30-6, Methyl dopa  
 577-11-7, Dioctyl sodium sulfosuccinate 603-50-9, Bisacodyl 630-93-3,  
 Phenytoin sodium 638-23-3, Carbocysteine 846-49-1, Lorazepam  
 846-50-4, Temazepam 915-30-0, Diphenoxylate 1069-66-5, Sodium  
 valproate 1309-42-8, Magnesium hydroxide 1404-88-2, Tyrothricin  
 1420-53-7, Codeine sulfate 1622-61-3, Clonazepam 1668-19-5, Doxepine  
 1847-24-1, Flucloxacillin sodium 2706-50-5, Amphetamine hydrochloride  
 3200-06-4, Naftidrofuryl oxalate 3737-09-5, Disopyramide 3930-20-9,  
 Sotalol 4205-90-7, Clonidine 5104-49-4, Flurbiprofen 5874-97-5,  
 Orciprenaline sulfate 5965-13-9, 6493-05-6, Pentoxifylline 6893-02-3,  
 Triiodothyronine 7054-25-3, Quinidine gluconate 7683-59-2,  
 Isoproterenol 7720-78-7, Ferrous sulphate 8067-24-1, Co-dergocrine  
 mesylate 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide  
 10347-81-6, Maprotiline hydrochloride 10377-48-7, Lithium sulfate  
 14663-23-1, Dantrolene sodium 14838-15-4, Phenylpropanolamine  
 15307-86-5, Diclofenac **15686-71-2**, Cephalexin 15687-27-1,  
 Ibuprofen 17617-23-1, Flurazepam 17693-51-5, Promethazine theoclate  
 18559-94-9, Salbutamol 21256-18-8, Oxaprozin 21645-51-2, Aluminum  
 hydroxide, biological studies 21829-25-4, Nifedipine 22204-53-1,  
 Naproxen 23031-32-5, Terbutaline sulfate 23887-31-2, Clorazepate  
 25812-30-0, Gemfibrozil 26652-09-5, Ritodrine 26807-65-8, Indapamide  
 28981-97-7, Alprazolam 29094-61-9, Glipizide 29975-16-4, Estazolam  
 30516-87-1, Zidovudine 34911-55-2, Bupropion 36505-84-7, Buspirone  
 36894-69-6, Labetalol 39860-99-6, Pipothiazine 42399-41-7, Diltiazem  
 51481-61-9, Cimetidine 53179-11-6, Loperamide **53994-73-3**,  
 Cefaclor 54910-89-3, Fluoxetine **55268-75-2**, Cefuroxime  
 59277-89-3, Acyclovir 62571-86-2, Captopril 63590-64-7, Terazosin  
 66357-35-5, Ranitidine 72509-76-3, Felodipine 73590-58-6, Omeprazole  
 75330-75-5, Lovastatin 75847-73-3, Enalapril 76584-70-8, Divalproex  
 sodium 76824-35-6, Famotidine 76963-41-2, Nizatidine 79617-96-2,  
 Sertraline 79794-75-5, Loratidine 79902-63-9, Simvastatin  
 81093-37-0, Pravastatin 81103-11-9, Clarithromycin 82419-36-1,  
 Ofloxacin 82626-48-0, Zolpidem 83799-24-0, Fexofenadine 83905-01-5,  
 Azithromycin 85441-61-8, Quinapril 85721-33-1, Ciprofloxacin  
 86541-75-5, Benazepril 87333-19-5, Ramipril 88150-42-9, Amlodipine  
 92665-29-7, Cefprozil 97322-87-7, Troglitazone 98048-97-6, Fosinopril  
 110268-21-8, Opadry clear

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(controlled and sustained release dosage forms containing hydrophilic  
 carriers and diffusion enhancers)

IT 9005-25-8, Starch, biological studies 9063-38-1, Sodium starch glycolate  
 74811-65-7, Sodium croscarmellose

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(diffusion enhancer; controlled and sustained release dosage forms  
 containing hydrophilic carriers and diffusion enhancers)

IT 71010-52-1, Gellan gum

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrophilic carrier or diffusion enhancer; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)

- IT 57-55-6D, Propylene glycol, esters 9000-01-5, Gum acacia 9000-07-1D, Carrageenan, salts or derivs. 9000-30-0, Guar gum 9000-40-2, Locust bean gum 9000-65-1, Gum tragacanth 9003-01-4, Carboxypolymethylene 9003-39-8, PVP 9004-32-4, Sodium carboxymethyl cellulose 9004-34-6D, Cellulose, derivs. 9004-42-6, Carboxyethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose 9005-32-7D, Alginic acid, derivs. or salts 9032-42-2, Hydroxyethyl methyl cellulose **11078-30-1**, **Galactomannan** 11078-31-2, Glucomannan 11138-66-2, Xanthan gum 25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrophilic carrier; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)

- IT 57-11-4, Stearic acid, biological studies 57-11-4D, Stearic acid, derivs. and salts 4070-80-8, Sodium stearyl fumarate 7631-86-9, Silica, biological studies 14807-96-6, Talc, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(lubricant; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)

- IT 77-93-0, Triethyl citrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(plasticizer; controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Bengtsson; US 5690960 A 1997 HCAPLUS


IT **15686-71-2**, Cephalexin **53994-73-3**, Cefaclor **55268-75-2**, Cefuroxime

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(controlled and sustained release dosage forms containing hydrophilic carriers and diffusion enhancers)

RN 15686-71-2 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53994-73-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 55268-75-2 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[aminocarbonyl]oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amin  
o]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



IT 11078-30-1, Galactomannan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrophilic carrier; controlled and sustained release dosage forms  
containing hydrophilic carriers and diffusion enhancers)

RN 11078-30-1 HCAPLUS

CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L44 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:814019 HCAPLUS

DN 135:348920

ED Entered STN: 09 Nov 2001

TI Modified release pharmaceutical formulations containing active principles  
having antibiotic activity

IN Maggi, Lauretta; Conte, Ubaldo

PA Laboratorio Italiano Biochimico Farmaceutico Lisapharma S.P.A., Italy

SO Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM A61K009-20

ICS A61K009-28; A61K031-545

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1151747	A1	20011107	EP 2001-110735	20010503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IT 2000MI0972	A1	20011105	IT 2000-MI972	20000504
IT 1318495	B1	20030825		
PRAI IT 2000-MI972	A	20000504		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 1151747	ICM	A61K009-20
	ICS	A61K009-28; A61K031-545
EP 1151747	ECLA	A61K009/20H6F2; A61K009/28H6F2


AB Formulations are based on substances endowed with antibiotic activity for the preparation of oral hydrophilic matrixes (modified release tablets). Said hydrophilic matrixes can release the carried antibiotic gradually and following a release profile which can be established by suitable in vitro tests. An essential feature of said hydrophilic matrixes consists in that they can provide a high bioavailability characterized by such extended effective plasma levels to enable only one or two daily administrations, thus simplifying dosage and correct use by the patient. Coated tablets were prepared containing cefaclor monohydrate.

ST controlled release tablet antibiotic; cephalosporin controlled release tablet

- IT Drug delivery systems  
(controlled-release; modified release pharmaceutical formulations containing active principles having antibiotic activity)
- IT Antibiotics  
Dissolution rate  
Drug bioavailability  
Fluidized beds  
Plasticizers  
(modified release pharmaceutical formulations containing active principles having antibiotic activity)
- IT Polyoxyalkylenes, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modified release pharmaceutical formulations containing active principles having antibiotic activity)
- IT Drug delivery systems  
(tablets, controlled-release; modified release pharmaceutical formulations containing active principles having antibiotic activity)
- IT **53994-73-3**, Cefaclor  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(modified release pharmaceutical formulations containing active principles having antibiotic activity)
- IT 1398-61-4, Chitin 7585-39-9,  $\beta$ -Cyclodextrin 8050-81-5, Simethicone 9000-07-1, Carrageenan 9000-69-5, Pectin 9002-18-0, Agar 9002-89-5 9003-39-8, Pvp 9004-32-4, Carboxymethyl cellulose 9004-53-9, Dextrin 9004-62-0, Hydroxyethyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl cellulose 9012-72-0, Glucan 9012-76-4, Chitosan 9036-88-8, Mannan 9057-02-7, Pullulan **11078-30-1**, Galactomannan 11138-66-2, Xanthan 25322-68-3, Peg 39464-87-4, Scleroglucan 106392-12-5, Poloxamer  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modified release pharmaceutical formulations containing active principles having antibiotic activity)
- IT 50-59-9, Cephaloridine **153-61-7**, Cephalothin 3577-01-3, Cephaloglycine 10206-21-0, Cefacetrile **11111-12-9**, Cephalosporin **15686-71-2**, Cephalixin **21593-23-7**, Cephapirin **25953-19-9**, Cephazolin **34444-01-4**, Cefamandol **38821-53-3**, Cephadrine **50370-12-2**, 51627-14-6, Cefatrizine 51762-05-1, Cefroxadine **55268-75-2**, Cefuroxime **56796-20-4**, Cefmetazole 60925-61-3, Ceforanide 61270-58-4, Cefonicid **62893-19-0**, Cefoperazone 63527-52-6, Cephotoxime 64544-07-6, Cefuroxime axetil 64952-97-2, Moxalactam 70797-11-4, Cefpiramide 82219-78-1, Cefuzonam  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(modified release pharmaceutical formulations containing active principles having antibiotic activity)
- IT 77-93-0, Triethyl citrate 77-94-1, Tributyl citrate 84-66-2, Diethylphthalate 102-76-1, Triacetin 109-43-3, Dibutyl sebacate  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(plasticizer; modified release pharmaceutical formulations containing active principles having antibiotic activity)
- RE. CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
- (1) Kim, H; WO 9949868 A 1999 HCAPLUS
  - (2) LI, X; HCAPLUS
  - (3) LI, X; GUANGDONG YAOXUEYUAN XUEBAO 2000, V16(1), P14 HCAPLUS
  - (4) Oren, P; US 4968508 A 1990 HCAPLUS
  - (5) Ranbaxy Lab Ltd; EP 0923934 A 1999 HCAPLUS
  - (6) Uemura, T; US 4695467 A 1987 HCAPLUS
- IT **53994-73-3**, Cefaclor  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(modified release pharmaceutical formulations containing active principles having antibiotic activity)
- RN 53994-73-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R, 7R)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



IT 11078-30-1, **Galactomannan**

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(modified release pharmaceutical formulations containing active principles  
having antibiotic activity)

RN 11078-30-1 HCAPLUS

CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 153-61-7, Cephalothin 11111-12-9, **Cephalosporin**

15686-71-2, Cephalexin 21593-23-7, Cephapirin

25953-19-9, Cephazolin 34444-01-4, Cefamandol

38821-53-3, Cephradine 50370-12-2 55268-75-2,

Cefuroxime 56796-20-4, Cefmetazole 62893-19-0,

Cefoperazone


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(modified release pharmaceutical formulations containing active principles  
having antibiotic activity)

RN 153-61-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R, 7R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 11111-12-9 HCAPLUS


CN Cephalosporin (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 15686-71-2 HCAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, (6R, 7R)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 21593-23-7 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio]acetyl]amino]-, (6R,7R)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 25953-19-9 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[5-methyl-1,3,4-thiadiazol-2-yl]thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 34444-01-4 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[2R]-hydroxyphenylacetyl]amino]-3-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 38821-53-3 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[2R]-amino-1,4-cyclohexadien-1-ylacetyl]amino]-3-methyl-8-oxo-,  
 (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 50370-12-2 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R, 7R)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 55268-75-2 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[[(aminocarbonyl)oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amin  
 o]-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 56796-20-4 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-  
 yl)thio]methyl]-8-oxo-, (6R, 7S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 62893-19-0 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-  
 hydroxyphenyl)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-  
 oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L44 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1999:640708 HCAPLUS

DN 131:262650

ED Entered STN: 08 Oct 1999

TI Sustained-release compositions containing cefaclor

IN Kim, Hyun Soo; Park, Young Joon

PA Yuhan Corp., S. Korea

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-545

ICS A61K009-22; A61K009-46

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9949868	A1	19991007	WO 1999-KR159	19990401
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9930572	A1	19991018	AU 1999-30572	19990401
	EP 1067937	A1	20010117	EP 1999-912140	19990401
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002509887	T2	20020402	JP 2000-540831	19990401
PRAI	KR 1998-11397	A	19980401		
	WO 1999-KR159	W	19990401		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9949868	ICM	A61K031-545
	ICS	A61K009-22; A61K009-46
WO 9949868	ECLA	A61K009/00L2; A61K033/00

AB A composition comprising 30-90 % cefaclor, 5-60 % a hydroswelling polymer, and 1-10 % a salt based on the total weight of the composition releases cefaclor in the gastric fluid in a steady sustained manner for > 20 h. Cefaclor 400 g was mixed with hydroxypropyl Me cellulose 20, CaCO<sub>3</sub> 20, NaHCO<sub>3</sub> 10, citric acid 10, hydroxypropyl Me cellulose phthalate 10, and colloidal silica 2 g. The mixture was granulated and the obtained granules were mixed with hydroxypropyl Me cellulose 60, CaCO<sub>3</sub> 20, NaHCO<sub>3</sub> 5, Na CMC 30, colloidal silica 1, and Mg stearate 3 g. The resulting mixture was formed into tablets. When the tablet thus obtained was added to an artificial fluid, it floated to the upper layer and remained afloat for > 6 h. The cumulative dissoln. rate of cefaclor from the tablet in 0.1 N HCl aqueous

Search done by Noble Jarrell

IN Rowe, James Baber  
 PA Australia  
 SO PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-71  
 ICS A61K038-43; A61K038-46; A61K038-47  
 CC 1-9 (Pharmacology)  
 Section cross-reference(s): 63

FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9900136	A1	19990107	WO 1998-AU495	19980626
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2294904	AA	19990107	CA 1998-2294904	19980626
AU 9880931	A1	19990119	AU 1998-80931	19980626
AU 746054	B2	20020411		
EP 1017402	A1	20000712	EP 1998-930541	19980626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9810944	A	20000926	BR 1998-10944	19980626
JP 2002511865	T2	20020416	JP 1999-505159	19980626
NZ 502445	A	20030328	NZ 1998-502445	19980626
US 6303572	B1	20011016	US 2000-446801	20000210
US 6468964	B1	20021022	US 2001-912886	20010725
PRAI AU 1997-7582	A	19970627		
WO 1998-AU495	W	19980626		
US 2000-446801	A3	20000210		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9900136	ICM	A61K031-71
	ICS	A61K038-43; A61K038-46; A61K038-47
WO 9900136	ECLA	A61K038/12
US 6303572	ECLA	A61K038/12
US 6468964	ECLA	A61K038/12

AB A method is provided for the treatment or prophylaxis of acidic gut syndrome resulting from the accumulation of acid and production of endotoxin in the gastrointestinal tract of a human or an animal, the accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of the human or animal. The method comprises administering to said human or animal an effective amount of an active agent capable of preventing or controlling acid and endotoxin accumulation in the gastrointestinal tract.

ST acidic gut syndrome acid endotoxin accumulation modulation

IT Intestine, disease

(Crohn's, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

IT Endocrine system

Kidney

Pancreas

Thyroid gland

(acidic gut syndrome-associated effect on; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

IT Alzheimer's disease

Arthritis

Asthma

Cachexia

Cystic fibrosis

Dermatitis

Diabetes mellitus

Hypertension

Mastitis

- Multiple sclerosis
- Myasthenia gravis
- Neoplasm
- Osteoarthritis
- Osteoporosis
- Rheumatoid arthritis
  - (acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Acidosis
  - Alfalfa (*Medicago sativa*)
  - Anaerovibrio
  - Antibiotics
  - Bacteria (*Eubacteria*)
  - Bacteroides
  - Barley
  - Butyrivibrio
  - Cottonseed meal
  - Drug targeting
  - Gram-positive bacteria (*Firmicutes*)
  - Immune system
  - Ions
  - Megasphaera
  - Peptococcus
  - Propionibacterium
  - Selenomonas
  - Sheep
  - Succinivibrio
  - Succinomonas
  - Swine
  - Vaccines
  - Veillonella
  - pH
    - (agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Bentonite, biological studies
  - Clays, biological studies
  - Enzymes, biological studies
  - Smectite-group minerals
  - Zeolite-group minerals
  - RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
    - (agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Acids, biological studies
  - Cytokines
  - Limestone, biological studies
  - Lipopolysaccharides
  - Polysaccharides, biological studies
  - Tumor necrosis factors
  - RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
    - (agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Antibiotics
  - (aminoglycoside; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Nervous system
  - (amyotrophic lateral sclerosis, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Ionophores
  - (antibiotic; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Glycolipids
  - Glycopeptides
  - Peptides, biological studies
  - Polythiazoles
  - Proteins, general, biological studies
  - Sulfonamides

## Tetracyclines

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibiotic; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

- IT Appendix
  - (appendicitis, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Infection
  - (bacterial, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Fermentation
  - (carbohydrate; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Tooth
  - (caries, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Fatigue, biological
  - (chronic fatigue syndrome, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Intestine, disease
  - (colitis, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Flours and Meals
  - (corn, hind gut fermentable diet containing; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Respiratory tract
  - (disease, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Digestive tract
  - (disease, acidic gut syndrome; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Mammary gland
  - (disease, infection, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Homeostasis
  - Immunity
    - (disorder, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Toxins
  - RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
    - (endotoxins; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Drug delivery systems
  - (enteric-coated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Carbohydrates, biological studies
  - RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
    - (fermentation; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Corn
  - (flour, hind gut fermentable diet containing; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Digestive tract
  - (gastroenteritis, immune condition associated with, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Stress, animal
  - (heat, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Infection
  - (helminth or microbial, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Lung, disease

- (hemorrhage, post-exercise, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Rice (*Oryza sativa*)  
(hind gut fermentable diet containing; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Electrolytes, biological  
(imbalance, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Minerals, biological studies  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(imbalance, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Aerococcus  
Alloicoccus  
Carnobacterium  
Enterococcus  
Lactobacillus  
Lactococcus  
Leuconostoc  
Pediococcus  
Streptococcus  
Streptococcus bovis  
Tetragenococcus  
(immunization against; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Hair  
Wool  
(impaired growth, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Reproductive tract  
(impaired reproductive performance, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Fungi  
Herpesviridae  
Parasitic worm  
Protozoa  
(infection, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Feed  
(intake reduction, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Intestine, disease  
(irritable bowel syndrome, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Antibiotics  
(macrolide; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Enzymes, biological studies  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pectic; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Opioids  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peptide; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Uronic acids  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(polyuronic acids; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Digestive tract  
Digestive tract

- Stomach, disease  
(ulcer, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Intestine, disease  
(ulcerative colitis; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Infection  
(viral, acidic gut syndrome-associated; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Fatty acids, biological studies  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(volatile; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Galactosides  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
( $\alpha$ -galactosides; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT Lactams  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\beta$ -, antibiotics; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT 56-75-7D, Chloramphenicol, derivs. 57-62-5, Chlortetracycline 59-87-0, Nitrofurazone 61-32-5, Methicillin 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 69-53-4, Ampicillin 79-57-2, Oxytetracycline 87-08-1, Penicillin V 114-07-8, Erythromycin 154-21-2, Lincomycin 804-36-4, Nitrovin 1066-17-7, Polymyxin E 1318-00-9, Vermiculite 1318-63-4, Heulandite 1318-74-7, Kaolinite, biological studies 1318-93-0, Montmorillonite, biological studies 1319-41-1, Saponite 1393-48-2, Thiostrepton 1401-69-0, Tylosin 1404-26-8, Polymyxin B 1404-90-6, Vancomycin 1405-89-6, Bacitracin zinc 1406-05-9, Penicillin 1476-53-5, Novobiocin sodium 1695-77-8, Spectinomycin 8025-81-8, Spiramycin 9000-92-4, Amylase 9001-22-3, Emulsin 9001-42-7,  $\alpha$ -Glucosidase 9001-57-4, Invertase 9001-75-6, Pepsin 9001-92-7, Protease 9002-07-7, Trypsin 9002-08-8, Trypsinogen 9004-07-3, Chymotrypsin 9011-97-6, Cholecystokinin 9012-54-8, Cellulase 9015-78-5, Glucanase 9025-35-8,  $\alpha$ -Galactosidase 9032-08-0, Amyloglucosidase 9040-13-5, Virginiamycin M 9074-98-0,  $\beta$ -Glucanase 11006-76-1, Virginiamycin 11006-76-1D, Virginiamycin, M1 fraction analogs 11015-37-5, Flavomycin 11017-43-9, Siomycin 11054-70-9, Lasalocid 11111-12-9, Cephalosporin 11115-82-5, Enramycin 12001-29-5, Chrysotile 12161-84-1, Lizardite 12172-85-9, Beidellite 12173-10-3, Clinoptilolite 12173-60-3, Illite 12174-11-7, Palygorskite 12269-78-2, Pyrophyllite 12298-43-0, Halloysite 12609-84-6, Thiopeptin 12650-69-0, Mupirocin 14807-96-6, Talc, biological studies 16846-24-5, Josamycin 18323-44-9, Clindamycin 23152-29-6, Virginiamycin S1 37244-77-2, Sporangiomyacin 37278-89-0, Xylanase 37332-99-3, Avoparcin 49648-37-5, Fluoramphenicol 51667-26-6D, Oxazolidinone, derivs. 53003-10-4, Salinomycin 53024-98-9D, Everninomycin, derivs. 55134-13-9, Narasin 55297-95-5, Tiamulin 55852-84-1, Bacitracin methylene disalicylate 56377-79-8, Nosiheptide 61036-62-2, Teicoplanin 65454-16-2, Taitomycin 65454-59-3, Sulfomycin 70324-48-0, Bottromycin tartrate 75139-06-9, Tetronasin 79805-24-6,  $\beta$ -Casomorphin 82419-36-1, Ofloxacin 85721-33-1, Ciprofloxacin 100986-85-4, Levofloxacin 105956-97-6, Clinafloxacin 109545-84-8, SCH 27899 110871-86-8, Sparfloxacin 113041-69-3, Magainin 117742-13-9, Ardacin 119914-60-2, Grepafloxacin 126602-89-9, RP 59500 127254-12-0, DU 6859a 147059-72-1, Trovafloxacin 165800-03-3, U-100766 219686-62-1, Thiopeptone 219686-64-3, U 100572  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)
- IT 50-21-5, biological studies 57-13-6, Urea, biological studies 59-23-4, Galactose, biological studies 64-19-7, Acetic acid, biological studies 79-09-4, Propanoic acid, biological studies 79-33-4, biological studies 107-92-6, Butyric acid, biological studies 147-81-9, Arabinose



9005-25-8, Starch, biological studies 9012-72-0, Glucan 9036-66-2, Arabinogalactan 9037-55-2, Galactan 9040-27-1, Arabinoxylan 9041-22-9,  $\beta$ -Glucan 9046-38-2, Galacturonan 9060-75-7, L-Arabinan 10326-41-7, D-Lactic acid, biological studies **11078-30-1**, **Galactomannan** 37294-28-3, Xyloglucan 39280-21-2, Rhamnogalacturonan

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

IT 27194-24-7D, Nitrofurans, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antibiotic; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

IT 187112-48-7, Raftilose

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(hind gut fermentable diet containing; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

IT 80738-43-8, Lincosamide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lincosamide antibiotics; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

IT 9073-60-3, Penicillinase

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(penicillins resistant to; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

IT 512-69-6, Raffinose

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(raffinose-series galactosides; agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

RE. CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Muir; Journal of Animal Science 1980, V50(3), P547 HCAPLUS

(2) Nagaraja; Journal of Animal Science 1981, V53(1), P206 HCAPLUS

(3) Rowe; AU 3228489 B 1989

(4) Rowe; AU 4324596 A 1996

IT **11111-12-9, Cephalosporin**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

RN 11111-12-9 HCAPLUS

CN Cephalosporin (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT **11078-30-1, Galactomannan**

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(agent controlling acid and endotoxin accumulation in GI tract for acidic gut syndrome control)

RN 11078-30-1 HCAPLUS

CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L44 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

AN **1998:742255** HCAPLUS

DN 130:17234

ED Entered STN: 23 Nov 1998

TI Preparation of microsphere drug delivery systems

IN Wu, Xiao Yu; Liu, Zhi

PA Can.

SO PCT Int. Appl., 47 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-16  
 ICS A61K047-48; A61K045-06; A61K031-475; A61K031-27  
 CC 63-6 (Pharmaceuticals)  
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850018	A1	19981112	WO 1998-CA419	19980506
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2288876	AA	19981112	CA 1998-2288876	19980506
	AU 9872019	A1	19981127	AU 1998-72019	19980506
PRAI	US 1997-45710P	P	19970506		
	WO 1998-CA419	W	19980506		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9850018	ICM	A61K009-16
	ICS	A61K047-48; A61K045-06; A61K031-475; A61K031-27
WO 9850018	ECLA	A61K009/16H6B; A61K009/16H6F; A61K009/16K; A61K031/475+M; A61K045/06; A61K047/48W8

AB A drug delivery composition comprising microspheres containing at least one chemotherapeutic agent and at least 1 chemosensitizer wherein the microspheres have a biodegradable polymer matrix with functional groups which associate with the chemotherapeutic agent and chemosensitizer is described. Carboxymethyl dextran microspheres were prepared and mixed with 1% verapamil or doxorubicin aqueous solution. The microspheres showed sustained drug release.

ST microsphere drug delivery system polymer

IT Calmodulins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (antagonists; preparation of polymeric microsphere drug delivery systems)

IT Polymers, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (biodegradable; preparation of polymeric microsphere drug delivery systems)

IT Ion channel blockers

(calcium; preparation of polymeric microsphere drug delivery systems)

IT Polyesters, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (caprolactone-based; preparation of polymeric microsphere drug delivery systems)

IT Polyesters, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydroxycarboxylic acid-based; preparation of polymeric microsphere drug delivery systems)

IT Alkaloids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (indole; preparation of polymeric microsphere drug delivery systems)

IT Polyesters, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lactic acid-based; preparation of polymeric microsphere drug delivery systems)

IT Drug delivery systems

(microspheres, sustained-release; preparation of polymeric microsphere drug delivery systems)

IT Polyethers, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ortho ester group-containing; preparation of polymeric microsphere drug delivery systems)

IT Antibiotics

Antitumor agents

- Ion exchangers  
(preparation of polymeric microsphere drug delivery systems)
- IT Albumins, biological studies  
Alkaloids, biological studies  
Glycosaminoglycans, biological studies  
Hormones, animal, biological studies  
Peptidoglycans  
Polyamides, biological studies  
Polyanhydrides  
Polyesters, biological studies  
Polysaccharides, biological studies  
Polyurethanes, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of polymeric microsphere drug delivery systems)
- IT 216099-82-0P  
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of polymeric microsphere drug delivery systems)
- IT 216099-81-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
USES (Uses)  
(preparation of polymeric microsphere drug delivery systems)
- IT 9005-80-5, Inulin  
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT  
(Reactant or reagent); USES (Uses)  
(preparation of polymeric microsphere drug delivery systems)
- IT 9044-05-7P, Carboxymethyl dextran  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological  
study); PREP (Preparation); USES (Uses)  
(preparation of polymeric microsphere drug delivery systems)
- IT 50-07-7, Mitomycin C 50-53-3, Chlorpromazine, biological studies  
52-53-9, Verapamil 56-54-2, Quinidine 57-22-7, Vincristine 83-89-6,  
Quinacrine 117-89-5, Trifluoperazine 130-95-0, Quinine 865-21-4,  
Vinblastine 1398-61-4, Chitin 9000-07-1D, Carrageenan, analogs  
9000-65-1, Tragacanth gum 9000-69-5D, Pectinic acid, analogs  
9002-18-0, Agar 9004-34-6, Cellulose, biological studies 9004-54-0,  
Dextran, biological studies 9004-61-9, Hyaluronic acid 9005-25-8,  
Starch, biological studies 9005-32-7, Alginic acid 9005-32-7D, Alginic  
acid, analogs 9005-49-6, Heparin, biological studies 9005-79-2,  
Glycogen, biological studies 9007-28-7D, Chondroitin sulfate, analogs  
9012-36-6, Agarose 9012-72-0D, Glucan, analogs 9014-63-5D, Xylan,  
analog 9036-66-2D, Arabinogalactan, analogs 9036-88-8D, Mannan,  
analog 9037-55-2D, Galactan, analogs 9037-90-5D, Fructan, analogs  
**9040-29-3D**, GalactoGlucomannan, analogs 9041-38-7D, Teichoic  
acid, analogs 9046-38-2D, Galacturonan, analogs 9046-40-6D, Pectic  
acid, analogs 9056-36-4, Keratan sulfate 10540-29-1, Tamoxifen  
11078-27-6D, Arabinan, analogs **11078-30-1D**,  
**Galactomannan**, analogs 11078-31-2D, Glucomannan, analogs  
11138-66-2, Xanthan gum 15802-18-3D, 2-Cyanoacrylic acid, alkyl esters,  
polymers 20830-81-3, Daunorubicin 21829-25-4, Nifedipine 23214-92-8,  
Doxorubicin 24937-72-2, Poly(maleic anhydride) 24967-94-0, Dermatan  
sulfate 24980-41-4, Poly( $\epsilon$ -caprolactone) 25086-15-1,  
Methacrylic acid-methyl methacrylate copolymer 25248-42-4,  
Poly[oxy(1-oxo-1,6-hexanediyl)] 26009-03-0, Poly(Glycolic acid)  
26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6,  
Poly(lactic acid) 26124-68-5, Poly(Glycolic acid) 26700-71-0D,  
Poly(L-glutamine), hydroxyalkyl derivs. 28728-97-4, Poly(hydroxybutyric  
acid), SRU 29323-51-1 34346-01-5, Glycolic acid-lactic acid copolymer  
37294-28-3D, Xyloglucan, analogs 42399-41-7, Diltiazem 52352-27-9,  
Poly(hydroxybutyric acid) 55985-32-5, Nicardipine **62893-19-0**,  
Cefoperazone 72509-76-3, Felodipine **73384-59-5**, Ceftriaxone  
80137-67-3,  $\epsilon$ -Caprolactone-lactic acid copolymer 128171-16-4,  
Hydroxybutyric acid-hydroxyvaleric acid copolymer 138735-56-5  
176442-72-1  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of polymeric microsphere drug delivery systems)

RE. CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


(1) Behringwerke Ag; EP 0595133 A 1994 HCAPLUS

(2) Biovecteurs As; FR 2702160 A 1994 HCAPLUS  
 (3) John, K; WO 9709036 A 1997 HCAPLUS  
 (4) Patrinove; CH 681780 A 1993 HCAPLUS  
 (5) Rene, F; US 4666641 A 1987 HCAPLUS  
 (6) Rolf, K; US 5057304 A 1991 HCAPLUS  
 (7) Univ Texas; WO 9402106 A 1994 HCAPLUS  
 IT 9040-29-3D, GalactoGlucomannan, analogs 11078-30-1D,  
 Galactomannan, analogs 62893-19-0, Cefoperazone  
 73384-59-5, Ceftriaxone  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of polymeric microsphere drug delivery systems)  
 RN 9040-29-3 HCAPLUS  
 CN D-Galacto-D-gluco-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 RN 11078-30-1 HCAPLUS  
 CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 RN 62893-19-0 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-[[[4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-  
 hydroxyphenyl)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-  
 oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 73384-59-5 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2Z)-[2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-  
 [[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-,  
 (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



L44 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1998:580026 HCAPLUS  
 DN 129:207213  
 ED Entered STN: 11 Sep 1998  
 TI Combination agent for oral administration of antibiotics  
 IN Posanski, Ulrich  
 PA Germany  
 SO Ger. Offen., 4 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 IC ICM A61K031-43  
 ICS A61K031-70; A61K031-495  
 ICI A61K031-43, A61K031-70, A61K031-495  
 CC 63-6 (Pharmaceuticals)  
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19706978	A1	19980827	DE 1997-19706978	19970221
	WO 9836732	A2	19980827	WO 1998-EP29	19980105
	WO 9836732	A3	19981022		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9860926	A1	19980909	AU 1998-60926	19980105
	EP 971691	A2	20000119	EP 1998-905269	19980105
	R:	AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL			
PRAI	DE 1997-19706978	A	19970221		
	WO 1998-EP29	W	19980105		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

DE 19706978	ICM	A61K031-43
	ICS	A61K031-70; A61K031-495
	ICI	A61K031-43, A61K031-70, A61K031-495
WO 9836732	ECLA	A61K009/00N2; A61K031/43+M; A61K031/70R5L

AB An aqueous suspension for oral administration of antibiotics comprises (a) antibiotic-containing particles with a polymeric, cationic, permeable, swellable and/or gastric juice-soluble coating and (b) a syrup base with pH 5-10; the 2 components are packaged sep. and combined immediately before administering the 1st dose to improve the stability of the composition during storage. The particle coating masks the bitter flavor of the antibiotic for pediatric use. Thus, a mixture of amoxicillin-3H<sub>2</sub>O 62.5, K clavulanate 32.813, and Avicel PH 101 15.0 kg was spray-coated with 150 kg 15 weight% Eudragit E solution in iso-PrOH-Me<sub>2</sub>CO (80:20) in an N<sub>2</sub> atmospheric, sieved, dried, mixed with 5.5 kg Syloid 244 FP, and dispensed in 11.065-g portions into sachets. A syrup base was prepared by dissolving Na saccharin 3, NaH<sub>2</sub>PO<sub>4</sub> 50, and Na<sub>2</sub>HPO<sub>4</sub> 950 g in 70 kg Karion FP at 40°, adjusting the pH to 7.2, adding 5 g raspberry flavoring, and dispensing into screw-capped brown glass bottles.

ST antibiotic coated particle oral syrup

IT Antibiotics

(combination agent for oral administration of antibiotics)

IT **Polymers, biological studies**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (films, permeable, **swellable**; combination agent for oral administration of antibiotics)

IT Drug delivery systems

(particles, coated; combination agent for oral administration of antibiotics)


IT Films

(polymeric, permeable, swellable; combination agent for oral administration of antibiotics)

IT Drug delivery systems


- (syrups; combination agent for oral administration of antibiotics)
- IT 79-10-7D, 2-Propenoic acid, polymers, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (coatings; combination agent for oral administration of antibiotics)
- IT 69-53-4, Ampicillin 132-98-9, Phenoxymethylpenicillin potassium 985-16-0, Sodium nafcillin 1245-44-9, Propicillin potassium 1405-10-3, Neomycin sulfate 3116-76-5, Dicloxacillin **15686-71-2**, Cephalixin 26787-78-0, Amoxicillin 28657-80-9, Cinoxacin **50370-12-2**, Cefadroxil 50972-17-3, Bacampicillin 51940-44-4, Pipemidic acid **53994-73-3**, Cefaclor **55268-75-2**, Cefuroxime 61177-45-5, Potassium clavulanate 61336-70-7, Amoxicillin trihydrate 70458-96-7, Norfloxacin 74011-58-8, Enoxacin 76470-66-1, Loracarbef 79198-29-1, Amoxicillin-clavulanic acid mixture **79350-37-1**, Cefixime 79660-72-3, Fleroxacin 80210-62-4, Cefpodoxime 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin 87239-81-4, Cefpodoxime-proxetil 92665-29-7, Cefprozil 98079-51-7, Lomefloxacin 147059-72-1, Trovafloxacin
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (combination agent for oral administration of antibiotics)
- IT 79-10-7D, 2-Propenoic acid, alkyl esters, polymers with methacrylic acid (esters), biological studies 79-41-4D, alkyl esters, polymers with acrylic acid (esters) 9003-21-8, Poly(methyl acrylate) 9003-32-1, Poly(ethyl acrylate) 9011-87-4, Methyl acrylate/methyl methacrylate copolymer 24938-16-7, Eudragit E 25751-21-7, Acrylic acid/methacrylic acid copolymer 56399-02-1, Ethyl acrylate/ethyl methacrylate copolymer 107500-57-2 211863-54-6 212058-93-0, Karion FP
- RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (combination agent for oral administration of antibiotics)
- IT **15686-71-2**, Cephalixin **50370-12-2**, Cefadroxil **53994-73-3**, Cefaclor **55268-75-2**, Cefuroxime **79350-37-1**, Cefixime
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (combination agent for oral administration of antibiotics)
- RN 15686-71-2 HCAPLUS
- CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[{(2R)-aminophenylacetyl]amino]-3-methyl-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 50370-12-2 HCAPLUS
- CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[{(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53994-73-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R, 7R)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 55268-75-2 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amin  
o]-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 79350-37-1 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2Z)-(2-amino-4-thiazolyl)[(carboxymethoxy)imino]acetyl]amino]-3-  
ethenyl-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L44 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:123996 HCAPLUS

DN 128:184696

ED Entered STN: 28 Feb 1998

TI Easy to swallow oral medicament composition

IN Gruber, Peter

PA Losan Pharma G.m.b.H., Germany; Gruber, Peter

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM A61K009-50

ICS A61K009-54

CC 63-6 (Pharmaceuticals)

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9806385	A1	19980219	WO 1997-CH299	19970814
	W: AU, BG, BR, CA, CN, CZ, HU, JP, NO, PL, RO, RU, SI, SK, TR, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2262595	AA	19980219	CA 1997-2262595	19970814
	AU 9736912	A1	19980306	AU 1997-36912	19970814
	EP 918513	A1	19990602	EP 1997-933611	19970814
	EP 918513	B1	20001206		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2000516222	T2	20001205	JP 1998-509262	19970814
	AT 197900	E	20001215	AT 1997-933611	19970814
	US 2002068088	A1	20020606	US 1999-242167	19990210
	US 6709678	B2	20040323		
	US 2004247675	A1	20041209	US 2003-706128	20031112
PRAI	CH 1996-2006	A	19960815		
	WO 1997-CH299	W	19970814		
	US 1999-242167	A1	19990210		

#### CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 9806385	ICM	A61K009-50
	ICS	A61K009-54
WO 9806385	ECLA	A61K009/00M18B; A61K009/00N2; A61K009/50K
US 2002068088	ECLA	A61K009/00M18B; A61K009/00N2; A61K009/50K
US 2004247675	ECLA	A61K009/00M18B; A61K009/00N2; A61K009/50K

AB An easy-to-swallow pharmaceutical composition consists of  $\geq 1$  coated particles with a core which contains an active substance and a coat with  $\geq 1$  layers. The coating layer(s) contains  $\geq 1$  hydratable, pharmaceutically acceptable polymer which, on contact with saliva or water, forms a coherent, moldable, viscous mass with a slippery surface which does not adhere to the mucous membranes of the mouth, and which prevents the active substance-containing particles from leaving the mass and releasing the active substance in the mouth cavity. The (outermost) coating layer contains  $\geq 1$  salivation-promoting agent. The properties of the coating make the composition suitable for administering highly dosed or bad-tasting active substances and even for swallowing



- without any liquid. Thus, a solution of ciprofloxacin 2000, Crospovidone XL-M 110, PVP K90 60, water 900, and EtOH 1800 g was spray-coated onto sucrose crystals 0.3-0.6 mm in diameter to produce core particles, which were then coated first with a powdered mixture of NaCl 50, Na saccharin 50, and Na carboxymethylstarch 50 g, and finally [after moistening with EtOH-H<sub>2</sub>O (1:1)] with a powdered mixture of Na CM-cellulose 275 and talc 75 g.
- ST oral pharmaceutical swallowing polymer coating; polysaccharide coating  
oral pharmaceutical swallowing
- IT Gelatins, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coatings, hydration of; easy-to-swallow oral medicament composition)
- IT Polymers, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coatings; easy-to-swallow oral medicament composition)
- IT Osmolytes  
(easy-to-swallow oral medicament composition)
- IT Carboxylic acids, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(easy-to-swallow oral medicament composition)
- IT Hydration, chemical  
(of polymer coating; easy-to-swallow oral medicament composition)
- IT Drug delivery systems  
Drug delivery systems  
(oral, controlled-release; easy-to-swallow oral medicament composition)
- IT Drug delivery systems  
Drug delivery systems  
(pellets, controlled-release; easy-to-swallow oral medicament composition)
- IT Saliva  
(polymer coating hydration by; easy-to-swallow oral medicament composition)
- IT Coating materials  
(polymers; easy-to-swallow oral medicament composition)
- IT Drug delivery systems  
(tablets, controlled-release; easy-to-swallow oral medicament composition)
- IT 9000-01-5, Gum arabic 9000-30-0, Guar gum 9000-69-5, Pectin 9003-01-4, Polyacrylic acid 9003-39-8, PVP 9004-32-4, Sodium CM-cellulose 9004-62-0, Hydroxyethylcellulose 9004-64-2, Hydroxypropylcellulose 9004-65-3, Hydroxypropylmethylcellulose 9004-67-5, Methylcellulose 9005-32-7, Alginic acid **11078-30-1**, **Galactomannan** 11138-66-2, Xanthan 39421-75-5, Hydroxypropyl guar gum  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coating, hydration of; easy-to-swallow oral medicament composition)
- IT 79-10-7D, Acrylic acid, esters, polymers 9005-32-7D, Alginic acid, salts  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coatings, hydration of; easy-to-swallow oral medicament composition)
- IT 50-48-6, Amitriptyline 50-78-2, Acetylsalicylic acid 52-53-9, Verapamil 57-27-2, Morphine, biological studies 58-55-9, Theophylline, biological studies 60-54-8, Tetracycline 89-57-6, Mesalazine 103-90-2, Paracetamol 114-07-8, Erythromycin 146-22-5, Nitrazepam 603-50-9, Bisacodyl 616-91-1, N-Acetyl-L-cysteine 4618-18-2, Lactulose 8049-47-6, Pancreatin 15307-86-5, Diclofenac 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7, Isosorbide mononitrate 18683-91-5, Ambroxol 21829-25-4, Nifedipine 22204-53-1, Naproxen 26787-78-0, Amoxicillin 27203-92-5, Tramadol 29122-68-7, Atenolol 36322-90-4, Piroxicam 42399-41-7, Diltiazem **50370-12-2**, Cefadroxil 50679-08-8, Terfenadine 51333-22-3, Budesonide 51481-61-9, Cimetidine 53179-11-6, Loperamide **53994-73-3**, Cefaclor 54182-58-0, Sucralfate 66357-35-5, Ranitidine 68844-77-9, Astemizole 70458-96-7, Norfloxacin 73590-58-6, Omeprazole 76824-35-6, Famotidine 76963-41-2, Nizatidine 82419-36-1, Ofloxacin 85721-33-1, Ciprofloxacin 93107-08-5, Ciprofloxacin hydrochloride 102625-70-7, Pantoprazole  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(easy-to-swallow oral medicament composition)
- IT 50-70-4, Sorbitol, biological studies 50-81-7, L-Ascorbic acid, biological studies 50-99-7, D-Glucose, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, Sucrose, biological studies 69-65-8, D-Mannitol 77-92-9, Citric acid, biological studies 87-69-4, Tartaric acid, biological studies 87-99-0, Xylitol 124-04-9, Adipic

acid, biological studies 134-03-2, Sodium ascorbate 585-09-1, Potassium malate 585-88-6, Maltitol 676-46-0, Sodium malate 994-36-5 6915-15-7, Malic acid 7647-14-5, Sodium chloride, biological studies 7778-49-6 9004-34-6D, Cellulose, ethers, biological studies 9063-38-1, Sodium carboxymethylstarch 14475-11-7, biological studies 15421-15-5, Potassium ascorbate 18996-35-5, Monosodium citrate 40968-90-9, Potassium tartrate, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses).

(easy-to-swallow oral medicament composition)

IT 9004-34-6, Cellulose, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(microcryst.; easy-to-swallow oral medicament composition)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Benzon Pharma AS; US 5288500 A 1988 HCAPLUS

(2) Benzon Pharma AS; WO 8806893 A 1988 HCAPLUS

(3) Ko; WO 9301800 A 1993 HCAPLUS

(4) Rhodia Farma Ltda; BR 9403617 A 1996 HCAPLUS

(5) Showa Yakuhin Kako Co Ltd; EP 0662320 A 1995 HCAPLUS

(6) Zyma Sa; EP 0281513 A 1988 HCAPLUS

(7) Zyma Sa; US 4882169 A 1988 HCAPLUS

IT 11078-30-1, Galactomannan

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coating, hydration of; easy-to-swallow oral medicament composition)

RN 11078-30-1 HCAPLUS

CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 50370-12-2, Cefadroxil 53994-73-3, Cefaclor


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(easy-to-swallow oral medicament composition)

RN 50370-12-2 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 53994-73-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R, 7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L44 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1996:544057 HCAPLUS

Search done by Noble Jarrell

DN 125:185914  
 ED Entered STN: 12 Sep 1996  
 TI Prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals  
 IN Rowe, James Baber  
 PA Australia  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-445  
 ICS A61K031-71; A61K033-06; A61K038-43; A61K038-46; A61K038-47  
 CC 1-12 (Pharmacology)  
 Section cross-reference(s): 17, 63

FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9620709	A1	19960711	WO 1995-AU884	19951229
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2208986	AA	19960711	CA 1995-2208986	19951229
AU 9643245	A1	19960724	AU 1996-43245	19951229
AU 698600	B2	19981105		
EP 800394	A1	19971015	EP 1995-942004	19951229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
NZ 297961	A	20000526	NZ 1995-297961	19951229
US 5985891	A	19991116	US 1997-860562	19970829
PRAI AU 1994-338	A	19941229		
WO 1995-AU884	W	19951229		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9620709	ICM	A61K031-445
	ICS	A61K031-71; A61K033-06; A61K038-43; A61K038-46; A61K038-47
WO 9620709	ECLA	A61K031/00+A; A61K031/424; A61K031/444; A61K038/46+M; A61K045/06
US 5985891	ECLA	A61K031/00+A; A61K031/424; A61K031/444; A61K038/46+M; A61K045/06

AB This invention relates to a method for the treatment or prophylaxis of adverse behavior, diarrhea, a skin disorder or an infection of the hind gut resulting from the accumulation of acid in the gastrointestinal tract of a human or an animal, said accumulation resulting from the fermentation of carbohydrate in the gastrointestinal tract of said human or animal, which method comprises administering to said human or animal an effective amount of an agent capable of preventing or controlling fermentative acidosis in the gastrointestinal tract.

ST antidiarrheal digestive tract disorder behavior therapy

IT Cereal

Hay

(digestion of; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)

IT Galactosides

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(enzymes degrading; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)

IT Carbohydrates and Sugars, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(fermentation of; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)

- IT Diarrhea  
(inhibitors; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Fermentation  
(of carbohydrates; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Swine  
(piglets; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Barley  
Canis familiaris  
Chicken  
Coprophagy  
Feeding experiment  
Horse  
Hyperkinesia  
Mental disorder  
Psoriasis  
Serpulina hyodysenteriae  
Sheep  
Skin, disease  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Polysaccharides, biological studies  
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Clays, biological studies  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Antibiotics  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Bentonite, biological studies  
Zeolite-group minerals  
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Sulfonamides  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Dysentery  
(swine; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Antibiotics  
(aminoglycoside, prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Mental disorder  
(attention deficit, prevention of adverse behavior, diarrhea, skin

- disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Intestine  
(cecum, prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Digestive tract  
(disease, prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Digestive tract  
(disease, indigestion, acid accumulation in; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Behavior  
(disorder, prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Bacteria  
(gram-pos., prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Digestive tract  
(hindgut, disorders; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Bacteria  
(intestinal, lactic acid production by; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Intestine, disease  
(large, irritable bowel disease; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT Pharmaceutical dosage forms  
(oral, prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT 50-21-5, Lactic acid, biological studies  
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)  
(bacterial production of; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT 512-69-6 9000-69-5, Pectins 9037-55-2, Galactan 9046-38-2, Galacturonan 9060-75-7, L-Arabinan **11078-30-1**, **Galactomannan** 37294-28-3, Xyloglucan 39280-21-2, Rhamnogalacturonan  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(enzymes degrading; prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT 9040-13-5, Virginiamycin m  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT 1318-74-7, Kaolinite, biological studies 1318-93-0, Montmorillonite  
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(prevention of adverse behavior, diarrhea, skin disorders and infections of the hind gut associated with acidic conditions in humans and animals)
- IT 60-54-8, Tetracycline 114-07-8, Erythromycin 804-36-4, Nitrovin 1393-48-2, Thiostrepton 1393-68-6, Botromycin 1405-89-6, Bacitracin zinc 1406-05-9D, Penicillin, derivs. 1476-53-5, Novobiocin sodium 1695-77-8, Spectinomycin 9000-92-4, Amylase 9001-22-3, Emulsin

9001-42-7, Maltase 9001-57-4, Invertase 9015-78-5, Glucanase  
 9025-35-8,  $\alpha$ -Galactosidase 9032-08-0, Amyloglucosidase  
 9074-98-0,  $\beta$ -Glucanase 11006-76-1, Streptogramin 11015-37-5,  
 Flavomycin 11017-43-9, Siomycin 11054-70-9, Lasalocid  
**11111-12-9D, Cephalosporin, derivs.**  
 11115-82-5, Enramycin 12609-84-6, Thiopeptin 13721-01-2D, derivs.  
 37244-77-2, Sporangiomycin 37278-89-0, Xylanase 37332-99-3, Avoparcin  
 53003-10-4, Salinomycin 55134-13-9, Narasin 55297-95-5, Tiamulin  
 55852-84-1, Bacitracin methylene disalicylate 65454-16-2, Taitomycin  
 65454-59-3, Sulfomycin 75139-06-9, Tetronasin 80738-43-8, Lincosamide  
 117742-13-9, Ardacin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (prevention of adverse behavior, diarrhea, skin disorders and  
 infections of the hind gut associated with acidic conditions in humans and  
 animals)

IT **11078-30-1, Galactomannan**

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (enzymes degrading; prevention of adverse behavior, diarrhea, skin  
 disorders and infections of the hind gut associated with acidic conditions  
 in humans and animals)

RN 11078-30-1 HCAPLUS

CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT **11111-12-9D, Cephalosporin, derivs.**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (prevention of adverse behavior, diarrhea, skin disorders and  
 infections of the hind gut associated with acidic conditions in humans and  
 animals)

RN 11111-12-9 HCAPLUS

CN Cephalosporin (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L44 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:842635 HCAPLUS

DN 123:237834

ED Entered STN: 10 Oct 1995

TI Transdermal patch for release of active agents from hot-melt adhesives

IN Hoffmann, Hans-Rainer; Roreger, Michael

PA ITs Lohmann Therapie-Systeme GmbH und Co. KG, Germany

SO Ger., 14 pp.

CODEN: GWXXAW

DT Patent

LA German

IC ICM A61L015-44

ICS C09J011-00; C09J007-02; A61K009-70; A01N025-34

ICI C09J011-00, C09J189-04, C09J171-02, C09J139-06, C09J129-04, C09J105-00,  
 C09J103-00, C09J101-08

CC 63-6 (Pharmaceuticals)

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4416927	C1	19950831	DE 1994-4416927	19940513
	IL 113611	A1	20000831	IL 1995-113611	19950503
	CA 2189996	AA	19951123	CA 1995-2189996	19950508
	WO 9531188	A1	19951123	WO 1995-EP1724	19950508
	W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, SI, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9526127	A1	19951205	AU 1995-26127	19950508
	AU 702502	B2	19990225		
	EP 758885	A1	19970226	EP 1995-920804	19950508
	EP 758885	B1	20001206		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	HU 75288	A2	19970528	HU 1996-3119	19950508
	JP 10500117	T2	19980106	JP 1995-529326	19950508
	AT 197901	E	20001215	AT 1995-920804	19950508
	ES 2154337	T3	20010401	ES 1995-920804	19950508
	ZA 9503894	A	19960307	ZA 1995-3894	19950512
	FI 9604534	A	19961112	FI 1996-4534	19961112

NO 9604799	A	19961112	NO 1996-4799	19961112
US 6190689	B1	20010220	US 1996-737224	19961113
GR 3035478	T3	20010531	GR 2001-400320	20010228
PRAI DE 1994-4416927	A	19940513		
WO 1995-EP1724	W	19950508		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 4416927	ICM	A61L015-44
	ICS	C09J011-00; C09J007-02; A61K009-70; A01N025-34
	ICI	C09J011-00, C09J189-04, C09J171-02, C09J139-06, C09J129-04, C09J105-00, C09J103-00, C09J101-08
DE 4416927	ECLA	A01N025/24; A61K009/70E; A61L015/44; A61L015/58; C09J011/00
WO 9531188	ECLA	A01N025/24; A61K009/70E; A61L015/44; A61L015/58; C09J011/00
US 6190689	ECLA	A01N025/24; A61K009/70E; A61L015/44; A61L015/58; C09J011/00

AB A device for release of active agents from a hot-melt adhesive, with uniform or nonuniform distribution of the agent in the adhesive, comprises a hydrophilic adhesive containing  $\geq 1$  water-soluble or water-swellaable polymer [e.g. gelatin, Na alginate, pectin, starch (derivative), PVP, PEG],  $\geq 1$  water-soluble, fusible adhesive resin [e.g. pantothenol, honey, low-mol.-weight sugar (derivative)], and the active agent. The processing temperature for the adhesive is 40-150°, preferably 80-120°. Thus, a melt containing hydroabietyl alc. 25, ethylene/vinyl acetate (72:28) copolymer 10, C4-5 polyalkadiene 10, and acetylsalicylic acid 10 parts was prepared at 120°, cooled to 90°, mixed with a melt containing pantothenol 25, Na alginate 10, and gelatin 10 parts, and spread on siliconized paper composite to a thickness of 300 g/m<sup>2</sup>.

ST transdermal patch hot melt adhesive

IT Resins

RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adhesive; transdermal patch for release of active agents from hot-melt adhesives)

IT Chamomile

Valerian

(extract; transdermal patch for release of active agents from hot-melt adhesives)

IT Plant

(exts.; transdermal patch for release of active agents from hot-melt adhesives)

IT Steroids, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hormones; transdermal patch for release of active agents from hot-melt adhesives)

IT Tobacco

(powdered; transdermal patch for release of active agents from hot-melt adhesives)

IT Arnica

Marigold

St.-John's-wort

(tincture; transdermal patch for release of active agents from hot-melt adhesives)

IT Cosmetics

Echinacea angustifolia

Fucus vesiculosus

Honey

Hop

Veterinary medicine

Wound healing promoters

(transdermal patch for release of active agents from hot-melt adhesives)

IT Chlorophylls, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

- (transdermal patch for release of active agents from hot-melt adhesives)
- IT Carbohydrates and Sugars, biological studies  
Collagens, biological studies  
Gelatins, biological studies  
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(transdermal patch for release of active agents from hot-melt adhesives)
- IT **Polymers, biological studies**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(water-soluble/-swellable; transdermal patch for release of active agents from hot-melt adhesives)
- IT Essential oils  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chamomile, German, transdermal patch for release of active agents from hot-melt adhesives)
- IT Essential oils  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(eucalyptus, transdermal patch for release of active agents from hot-melt adhesives)
- IT Tea products  
(green, transdermal patch for release of active agents from hot-melt adhesives)
- IT Adhesives  
(hot-melt, transdermal patch for release of active agents from hot-melt adhesives)
- IT Essential oils  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pine leaf, transdermal patch for release of active agents from hot-melt adhesives)
- IT Alkadienes  
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polymers, transdermal patch for release of active agents from hot-melt adhesives)
- IT Pharmaceutical dosage forms  
(transdermal, transdermal patch for release of active agents from hot-melt adhesives)
- IT 50-28-2, Estradiol, biological studies 50-78-2, Acetylsalicylic acid 69-72-7, Salicylic acid, biological studies 137-58-6D, Lidocaine, eutectic with prilocaine 721-50-6D, Prilocaine, eutectic with lidocaine 1406-18-4, Vitamin E 18472-51-0, Chlorhexidine digluconate  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(transdermal patch for release of active agents from hot-melt adhesives)
- IT 50-99-7, Glucose, biological studies 56-81-5, Glycerin, biological studies 57-48-7, D-Fructose, biological studies 57-50-1, Sucrose, biological studies 81-13-0, Pantothenol 126-13-6, Sucrose acetate isobutyrate 9000-07-1, Carrageenan 9000-69-5, Pectin 9002-89-5, Poly(vinyl alcohol) 9003-39-8, PVP 9004-32-4, Sodium CM-cellulose 9004-34-6D, Cellulose, derivs. 9004-57-3, Ethylcellulose 9005-25-8, Starch, biological studies 9005-25-8D, Starch, derivs. 9005-38-3, Sodium alginate 9063-38-1, Sodium carboxymethylstarch 11078-30-1, Galactomannan 11078-30-1D, Galactomannan, derivs. 11138-66-2, Xanthan 24937-78-8, Ethylene/vinyl acetate copolymer 25086-89-9, Vinylpyrrolidone/vinyl acetate copolymer 25322-68-3, PEG 25322-69-4, Polypropylene glycol 26266-77-3, Dihydroabietyl alcohol  
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(transdermal patch for release of active agents from hot-melt



adhesives)  
 IT 11078-30-1, Galactomannan 11078-30-1D,  
 Galactomannan, derivs.  
 RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (transdermal patch for release of active agents from hot-melt adhesives)  
 RN 11078-30-1 HCAPLUS  
 CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

RN 11078-30-1 HCAPLUS  
 CN D-Galacto-D-mannan (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L44 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1977:411647 HCAPLUS  
 DN 87:11647  
 ED Entered STN: 12 May 1984  
 TI Controlled release tablets  
 IN Walton, Richard Wiegmann; De Lorimier, Albert Emmanuel  
 PA E. R. Squibb and Sons, Inc., USA  
 SO Ger. Offen., 19 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 IC A61K009-26  
 CC 63-6 (Pharmaceuticals)  
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2645547	A1	19770414	DE 1976-2645547	19761008
	GB 1568837	A	19800604	GB 1976-41121	19761004
	CA 1097220	A1	19810310	CA 1976-262583	19761004
	AU 516051	B2	19810514	AU 1976-18446	19761007
	BE 847095	A1	19770131	BE 1976-171358	19761008
	DK 7604548	A	19770411	DK 1976-4548	19761008
	SE 7611241	A	19770411	SE 1976-11241	19761008
	SE 435569	B	19841008		
	SE 435569	C	19850117		
	NL 7611148	A	19770413	NL 1976-11148	19761008
	NO 7603450	A	19770413	NO 1976-3450	19761008
	FR 2326933	A1	19770506	FR 1976-30362	19761008
	FR 2326933	B1	19790302		
	CH 616843	A	19800430	CH 1976-12758	19761008
	HU 175540	P	19800828	HU 1976-SU927	19761008
	JP 52064420	A2	19770527	JP 1976-121755	19761009
PRAI	US 1975-621316	A	19751010		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
DE 2645547	IC	A61K009-26

AB Controlled release tablets comprise a matrix of a drug dispersed in a mixture of polyvinylpyrrolidone (PVP) [9003-39-8] and a hydrophilic carboxy group-containing vinyl polymer coated with an H2O-insol., H2O-permeable mixture of a moderately H2O-soluble hydrophobic polymer and an H2O-soluble hydrophilic polymer. The coating breaks open when the matrix swells. For example, 790 mg tablets were compressed from a mixture of procaineamide-HCl [614-39-1] 500, PVP 144, carbopol 934 [9007-16-3] 96, microcryst. cellulose 23.4, powdered carnauba wax 15.6, stearic acid 7.8, and silicic acid 3.95 g. The tablets were coated with a 0.09-0.1 mm layer of a mixture of hydroxypropyl methyl cellulose [9004-65-3] 30, ethyl cellulose [9004-57-3] 20 and triethyl citrate 2 g/L, 284.4 mL 99% iso-PrOH and 664 mL CH2Cl2. In H2O at 37°, the tablets released 14.6, 20.1, 13.3, 20.0, 1.5, and 2.1% of the initial drug content during h 1, 2, 3, 4, 5 and 8, resp., compared to 40.0, 11.8, 14.4, 9.8, 3.6 and 0% from uncoated tablets.

ST tablet controlled release; procainamide controlled release tablet; cephradrin controlled release tablet

IT Tablets  
 (controlled-release, vinyl polymers in)  
 IT 614-39-1 **38821-53-3**  
 RL: BIOL (Biological study)  
 (controlled-release tablet)  
 IT 9004-57-3 9004-65-3 9050-31-1  
 RL: BIOL (Biological study)  
 (in controlled release tablet coating)  
 IT 9003-39-8 9007-16-3  
 RL: BIOL (Biological study)  
 (in controlled-release tablet matrix)  
 IT **38821-53-3**  
 RL: BIOL (Biological study)  
 (controlled-release tablet)  
 RN 38821-53-3 HCAPLUS  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-amino-1,4-cyclohexadien-1-ylacetyl]amino]-3-methyl-8-oxo-,  
 (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> b home  
 FILE 'HOME' ENTERED AT 16:31:22 ON 15 APR 2005

=> b reg  
 FILE 'REGISTRY' ENTERED AT 08:03:24 ON 19 APR 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2005 HIGHEST RN 848724-42-5  
 DICTIONARY FILE UPDATES: 18 APR 2005 HIGHEST RN 848724-42-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

\*\*\*\*\*  
 \*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERL, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*  
 \*\*\*\*\*


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
 information enter HELP PROP at an arrow prompt in the file or refer  
 to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d ide l29 tot

L29 ANSWER 1 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 770660-21-4 REGISTRY  
 ED Entered STN: 27 Oct 2004  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
 [6R-(6 $\alpha$ , 7 $\beta$ )]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C13 H13 N5 O5 S2  
 CI COM  
 SR CA

Absolute stereochemistry.  
 Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L29 ANSWER 2 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

Search done by Noble Jarrell


RN 746546-33-8 REGISTRY  
 ED Entered STN: 17 Sep 2004  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[4-(pyridinylthio)acetyl]amino]-, (6R-cis)-  
 (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C17 H17 N3 O6 S2  
 CI COM  
 SR CA

Absolute stereochemistry.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


L29 ANSWER 3 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 481649-28-9 REGISTRY  
 ED Entered STN: 27 Jan 2003  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]- (9CI) (CA INDEX  
 NAME)  
 FS 3D CONCORD  
 MF C16 H16 N2 O6 S2  
 SR Chemical Library  
 LC STN Files: CHEMCATS



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

L29 ANSWER 4 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 442852-34-8 REGISTRY  
 ED Entered STN: 07 Aug 2002  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-  
 methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl  
 ester, dihydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C25 H28 N6 O7 S3 . 2 Cl H  
 SR CA  
 LC STN Files: CA, CAPLUS  
 CRN (117467-28-4)

Absolute stereochemistry.  
Double bond geometry as shown.



●2 HCl


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 5 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 442852-33-7 REGISTRY  
ED Entered STN: 07 Aug 2002  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-  
methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl  
ester, (6R,7R)-, sulfate (1:1) (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C25 H28 N6 O7 S3 . H2 O4 S  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 117467-28-4  
CMF C25 H28 N6 O7 S3


Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 7664-93-9  
CMF H2 O4 S

Search done by Noble Jarrell




1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 6 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 442852-32-6 REGISTRY  
ED Entered STN: 07 Aug 2002  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2Z)-(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-  
methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl  
ester, (6R,7R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX  
NAME)  
FS STEREOSEARCH  
MF C25 H28 N6 O7 S3 . C4 H6 O6  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 117467-28-4  
CMF C25 H28 N6 O7 S3


Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 7 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 442852-31-5 REGISTRY  
ED Entered STN: 07 Aug 2002  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2Z)-(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-

methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6R,7R)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C25 H28 N6 O7 S3 . C2 H2 O4

SR CA


LC STN Files: CA, CAPLUS

CM 1

CRN 117467-28-4

CMF C25 H28 N6 O7 S3


Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 144-62-7

CMF C2 H2 O4



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 8 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 442852-30-4 REGISTRY

ED Entered STN: 07 Aug 2002

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6R,7R)-, diethanesulfonate (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C25 H28 N6 O7 S3 . 2 C2 H6 O3 S

SR CA


LC STN Files: CA, CAPLUS

CM 1

CRN 117467-28-4


CMF C25 H28 N6 O7 S3

Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 594-45-6  
CMF C2 H6 O3 S




1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 9 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 442852-29-1 REGISTRY  
ED Entered STN: 07 Aug 2002  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2Z)-(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-  
methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl  
ester, (6R,7R)-, dimethanesulfonate (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C25 H28 N6 O7 S3 . 2 C H4 O3 S  
SR CA  
LC STN Files: CA, CAPLUS

CM 1

CRN 117467-28-4  
CMF C25 H28 N6 O7 S3


Absolute stereochemistry.  
Double bond geometry as shown.



CM 2



CRN 75-75-2  
CMF C H4 03 S



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 10 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 352467-09-5 REGISTRY  
ED Entered STN: 23 Aug 2001  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R,7R)-,  
mononitrate (salt) (9CI) (CA INDEX NAME)


## OTHER NAMES:

CN **Cefadroxil nitrate**  
FS STEREOSEARCH  
MF **C16 H17 N3 O5 S . H N 03**  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

CM 1


CRN 50370-12-2  
CMF C16 H17 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 7697-37-2  
CMF H N 03



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 11 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **352465-77-1** REGISTRY  
ED Entered STN: 23 Aug 2001  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
(6R,7R)-, nitrate (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN **Ceftizoxime nitrate**  
FS STEREOSEARCH  
MF **C13 H13 N5 O5 S2 . x H N 03**  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL


Search done by Noble Jarrell

CM 1

CRN 68401-81-0

CMF C13 H13 N5 O5 S2


Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 7697-37-2

CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 12 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 352465-69-1 REGISTRY  
ED Entered STN: 23 Aug 2001  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-  
(methoxymethyl)-8-oxo-, 1-[[[(1-methylethoxy)carbonyl]oxy]ethyl ester,  
(6R, 7R)-, nitrate (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN **Cefpodoxime proxetil nitrate**

FS STEREOSEARCH

MF **C21 H27 N5 O9 S2 . x H N O3**

SR CA


LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

CM 1


CRN 87239-81-4

CMF C21 H27 N5 O9 S2

Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 7697-37-2  
CMF H N 031 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 13 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 352465-61-3 REGISTRY  
 ED Entered STN: 23 Aug 2001  
 CN 15-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-hydroxyphenylacetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, (6R,7R)-, mononitrate (salt) (9CI) (CA INDEX NAME)


## OTHER NAMES:

CN **Cefamandole nitrate**  
 FS STEREOSEARCH  
 MF **C18 H18 N6 O5 S2 . H N 03**  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

CM 1

CRN 34444-01-4  
CMF C18 H18 N6 O5 S2


Absolute stereochemistry.



CM 2

CRN 7697-37-2

CMF H N 03



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 14 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 352465-55-5 REGISTRY  
ED Entered STN: 23 Aug 2001  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2R)-amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-,  
(6R,7R)-, mononitrate (salt) (9CI) (CA INDEX NAME)


## OTHER NAMES:

CN **Cefprozil nitrate**  
FS STEREOSEARCH  
MF **C18 H19 N3 O5 S . H N 03**  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

CM 1


CRN 92665-29-7  
CMF C18 H19 N3 O5 S

Absolute stereochemistry.  
Double bond geometry unknown.



CM 2

CRN 7697-37-2  
CMF H N 03



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 15 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 352465-52-2 REGISTRY  
ED Entered STN: 23 Aug 2001  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R,7R)-, mononitrate  
(9CI) (CA INDEX NAME)


## OTHER NAMES:

CN **Cefaclor nitrate**  
FS STEREOSEARCH  
MF **C15 H14 Cl N3 O4 S . H N 03**  
SR CA  
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL

CM 1


CRN 53994-73-3  
CMF C15 H14 Cl N3 O4 S

Absolute stereochemistry.



CM 2

CRN 7697-37-2  
CMF H N O3




1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 16 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **350230-49-8** REGISTRY  
ED Entered STN: 03 Aug 2001  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, dihydrate,  
(6R,7R)- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Cephalothin dihydrate  
FS STEREOSEARCH  
MF **C16 H16 N2 O6 S2 . 2 H2 O**  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL  
CRN (153-61-7)

Absolute stereochemistry.




●2 H2O

4 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 17 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 190181-58-9 REGISTRY  
ED Entered STN: 20 Jun 1997  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, disodium salt, [6R-(6α,7β)]-[partial]- (9CI)

(CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C18 H18 N6 O8 S3 . 2 Na  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL  
 CRN (69088-92-2)

Absolute stereochemistry.




●2 Na

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 18 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 155723-35-6 REGISTRY  
 ED Entered STN: 15 Jun 1994  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[2-(3-methyl-4-  
 isothiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester,  
 [6R-[3(Z),6α,7β(Z)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C25 H28 N6 O7 S3  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.  
 Double bond geometry as shown.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 19 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 148774-47-4 REGISTRY  
 ED Entered STN: 20 Jul 1993  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[2-(4-methyl-5-  
 thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester,  
 [6R-[3(Z),6α,7β(Z)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH

Search done by Noble Jarrell

MF C25 H28 N6 O7 S3  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.  
 Double bond geometry as shown.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 20 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 144790-28-3 REGISTRY  
 ED Entered STN: 08 Dec 1992  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2S)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R, 7R)-  
 (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-,  
 [6R-[6 $\alpha$ , 7 $\beta$ (S\*)]]-

OTHER NAMES:

CN **L-Cefadroxil**  
 FS STEREOSEARCH  
 MF **C16 H17 N3 O5 S**

SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 21 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 138514-32-6 REGISTRY  
 ED Entered STN: 24 Jan 1992  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[2-(4-methyl-5-  
 thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester,


Search done by Noble Jarrell

[6R-[3(E), 6 $\alpha$ , 7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN ME 1207E  
 FS STEREOSEARCH  
 MF C25 H28 N6 O7 S3  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.  
 Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 22 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 132850-29-4 REGISTRY  
 ED Entered STN: 29 Mar 1991  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, monosodium  
 salt, hydrate, [6R-[6 $\alpha$ , 7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C13 H13 N5 O5 S2 . x H2 O . Na  
 SR CA  
 LC STN Files: CA, CAPLUS, IMSPATENTS  
 CRN (68401-81-0)

Absolute stereochemistry.  
 Double bond geometry as shown.






1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 23 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 123458-61-7 REGISTRY  
ED Entered STN: 27 Oct 1989  
CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, 1-(acetyloxy)ethyl ester, (6R,7R)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-[[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, 1-(acetyloxy)ethyl ester, [6R-[6 $\alpha$ , 7 $\beta$ (Z)]]-  
OTHER NAMES:  
CN  **$\Delta$ 2-Cefuroxime axetil**  
FS STEREOSEARCH  
MF **C20 H22 N4 O10 S**  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.  
Double bond geometry as shown.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

4 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 24 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 121412-77-9 REGISTRY  
ED Entered STN: 30 Jun 1989  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1Z)-1-propenyl-,  
(6R,7R)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-,  
[6R-[3(Z), 6 $\alpha$ , 7 $\beta$ (R\*)]]-  
OTHER NAMES:  
CN **cis-Cefprozil**  
FS STEREOSEARCH  
DR 136427-55-9  
MF **C18 H19 N3 O5 S**  
CI COM  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, IMSPATENTS, IMSRESEARCH, MRCK\*,  
USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10 REFERENCES IN FILE CA (1907 TO DATE)  
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 25 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 121123-17-9 REGISTRY  
ED Entered STN: 16 Jun 1989  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)]-,  
monohydrate, (6R, 7R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-,  
monohydrate, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

OTHER NAMES:

CN **Cefprozil monohydrate**

FS STEREOSEARCH

MF **C18 H19 N3 O5 S . H2 O**

SR CAS Client Services


LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, MRCK\*, PROUSDDR, PS,  
SYNTHLINE, TOXCENTER, USAN, USPATFULL

(\*File contains numerically searchable property data)

CRN (92665-29-7)

Absolute stereochemistry.

Double bond geometry unknown.



● H2O

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 26 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 119922-85-9 REGISTRY  
ED Entered STN: 07 Apr 1989  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, hydrate  
(2:1), (6R, 7R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, hydrate (2:1),

Search done by Noble Jarrell

[6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

## OTHER NAMES:

CN **Cefadroxil hemihydrate**

FS STEREOSEARCH

MF **C16 H17 N3 O5 S . 1/2 H2 O**


SR CA

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CIN, DIOGENES, IMSPATENTS, USAN, USPATFULL

(\*File contains numerically searchable property data)

CRN (50370-12-2)

Absolute stereochemistry.



● 1/2 H2O

3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 27 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 117467-28-4 REGISTRY

ED Entered STN: 11 Nov 1988

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[ (2Z)-(2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (6R,7R)- (9CI) (CA INDEX NAME)

## OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[ (2-amino-4-thiazolyl) (methoxyimino)acetyl]amino]-3-[2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [6R-[3(Z), 6 $\alpha$ , 7 $\beta$ (Z)]]-

## OTHER NAMES:

CN CCRIS 7768

CN Cefditoren pivaloyloxymethyl ester

CN Cefditoren pivoxil

CN Cefditoren pivoxyl

CN Cefditorin

CN ME 1207

CN Meiact

CN Spectracef

FS STEREOSEARCH

MF **C25 H28 N6 O7 S3**

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry.

Double bond geometry as shown.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

123 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 124 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 28 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **117091-43-7** REGISTRY  
 ED Entered STN: 22 Oct 1988  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyl-113C-oxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-  
 (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C16 H16 N2 O6 S2**  
 SR CA  
 LC STN Files: CA, CAPLUS


Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 29 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **109323-67-3** REGISTRY  
 ED Entered STN: 18 Jul 1987  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
 monohydrochloride, monohydrate, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA  
 INDEX NAME)  
 FS STEREOSEARCH  
 MF **C13 H13 N5 O5 S2 . C1 H . H2 O**  
 SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IMSPATENTS  
 (\*File contains numerically searchable property data)  
 CRN (68401-81-0)


Absolute stereochemistry.  
 Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 30 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 104145-87-1 REGISTRY  
ED Entered STN: 13 Sep 1986  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[2-(4-methyl-5-  
thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester,  
[6R-[6 $\alpha$ , 7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C25 H28 N6 O7 S3  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, IMSPATENTS, IMSRESEARCH, PS,  
USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry.  
Double bond geometry as described by E or Z.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 31 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **102044-69-9** REGISTRY  
ED Entered STN: 10 May 1986  
CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
[2R-[2 $\alpha$ , 6 $\alpha$ , 7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C13 H13 N5 O5 S2

Search done by Noble Jarrell

SR CA  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.  
 Double bond geometry as shown.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 32 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **97164-53-9** REGISTRY  
 ED Entered STN: 13 Jul 1985  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, monosodium  
 salt, [6R-[6α,7β(E)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C13 H13 N5 O5 S2 . Na**  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, USPATFULL  
 (\*File contains numerically searchable property data)  
 CRN (68403-31-6)

Absolute stereochemistry.  
 Double bond geometry as shown.



● Na


1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 33 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **94539-08-9** REGISTRY  
 ED Entered STN: 03 Feb 1985  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(3-thienyl)acetamido]-, acetate (7CI) (CA

Search done by Noble Jarrell

INDEX NAME)  
 FS STEREOSEARCH  
 MF C16 H16 N2 O6 S2  
 LC STN Files: CAOLD

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L29 ANSWER 34 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 92676-86-3 REGISTRY  
 ED Entered STN: 17 Dec 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1E)-1-propenyl]-,  
 (6R, 7R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-,  
 [6R-[3(E), 6 $\alpha$ , 7 $\beta$ (R\*)]]-

OTHER NAMES:

CN BMY 28167  
 CN **trans-Cefprozil**  
 FS STEREOSEARCH  
 DR 136427-56-0  
 MF C18 H19 N3 O5 S  
 CI COM  
 LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, MRCK\*, TOXCENTER,  
 USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

13 REFERENCES IN FILE CA (1907 TO DATE)

13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 35 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 92665-29-7 REGISTRY  
 ED Entered STN: 17 Dec 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-,  
 (6R, 7R)- (9CI) (CA INDEX NAME)


OTHER CA INDEX NAMES:

Search done by Noble Jarrell

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-,  
[6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

OTHER NAMES:  
CN BMY 28100  
CN **Cefprozil**  
CN **Cefprozile**  
CN Cefzil  
CN Procef  
CN Prozef  
FS STEREOSEARCH  
MF **C18 H19 N3 O5 S**  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN,  
DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH,  
IPA, MEDLINE, MRCK\*, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE,  
TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO

Absolute stereochemistry.  
Double bond geometry unknown.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


309 REFERENCES IN FILE CA (1907 TO DATE)  
7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
311 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 36 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 91828-55-6 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, dihydrate, (6R,7R)-  
(9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, dihydrate,  
[6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

OTHER NAMES:  
CN **Cefaclor dihydrate**  
FS STEREOSEARCH  
MF **C15 H14 Cl N3 O4 S . 2 H2 O**  
LC STN Files: BIOSIS, CA, CAPLUS, IMSPATENTS, IPA, USPATFULL  
CRN (53994-73-3)

Absolute stereochemistry.






●2 H2O

3 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 37 OF 118 REGISTRY COPYRIGHT. 2005 ACS on STN  
RN 87239-81-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-  
(methoxymethyl)-8-oxo-, 1-[[[(1-methylethoxy)carbonyl]oxy]ethyl ester,  
(6R, 7R)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-  
oxo-, 1-[[[(1-methylethoxy)carbonyl]oxy]ethyl ester, [6R-  
[6α, 7β(Z)]]-  
OTHER NAMES:  
CN (RS)-1-(Isopropoxycarbonyloxy)ethyl (+)-(6R, 7R)-7-[2-(2-amino-4-thiazolyl)-  
2-[(Z)-(methoxyimino)acetamido]-3-methoxymethyl-8-oxo-5-thia-1-  
azabicyclo[4.2.0]oct-2-ene-2-carboxylate  
CN Antibiotic CS 807  
CN Banan  
CN Cefodox  
CN **Cefpodoxime proxetil**  
CN Cephodoxime proxetil  
CN CS 807  
CN CS 807 (pharmaceutical)  
CN Orelox  
CN Otreon  
CN RU 51807  
CN U 76252  
CN Vantin  
FS STEREOSEARCH  
DR 95242-58-3  
MF **C21 H27 N5 O9 S2**  
CI COM  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DIOGENES, EMBASE,  
IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*,  
PATDPASPC, PHAR, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER, USAN,  
USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry.  
Double bond geometry as shown.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

253 REFERENCES IN FILE CA (1907 TO DATE)  
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 254 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 38 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **87018-84-6** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, monopotassium  
 salt, [6R-[6 $\alpha$ , 7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C13 H13 N5 O5 S2 . K**  
 LC STN Files: CA, CAPLUS, IMSPATENTS  
 CRN (68401-81-0)

Absolute stereochemistry.  
 Double bond geometry as shown.




● K

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 39 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **86068-04-4** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(thienylacetyl)amino]-, monosodium salt,  
 (6R-trans)- (9CI) (CA INDEX NAME)  
 MF **C16 H16 N2 O6 S2 . Na**

CI IDS  
 LC STN Files: CA, CAPLUS  
 CRN (50674-67-4)




● Na

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 40 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 86005-06-3 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
 , monolithium salt, (6R-cis)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C16 H17 N3 O7 S2 . Li  
 LC STN Files: CA, CAPLUS, IMSPATENTS, USPATFULL  
 CRN (35607-66-0)

Absolute stereochemistry.



● Li

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 41 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 85643-59-0 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[[4-pyridinylthio]acetyl]amino]-,  
 (6R-trans)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Acetic acid, trifluoro-, compd. with (6R-trans)-3-[(acetyloxy)methyl]-8-  
 oxo-7-[[[4-pyridinylthio]acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-  
 2-carboxylic acid (1:1)


Search done by Noble Jarrell

FS STEREOSEARCH  
 MF C17 H17 N3 O6 S2 . C2 H F3 O2  
 LC STN Files: CA, CAPLUS

CM 1


CRN 21593-23-7  
 CMF C17 H17 N3 O6 S2

Absolute stereochemistry.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 42 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 85643-58-9 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio]acetyl]amino]-,  
 monohydrochloride, (6R-trans)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C17 H17 N3 O6 S2 . C1 H  
 LC STN Files: CA, CAPLUS  
 CRN (21593-23-7)

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 43 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN


Search done by Noble Jarrell

RN 85293-56-7 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[4-(pyridinylthio)acetyl]amino]-,  
 (6R-trans)-, sulfite (1:1) (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C17 H17 N3 O6 S2 . H2 O3 S  
 LC STN Files: CA, CAPLUS

CM 1


CRN 21593-23-7  
 CMF C17 H17 N3 O6 S2

Absolute stereochemistry.



CM 2


CRN 7782-99-2  
 CMF H2 O3 S



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 44 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 82136-28-5 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[aminocarbonyl]oxymethyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
 , hydrate, (6R-cis)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C16 H17 N3 O7 S2 . x H2 O  
 CRN (35607-66-0)

Absolute stereochemistry.




● x H2O

L29 ANSWER 45 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **80823-78-5** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN L-Lysine, mono[(6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate] (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-, (6R-trans)-, compd. with L-lysine (1:1) (9CI)  
 FS STEREOSEARCH  
 MF **C17 H17 N3 O6 S2 . C6 H14 N2 O2**  
 LC STN Files: CA, CAPLUS

CM 1

CRN 21593-23-7  
 CMF C17 H17 N3 O6 S2


Absolute stereochemistry.



CM 2

CRN 56-87-1  
 CMF C6 H14 N2 O2

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 46 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **80813-08-7** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN L-Cysteine, N-acetyl-, (6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (salt) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-, (6R-trans)-, compd. with N-acetyl-L-cysteine (1:1) (9CI)  
 OTHER NAMES:  
 CN Cephalirin acetylcysteinate  
 FS STEREOSEARCH  
 MF **C17 H17 N3 O6 S2 . C5 H9 N O3 S**  
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 21593-23-7  
 CMF C17 H17 N3 O6 S2


Absolute stereochemistry.



CM 2

CRN 616-91-1  
CMF C5 H9 N O3 S

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 47 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 80813-07-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN L-Cysteine, N-acetyl-, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (salt) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-, compd. with N-acetyl-L-cysteine (1:1) (9CI)

OTHER NAMES:

CN **Cefadroxil N-acetylcysteinate**

FS STEREOSEARCH


MF **C16 H17 N3 O5 S . C5 H9 N O3 S**

LC STN Files: CA, CAPLUS, IMSPATENTS, USPATFULL

CM 1

CRN 50370-12-2  
CMF C16 H17 N3 O5 S

Absolute stereochemistry.




CM 2

CRN 616-91-1  
CMF C5 H9 N O3 S

Absolute stereochemistry.


Search done by Noble Jarrell



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 48 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 80525-84-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, calcium salt (2:1), (6R)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C16 H17 N3 O7 S2 . 1/2 Ca  
LC STN Files: CA, CAPLUS, IMSPATENTS, TOXCENTER, USPATFULL  
CRN (40126-15-6)

Absolute stereochemistry.




● 1/2 Ca

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 49 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 79226-63-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-5-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
[6R-[6α,7β(Z)]]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C13 H13 N5 O5 S2  
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


Search done by Noble Jarrell



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 50 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **75859-41-5** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, monosodium  
salt, [6R-(6 $\alpha$ , 7 $\beta$ )]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C13 H13 N5 O5 S2 . Na**  
LC STN Files: CA, CAPLUS  
CRN (770660-21-4)

Absolute stereochemistry.  
Double bond geometry unknown.




● Na

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 51 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **75360-38-2** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
hydrochloride, [6R-[6 $\alpha$ , 7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C13 H13 N5 O5 S2 . x Cl H**  
LC STN Files: CA, CAPLUS, IMSPATENTS, TOXCENTER  
CRN (68401-81-0)

Absolute stereochemistry.  
Double bond geometry as shown.




●x HCl

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 52 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **75275-72-8** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
monohydrochloride, [6R-[6α,7β(E)]]- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C13 H13 N5 O5 S2 . C1 H**  
LC STN Files: CA, CAPLUS, TOXCENTER  
CRN (68403-31-6)

Absolute stereochemistry.  
Double bond geometry as shown.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 53 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **74708-63-7** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R-trans)-  
(9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C13 H13 N5 O5 S2**  
CI COM  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL  
(\*File contains numerically searchable property data)

Search done by Noble Jarrell

Absolute stereochemistry.  
Double bond geometry unknown.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

5 REFERENCES IN FILE CA (1907 TO DATE)  
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 54 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **74708-62-6** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[2-amino-4-thiazolyl] (methoxyimino)acetyl]amino]-8-oxo-, monosodium  
salt, (6R-trans)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C13 H13 N5 O5 S2 . Na**  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, TOXCENTER  
(\*File contains numerically searchable property data)  
CRN (74708-63-7)

Absolute stereochemistry.  
Double bond geometry unknown.



● Na


3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 55 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 74660-11-0 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[2-(aminooxy)-2-oxoethyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-,  
(6R-cis)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C16 H17 N3 O7 S2**

Search done by Noble Jarrell

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 56 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 73356-25-9 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, (6R-trans)-, sulfate (salt) (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C16 H17 N3 O7 S2 . x H2 O4 S  
LC STN Files: CA, CAPLUS

CM 1


CRN 73356-24-8  
CMF C16 H17 N3 O7 S2

Absolute stereochemistry.



CM 2

CRN 7664-93-9  
CMF H2 O4 S




1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 57 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 73356-24-8 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-

Search done by Noble Jarrell

Absolute stereochemistry.




CRN (61270-58-4)

● Na

Search done by Noble Jarrell

RN 70356-03-5 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, monohydrate, (6R,7R)-  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, monohydrate,  
 [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-  
 OTHER NAMES:  
 CN **Cefaclor monohydrate**  
 CN Cephacolor monohydrate  
 FS STEREOSEARCH  
 DR 126269-39-4  
 MF **C15 H14 Cl N3 O4 S . H2 O**  
 LC STN Files: ANABSTR, BIOSIS, CA, CAPLUS, CHEMCATS, EMBASE, IMSPATENTS,  
 IPA, MEDLINE, MRCK\*, PHAR, PROUSDDR, RTECS\*, SYNTHLINE, USAN, USPAT2,  
 USPATFULL  
 (\*File contains numerically searchable property data)  
 CRN (53994-73-3)

Absolute stereochemistry.




● H2O

15 REFERENCES IN FILE CA (1907 TO DATE)  
 15 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 60 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 69088-92-2 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-  
 yl]thio]methyl]-, [6R-(6 $\alpha$ , 7 $\beta$ )]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C18 H18 N6 O8 S3**  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IMSPATENTS  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


1 REFERENCES IN FILE CA (1907 TO DATE)

Search done by Noble Jarrell

## 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 61 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **68401-84-3** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[2-amino-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-, magnesium  
 salt (2:1), [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C13 H13 N5 O5 S2 . 1/2 Mg**  
 LC STN Files: CA, CAPLUS, IMSPATENTS, TOXCENTER, USPATFULL  
 CRN (68401-81-0)

Absolute stereochemistry.  
 Double bond geometry as shown.




●1/2 Mg

2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 62 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **68401-83-2** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[2-amino-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-, calcium salt  
 (2:1), [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C13 H13 N5 O5 S2 . 1/2 Ca**  
 LC STN Files: CA, CAPLUS, IMSPATENTS, TOXCENTER, USPATFULL  
 CRN (68401-81-0)

Absolute stereochemistry.  
 Double bond geometry as shown.



● 1/2 Ca

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 63 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **68401-82-1** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
monosodium salt, (6R,7R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, monosodium  
salt, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]-

OTHER NAMES:

CN Cefizox

CN Ceftix

CN Ceftizon

CN Ceftizoxime sodium

CN Ceftizoxime sodium salt

CN Eposerin

CN FK 749

CN FR 13479

CN SKF 88373

CN Sodium 7-[2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-4-  
carboxylate

FS STEREOSEARCH

MF **C13 H13 N5 O5 S2 . Na**

CI COM

LC STN Files: BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS,  
CASREACT, CBNB, CHEMLIST, CIN, DIOGENES, EMBASE, IFICDB, IFIUDB,  
IMSPATENTS, IPA, MRCK\*, MSDS-OHS, PHAR, PROMT, PS, RTECS\*, TOXCENTER,  
USAN, USPATFULL


(\*File contains numerically searchable property data)

CRN (68401-81-0)

Absolute stereochemistry.

Double bond geometry as shown.





● Na

95 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
95 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 64 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **68401-81-0** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, (6R,7R)-  
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
[6R-[6 $\alpha$ , 7 $\beta$ (Z)]]-

OTHER NAMES:

CN Ceftisomin

CN Ceftizoxime

CN Epocelin

FS STEREOSEARCH

MF **C13 H13 N5 O5 S2**


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,  
CHEMCATS, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIUDB,  
IMSCOSEARCH, IMPATENTS, IPA, MEDLINE, MRCK\*, NIOSHTIC, PHAR, PROMT, PS,  
RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
(\*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.

Double bond geometry as shown.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

Search done by Noble Jarrell

1069 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1070 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 65 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **68401-80-9** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,  
 monohydrochloride, [6R-[6 $\alpha$ , 7 $\beta$ (Z)]]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C13 H13 N5 O5 S2 . C1 H**  
 LC STN Files: CA, CAPLUS, IMSPATENTS, PS, TOXCENTER, USPATFULL  
 CRN (68401-81-0)

Absolute stereochemistry.  
 Double bond geometry as shown.



● HCl


2 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 66 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 67022-10-0 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
 , (6R-cis)-, mixt. with [R-(R\*, S\*)]-[1-[(2-amino-1-  
 oxopropyl)amino]ethyl]phosphonic acid (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Phosphonic acid, [1-[(2-amino-1-oxopropyl)amino]ethyl]-, [R-(R\*, S\*)]-,  
 mixt. contg. (9CI)  
 FS STEREOSEARCH  
 MF **C16 H17 N3 O7 S2 . C5 H13 N2 O4 P**  
 CI MXS  
 LC STN Files: CA, CAPLUS, IMSPATENTS

CM 1

CRN 60668-24-8  
 CMF C5 H13 N2 O4 P

Absolute stereochemistry.




CM 2

CRN 35607-66-0

CMF C16 H17 N3 07 S2

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 67 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 66911-02-2 REGISTRY


ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[ (aminocarbonyl)oxy]methyl]-6-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C16 H17 N3 07 S2

LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 68 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 66592-87-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monohydrate,  
(6R, 7R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monohydrate,  
[6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

OTHER NAMES:

CN Cefadroxil monohydrate

CN Duricef

FS STEREOSEARCH

MF C16 H17 N3 05 S . H2 O

LC STN Files: ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CBNB,


Search done by Noble Jarrell

CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, IFICDB,  
 IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK\*, PROMT, RTECS\*,  
 TOXCENTER, USAN, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

CRN (50370-12-2)

Absolute stereochemistry.



● H<sub>2</sub>O

19 REFERENCES IN FILE CA (1907 TO DATE)

19 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L29 ANSWER 69 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **66065-78-9** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[ (4-pyridinylthio)acetyl]amino]-,  
 (6R-trans)-, sulfate (1:1) (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C17 H17 N3 O6 S2 . H2 O4 S**  
 LC STN Files: CA, CAPLUS

CM 1

CRN 21593-23-7

CMF C17 H17 N3 O6 S2


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S




3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Search done by Noble Jarrell

L29 ANSWER 70 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 64544-07-6 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[[(aminocarbonyl)oxy]methyl]-7-[[[(2Z)-2-furanyl(methoxyimino)acetyl]amin  
 ol-8-oxo-, 1-(acetyloxy)ethyl ester, (6R,7R)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[[(aminocarbonyl)oxy]methyl]-7-[[[2-furanyl(methoxyimino)acetyl]amino]-8-  
 oxo-, 1-(acetyloxy)ethyl ester, [6R-[6 $\alpha$ ,7 $\beta$ (Z)]]-  
 OTHER NAMES:  
 CN CCI 15641  
 CN Cefazine  
 CN Ceftin  
 CN Cefurax  
 CN Cefuroxime 1-acetoxyethyl ester  
 CN Cefuroxime axetil  
 CN Elobact  
 CN Oraxim  
 CN Zinat  
 CN Zinnat  
 FS STEREOSEARCH  
 MF C20 H22 N4 O10 S  
 CI COM  
 LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,  
 CIN, DDFU, DIOGENES, DRUGU, EMBASE, IMSCOSEARCH, IMSDRUGNEWS,  
 IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS\*,  
 SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.  
 Double bond geometry as shown.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

407 REFERENCES IN FILE CA (1907 TO DATE)  
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 408 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 71 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 63824-86-2 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
 , monosodium salt, (6S-cis)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C16 H17 N3 O7 S2 . Na  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IMSPATENTS  
 (\*File contains numerically searchable property data)  
 CRN (56082-95-2)

Absolute stereochemistry.




● Na

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 72 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 61270-78-8 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-hydroxyphenylacetyl]amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, disodium salt, (6R,7R)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, disodium salt, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-  
OTHER NAMES:  
CN Cefonicid disodium salt  
CN Cefonicid sodium  
CN Disodium cefonicid  
CN SKF 75073  
FS STEREOSEARCH  
MF C18 H18 N6 O8 S3 . 2 Na  
LC STN Files: ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CIN, DIOGENES, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MRCK\*, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
CRN (61270-58-4)

Absolute stereochemistry.



●2 Na

39 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 73 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 61270-58-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

Search done by Noble Jarrell

7-[[[(2R)-hydroxyphenylacetyl]amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, (6R,7R)- (9CI) (CA INDEX NAME)

## OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[1-(sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-


## OTHER NAMES:

CN Cefonicid  
FS STEREOSEARCH  
DR 162143-29-5  
MF **C18 H18 N6 O8 S3**  
CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CIN, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK\*, PROMT, PROUSDDR, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

199 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
200 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L29 ANSWER 74 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 58648-57-0 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(hydroxyphenylacetyl)amino]-3-[[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-  
8-oxo-, monolithium salt, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]- (9CI) (CA INDEX  
NAME)

## OTHER NAMES:

CN **Cefamandole lithium**  
CN **Cefamandole lithium salt**  
FS STEREOSEARCH  
MF **C18 H18 N6 O5 S2 . Li**  
CI COM

LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, CSCHEM, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, TOXCENTER, USPATFULL  
CRN (34444-01-4)

Absolute stereochemistry.




● Li

33 REFERENCES IN FILE CA (1907 TO DATE)  
33 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 75 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **57320-88-4** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-7-(acetyl-2-thienylamino)-8-oxo-, sodium salt,  
(6R-trans)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C16 H16 N2 O6 S2 . Na**  
LC STN Files: CA, CAPLUS, TOXCENTER  
CRN (758628-65-8)

Absolute stereochemistry.




● Na

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 76 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 56540-85-3 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, monosodium salt, (6R)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C16 H17 N3 O7 S2 . Na**  
LC STN Files: BEILSTEIN\*  
(\*File contains numerically searchable property data)  
CRN (40126-15-6)

Absolute stereochemistry.






● Na

L29 ANSWER 77 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 56082-95-2 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
 , (6S-cis)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C16 H17 N3 O7 S2  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IMSPATENTS  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L29 ANSWER 78 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 55944-32-6 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-,  
 compd. with N,N-dimethylacetamide (1:1) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Acetamide, N,N-dimethyl-, (6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-  
 thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate  
 (9CI)  
 FS STEREOSEARCH  
 MF C16 H16 N2 O6 S2 . C4 H9 N O  
 LC STN Files: CA, CAPLUS, TOXCENTER  
 CM 1  
 CRN 153-61-7  
 CMF C16 H16 N2 O6 S2

Absolute stereochemistry.



CM 2


CRN 127-19-5  
CMF C4 H9 N O



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 79 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **54600-91-8** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio]acetyl]amino]-,  
monosodium salt, (6R-cis)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C17 H17 N3 O6 S2 . Na**  
LC STN Files: BEILSTEIN\*, CA, CAPLUS  
(\*File contains numerically searchable property data)  
CRN (746546-33-8)

Absolute stereochemistry.



● Na

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 80 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **54544-02-4** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(carboxymethyl)thio]acetyl]amino]-8-oxo-3-(3-pyridinylmethyl)-,  
(6R-trans)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Acetic acid, trifluoro-, compd. with (6R-trans)-7-  
[[[(carboxymethyl)thio]acetyl]amino]-8-oxo-3-(3-pyridinylmethyl)-5-thia-1-  
azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (1:1)  
FS STEREOSEARCH  
MF **C17 H17 N3 O6 S2 . C2 H F3 O2**  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB


Search done by Noble Jarrell

(\*File contains numerically searchable property data)

CM 1


CRN 54544-01-3  
CMF C17 H17 N3 O6 S2

Absolute stereochemistry.



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 81 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **54544-01-3** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(carboxymethyl)thio]acetyl]amino]-8-oxo-3-(3-pyridinylmethyl)-,  
(6R-trans)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C17 H17 N3 O6 S2**  
CI COM  
LC STN Files: BEILSTEIN\*  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


L29 ANSWER 82 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 53994-73-3 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[[(2R)-aminophenylacetyl]amino]-3-chloro-8-oxo-, (6R, 7R)- (9CI) (CA  
INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

Search done by Noble Jarrell

## OTHER NAMES:

CN 7-(D-2-Amino-2-phenylacetamido)-3-chloro-3-cephem-4-carboxylic acid  
 CN Alfacet  
 CN Ceclor  
 CN **Cefaclor**  
 CN Cephacolor  
 CN Kefral  
 CN Lilly 99638  
 CN Panorol  
 CN S 6472  
 FS STEREOSEARCH  
 DR 142975-47-1  
 MF **C15 H14 Cl N3 O4 S**  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUBB, IMSCSEARCH, IMSPATENTS, IPA, MEDLINE, MSDS-OHS, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1479 REFERENCES IN FILE CA (1907 TO DATE)  
 20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1483 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 83 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **53950-16-6** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN L-Arginine, mono[(6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate] (9CI) (CA INDEX NAME)


## OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-,  
 (6R-trans)-, compd. with L-arginine (1:1) (9CI)  
 FS STEREOSEARCH  
 MF **C17 H17 N3 O6 S2 . C6 H14 N4 O2**  
 LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 21593-23-7  
 CMF C17 H17 N3 O6 S2

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 84 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 52128-54-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, monosodium salt, cis- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, monosodium salt, cis-(±)-


FS STEREOSEARCH

MF C16 H17 N3 O7 S2 . Na

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CHEMCATS, IMSPATENTS, TOXCENTER  
(\*File contains numerically searchable property data)

CRN (51014-44-9)

Relative stereochemistry.



● Na

2 REFERENCES IN FILE CA (1907 TO DATE)


2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 85 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

Search done by Noble Jarrell

RN 51829-86-8 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
 , monosodium salt, (6R,7R)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
 , monosodium salt, (6R-trans)-  
 OTHER NAMES:  
 CN Sodium cefoxitin  
 FS STEREOSEARCH  
 MF **C16 H17 N3 O7 S2 . Na**  
 LC STN Files: AGRICOLA, BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA, CAPLUS,  
 IMSPATENTS, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 CRN (73356-24-8)

Absolute stereochemistry.



● Na


39 REFERENCES IN FILE CA (1907 TO DATE)  
 39 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 86 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **51596-58-8** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN L-Arginine, mono[(6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate]  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-,  
 compd. with L-arginine (1:1) (9CI)  
 OTHER NAMES:  
 CN Cephalothin arginine salt  
 FS STEREOSEARCH  
 MF **C16 H16 N2 O6 S2 . C6 H14 N4 O2**  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER,  
 USPATFULL  
 (\*File contains numerically searchable property data)

CM 1

CRN 153-61-7  
 CMF C16 H16 N2 O6 S2

Absolute stereochemistry.




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 87 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 51596-52-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN L-Lysine, mono[(6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate] (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-, compd. with L-lysine (1:1) (9CI)

OTHER NAMES:

CN Lysine 3-(acetoxymethyl)-7-(2-thienylacetamido)-Δ3-cephem-4-carboxylate

FS STEREOSEARCH

MF C16 H16 N2 O6 S2 . C6 H14 N2 O2

LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL


(\*File contains numerically searchable property data)

CM 1

CRN 153-61-7

CMF C16 H16 N2 O6 S2

Absolute stereochemistry.




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 88 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **51266-76-3** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-,  
compd. with gentamicin (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Gentamicin, compd. with (6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (9CI)

OTHER NAMES:

CN Gentamicin cephalothinate

FS STEREOSEARCH

MF **C16 H16 N2 O6 S2 . x Unspecified**

LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 1403-66-3

CMF Unspecified

CCI MAN


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 153-61-7

CMF C16 H16 N2 O6 S2

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 89 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **51266-75-2** REGISTRY

ED Entered STN: 16 Nov 1984

CN Polymyxin, compd. with (6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-,  
compd. with polymyxin (9CI)

OTHER NAMES:

CN Polymyxin cephalothinate

FS STEREOSEARCH

MF **C16 H16 N2 O6 S2 . x Unspecified**

LC STN Files: CA, CAPLUS



CM 1


CRN 1406-11-7  
 CMF Unspecified  
 CCI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

CM 2

CRN 153-61-7  
 CMF C16 H16 N2 O6 S2

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 90 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **51098-29-4** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, trans- (9CI) (CA  
 INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, trans-(±)-

OTHER NAMES:

CN (±)-Cephalothin


FS STEREOSEARCH

MF **C16 H16 N2 O6 S2**

CI COM

LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, IFICDB,  
 IFIPAT, IFIUDB, SYNTHLINE, USPATFULL  
 (\*File contains numerically searchable property data)

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 91 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **51014-52-9** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, monosodium salt,  
 trans- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

Search done by Noble Jarrell

3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, monosodium salt,  
trans-(±)-

FS STEREOSEARCH


MF C16 H16 N2 O6 S2 . Na

LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, CHEMCATS, IFICDB, IFIPAT,  
IFIUDB, USPATFULL

(\*File contains numerically searchable property data)

CRN (51098-29-4)

Relative stereochemistry.



● Na

4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 92 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 51014-44-9 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, cis- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, cis-(±)-

FS STEREOSEARCH


MF C16 H17 N3 O7 S2

CI COM

LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, IMSPATENTS,  
TOXCENTER, USPATFULL

(\*File contains numerically searchable property data)

Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)

5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 93 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN


RN 50674-67-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(thienylacetyl)amino]-, (6R-trans)- (9CI)

Search done by Noble Jarrell

(CA INDEX NAME)  
 MF **C16 H16 N2 O6 S2**  
 CI IDS, COM  
 LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL



3 REFERENCES IN FILE CA (1907 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 94 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 50370-12-2 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[ (2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, (6R, 7R)-  
 (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-,  
 [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

OTHER NAMES:

CN Bidocef  
 CN BL-S 578  
 CN **Cefadroxil**  
 CN Cephadroxil  
 CN **D-Cefadroxil**  
 CN Oracefal  
 CN Roxil  
 CN S 578  
 CN Ultracef

FS STEREOSEARCH

MF **C16 H17 N3 O5 S**

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,  
 CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT,  
 IFIUDB, IMSCOSEARCH, IMSPATENTS, MEDLINE, PHAR, PROMT, PS, RTECS\*,  
 TOXCENTER, USAN, USPAT2, USPATFULL, VETU, VTB

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Search done by Noble Jarrell

879 REFERENCES IN FILE CA (1907 TO DATE)  
 19 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 881 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 95 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **47489-80-5** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-,  
 [2R-(2 $\alpha$ , 6 $\alpha$ , 7 $\beta$ )]- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF **C16 H16 N2 O6 S2**  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER,  
 USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 96 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 42284-83-3 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[ (2R)-amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monosodium  
 salt, (6R, 7R)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monosodium salt,  
 [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-  
 OTHER NAMES:  
 CN p-Hydroxycephalexin  
 CN **Sodium cefadroxil**  
 FS STEREOSEARCH  
 MF **C16 H17 N3 O5 S . Na**  
 LC STN Files: CA, CAPLUS, CHEMLIST, IFICDB, IFIPAT, IFIUDB, IMSPATENTS,  
 TOXCENTER, USPATFULL  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (50370-12-2)

Absolute stereochemistry.



● Na


10 REFERENCES IN FILE CA (1907 TO DATE)  
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 97 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **42231-00-5** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-,  
homopolymer (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Cephalothin polymer  
FS STEREOSEARCH  
DR 100296-27-3  
MF **(C16 H16 N2 O6 S2)x**  
CI PMS  
PCT Polyamine, Polyester, Polyester formed  
LC STN Files: ADISNEWS, AGRICOLA, CA, CAPLUS, DIOGENES, MEDLINE, PROMT

CM 1

CRN 153-61-7  
CMF C16 H16 N2 O6 S2


Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 98 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **40126-15-6** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-,  
(6R)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF **C16 H17 N3 O7 S2**  
CI COM  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, IMSPATENTS,  
TOXCENTER, USPATFULL  
(\*File contains numerically searchable property data)

Absolute stereochemistry.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 99 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 39225-53-1 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-,  
compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

**OTHER CA INDEX NAMES:**

CN Ethanamine, N,N-diethyl-, (6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

FS STEREOSEARCH

MF C16 H16 N2 O6 S2 . C6 H15 N


LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER

CM 1

CRN 153-61-7

CMF C16 H16 N2 O6 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 100 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 35607-66-0 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-,  
(6R,7S)- (9CI) (CA INDEX NAME)

**OTHER CA INDEX NAMES:**

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

Search done by Noble Jarrell

3-[[aminocarbonyl]oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, (6R-cis)-

## OTHER NAMES:

CN Cefoxitin

CN Cephoxitin

FS STEREOSEARCH

DR 39951-67-2

MF C16 H17 N3 O7 S2


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMLIST, CIN,  
CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB,  
IMSCOSEARCH, IMSPATENTS, IPA, MEDLINE, MRCK\*, NAPRALERT, PROMT, PS,  
RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3067 REFERENCES IN FILE CA (1907 TO DATE)

17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

3075 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 101 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 34444-01-4 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[2-(hydroxyphenyl)acetyl]amino]-3-[[1-methyl-1H-tetrazol-5-  
yl]thio]methyl]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

## OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(hydroxyphenyl)acetyl]amino]-3-[[1-methyl-1H-tetrazol-5-yl]thio]methyl]-  
8-oxo-, [6R-[6 $\alpha$ ,7 $\beta$ (R\*)]]-

## OTHER NAMES:

CN 3-(1-Methyltetrazol-5-ylthiomethyl)-7-D-mandelamido-3-cephem-4-carboxylic  
acid

CN Cefadole

CN Cefamandol

CN Cefamandole

CN Cephadole

CN Cephamandole

CN CMT

CN L-Cefamandole

FS STEREOSEARCH

MF C18 H18 N6 O5 S2


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,  
CIN, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB,  
IMSPATENTS, IPA, MEDLINE, MRCK\*, NAPRALERT, PHAR, PROMT, PS, RTECS\*,  
SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1637 REFERENCES IN FILE CA (1907 TO DATE)  
9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1642 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 102 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 33564-30-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, monosodium salt, (6R,7S)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[[[(aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-  
, monosodium salt, (6R-cis)-

OTHER NAMES:

CN Betacef  
CN Cefaxilin sodium  
CN Cefoxitin sodium  
CN Cefoxitin sodium salt  
CN Cenomycin  
CN Farmoxin  
CN Mefoxin  
CN Mefoxithin  
CN Mefoxitin  
CN Merxin  
CN MK 306  
CN Monosodium cefoxitin  
FS STEREOSEARCH  
DR 41224-60-6  
MF C16 H17 N3 O7 S2 . Na  
CI COM  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,

BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,  
DIOGENES, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MRCK\*,  
MSDS-OHS, PHAR, PIRA, PROMT, PS, RTECS\*, TOXCENTER, USAN, USPAT2,  
USPATFULL

(\*File contains numerically searchable property data)


Other Sources: EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (35607-66-0)

Absolute stereochemistry.





● Na

148 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
148 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 103 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN 30034-03-8 REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[[ (2R)-hydroxyphenylacetyl]amino]-3-[[ (1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, monosodium salt, (6R,7R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-mandelamido-3-[[ (1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-,  
monosodium salt, D- (8CI)

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
7-[(hydroxyphenylacetyl)amino]-3-[[ (1-methyl-1H-tetrazol-5-yl)thio]methyl]-  
8-oxo-, monosodium salt, [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-

OTHER NAMES:

CN **Cefamandole sodium**

CN **Cefamandole sodium salt**

CN Sodium 7-D-mandelamido-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-3-cephem-4-carboxylate

CN **Sodium cefamandole**

CN Sodium [6R-[6 $\alpha$ , 7 $\beta$ (R\*)]]-7-[(hydroxyphenylacetyl)amino]-3-[[ (1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

FS STEREOSEARCH

MF **C18 H18 N6 O5 S2 . Na**

CI COM


LC STN Files: BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS,  
CASREACT, CHEMCATS, CHEMLIST, CIN, DIOGENES, EMBASE, IFICDB, IFIPAT,  
IFIUDB, IMPATENTS, IPA, RTECS\*, TOXCENTER, USAN, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (34444-01-4)

Absolute stereochemistry.




● Na

62 REFERENCES IN FILE CA (1907 TO DATE)  
62 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 104 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **24412-14-4** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
monosilver(1+) salt (8CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Silver cephalothin  
FS STEREOSEARCH  
DR 25047-35-2  
MF **C16 H16 N2 O6 S2 . Ag**  
LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER  
CRN (153-61-7)

Absolute stereochemistry.



● Ag(I)


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 105 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **24356-60-3** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[[4-(pyridinylthio)acetyl]amino]-,  
monosodium salt, (6R, 7R)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(4-pyridylthio)acetamido]-, acetate (ester),  
monosodium salt (8CI)  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[[4-(pyridinylthio)acetyl]amino]-,  
monosodium salt, (6R-trans)-  
OTHER NAMES:  
CN 7-[α-(4-Pyridylthio)acetamido]cephalosporanic acid sodium salt  
CN Ambrocef  
CN BLP 1322  
CN Brisfirina  
CN Bristocef  
CN Cef-Lak  
CN Cefa-Lak  
CN Cefadyl  
CN Cefaloject  
CN Cefapirin sodium  
CN Cefaprin sodium  
CN Cefatrexyl  
CN Cephapirin sodium  
CN Cephatrexil  
CN NSC 179171  
CN Piricef  
CN Sodium cefapirin  
CN Sodium cephapirin  
CN Today  
FS STEREOSEARCH  
MF **C17 H17 N3 O6 S2 . Na**

Search done by Noble Jarrell

CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, CSCHEM, DIOGENES, EMBASE, HSDB\*, IFCDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MRCK\*, PROMT, PS, RTECS\*, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (21593-23-7)

Absolute stereochemistry.



● Na


126 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 126 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 106 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 22739-71-5 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
 compd. with diethylamine (1:1) (8CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Diethylamine, 3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-  
 azabicyclo[4.2.0]oct-2-ene-2-carboxylate acetate (ester) (8CI)  
 FS STEREOSEARCH  
 MF C16 H16 N2 O6 S2 . C4 H11 N  
 LC STN Files: CA, CAPLUS

CM 1

CRN 153-61-7  
 CMF C16 H16 N2 O6 S2

Absolute stereochemistry.



CM 2

CRN 109-89-7  
 CMF C4 H11 N

H<sub>3</sub>C-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>3</sub>


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 107 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **22612-01-7** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
compd. with 1-deoxy-1-(methylamino)glucitol (1:1) (8CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Glucitol, 1-deoxy-1-(methylamino)-, 3-(hydroxymethyl)-8-oxo-7-[2-(2-  
thienyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate  
3-acetate (salt) (8CI)  
FS STEREOSEARCH  
MF **C16 H16 N2 O6 S2 . C7 H17 N O5**  
LC STN Files: CA, CAPLUS

CM 1

CRN 6284-40-8  
CMF C7 H17 N O5


Absolute stereochemistry.



CM 2

CRN 153-61-7  
CMF C16 H16 N2 O6 S2

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L29 ANSWER 108 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
RN **22611-99-0** REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
compd. with 2,2'-iminodiethanol (1:1) (8CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Ethanol, 2,2'-iminodi-, 3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-  
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 3-acetate (salt) (8CI)  
FS STEREOSEARCH  
MF **C16 H16 N2 O6 S2 . C4 H11 N O2**  
LC STN Files: CA, CAPLUS

CM 1

CRN 153-61-7  
CMF C16 H16 N2 O6 S2

Absolute stereochemistry.

Search done by Noble Jarrell



CM 2

CRN 111-42-2  
CMF C4 H11 N O2HO-CH<sub>2</sub>-CH<sub>2</sub>-NH-CH<sub>2</sub>-CH<sub>2</sub>-OH1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 109 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **22199-74-2** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-,  
compd. with 2-aminoethanol (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
compd. with 2-aminoethanol (1:1) (8CI)CN Ethanol, 2-amino-, (6R-trans)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-  
thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate  
(salt) (9CI)

OTHER NAMES:

CN 7-(2-Thienylacetamido)cephalosporanic acid ethanolamine salt

FS STEREOSEARCH

DR 22611-98-9


MF **C16 H16 N2 O6 S2 . C2 H7 N O**

LC STN Files: CA, CAPLUS

CM 1

CRN 153-61-7  
CMF C16 H16 N2 O6 S2

Absolute stereochemistry.



CM 2

CRN 141-43-5  
CMF C2 H7 N OH<sub>2</sub>N-CH<sub>2</sub>-CH<sub>2</sub>-OH


1 REFERENCES IN FILE CA (1907 TO DATE)

Search done by Noble Jarrell

## 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 110 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **21593-24-8** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[3-pyridinylthio)acetyl]amino]-,  
 (6R-trans)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(3-pyridylthio)acetamido]-, acetate (ester)  
 (8CI)  
 FS STEREOSEARCH  
 MF **C17 H17 N3 O6 S2**  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

4 REFERENCES IN FILE CA (1907 TO DATE)  
 4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 111 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **21593-23-7** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-, (6R, 7R)-  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(4-pyridylthio)acetamido]-, acetate (ester)  
 (8CI)  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[4-pyridinylthio)acetyl]amino]-,  
 (6R-trans)-  
 OTHER NAMES:  
 CN 7-[2-(4-Pyridylthio)acetamido]cephalosporanic acid  
 CN Cefapirin  
 CN Cefaprin  
 CN Cephapirin  
 CN Cephapirine  
 CN Cephaprin  
 FS STEREOSEARCH  
 DR 25279-35-0  
 MF **C17 H17 N3 O6 S2**  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMLIST, DDFU,  
 DIOGENES, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA,  
 MEDLINE, NAPRALERT, NIOSHTIC, PROMT, PS, RTECS\*, TOXCENTER, USAN,  
 USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.

Search done by Noble Jarrell



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

557 REFERENCES IN FILE CA (1907 TO DATE)  
 8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 561 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 112 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **21593-22-6** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[2-(2-pyridylthio)acetyl]amino]-,  
 (6R-trans)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(2-pyridylthio)acetamido]-, acetate (ester)  
 (8CI)

OTHER NAMES:


CN NSC 270289

FS STEREOSEARCH

MF **C17 H17 N3 O6 S2**

LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L29 ANSWER 113 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **3432-90-4** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[2-(3-thienyl)acetyl]amino]-, (6R,7R)- (9CI)  
 (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(3-thienyl)acetamido]-, acetate (ester) (8CI)

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[[2-(3-thienyl)acetyl]amino]-, (6R-trans)-


FS STEREOSEARCH

MF **C16 H16 N2 O6 S2**

LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)

Search done by Noble Jarrell

Absolute stereochemistry.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

3 REFERENCES IN FILE CA (1907 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L29 ANSWER 114 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **1051-68-9** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, monosodium salt,  
[6R-(6α,7β)]- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
monosodium salt (8CI)

CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate, sodium salt  
(7CI)

FS STEREOSEARCH


MF **C16 H16 N2 O6 S2 . Na**

LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB,  
USPATFULL

(\*File contains numerically searchable property data)

CRN (979-94-2)

Absolute stereochemistry.



● Na

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L29 ANSWER 115 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN

RN **979-95-3** REGISTRY

ED Entered STN: 16 Nov 1984

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, monopotassium  
salt, (6R-trans)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
monopotassium salt (8CI)


Search done by Noble Jarrell



## OTHER NAMES:

CN Cephalothin potassium salt  
 CN Potassium 7-(2-thienylacetamido)cephalosporanate  
 FS STEREOSEARCH  
 MF **C16 H16 N2 O6 S2 . K**  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB,  
 TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 CRN (153-61-7)

Absolute stereochemistry.



● K

6 REFERENCES IN FILE CA (1907 TO DATE)  
 6 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L29 ANSWER 116 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **979-94-2** REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7R)- (9CI)  
 (CA INDEX NAME)


## OTHER CA INDEX NAMES:

CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester) (8CI)  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (7CI)  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-,  
 [6R-(6 $\alpha$ , 7 $\beta$ )]-

## OTHER NAMES:

CN 3-Acetoxyethyl-7-thiopheneacetamido-2-cephem-4-carboxylic acid  
 FS STEREOSEARCH  
 DR 94094-06-1, 96265-55-3  
 MF **C16 H16 N2 O6 S2**  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, IFICDB, IFIPAT,  
 IFIUDB, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Search done by Noble Jarrell

16 REFERENCES IN FILE CA (1907 TO DATE)  
 16 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L29 ANSWER 117 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 153-61-7 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R,7R)- (9CI)  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester) (8CI)  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, (6R-trans)-  
 OTHER NAMES:  
 CN 3-(Acetoxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-5-thia-1-  
 azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid  
 CN 3-Acetoxymethyl-7-(2-thienylacetamido)-3-cephem-4-carboxylic acid  
 CN 7-(2-Thienylacetamido)cephalosporanic acid  
 CN 7-(Thiophene-2-acetamido)cephalosporin  
 CN 7-[2-(2-Thienyl)acetylamido]cephalosporanic acid  
 CN Cefalotin  
 CN Cephalothin  
 CN Cephalotin  
 CN CT  
 FS STEREOSEARCH  
 DR 2073-29-2  
 MF C16 H16 N2 O6 S2  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,  
 CHEMLIST, CIN, CSChem, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*,  
 IFICDB, IFIPAT, IFIUDB, IMSPATENTS, IPA, MEDLINE, MRCK\*, NAPRALERT,  
 NIOSHTIC, PROMT, PS, RTECS\*, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4122 REFERENCES IN FILE CA (1907 TO DATE)  
 37 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 4128 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 43 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L29 ANSWER 118 OF 118 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 58-71-9 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, monosodium salt,  
 (6R,7R)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,  
 3-(hydroxymethyl)-8-oxo-7-[2-(2-thienyl)acetamido]-, acetate (ester),  
 monosodium salt (8CI)  
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,

3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-, monosodium salt,  
(6R-trans)-

## OTHER NAMES:

CN 38253  
CN Averon 1  
CN Cefalothin sodium  
CN Cefalothine sodium  
CN Cemastin  
CN Cephalothin sodium  
CN Cephalothin sodium salt  
CN Cephation  
CN Ceporacin  
CN Cepovenin  
CN Coaxin  
CN Keflin  
CN Lilly 38253  
CN Lospoven  
CN Microtin  
CN Seffin  
CN Sodium (thienylacetamido)cephalosporanate  
CN Sodium 3-acetoxymethyl-7 $\beta$ -(2-thienylacetamido)ceph-3-em-4-carboxylate  
CN Sodium 7-(2-thienylacetamido)-3-acetoxymethyl-3-cephem-4-carboxylate  
CN Sodium 7-[2-(2-thienyl)acetamido]cephalosporanate  
CN Sodium cefalotin  
CN Sodium cephalothin  
CN Sodium cephalotin  
CN Synclotin  
CN Toricelocin

## FS STEREOSEARCH

DR 11048-05-8, 63-60-5, 53493-25-7, 115699-56-4, 297760-78-2

MF C16 H16 N2 O6 S2 . Na

CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN,  
CSCHEM, DIOGENES, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IMSPATENTS,  
IPA, MRCK\*, NAPRALERT, PROMT, PS, RTECS\*, TOXCENTER, USAN, USPAT2,  
USPATFULL


(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CRN (153-61-7)

Absolute stereochemistry.



● Na

588 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
588 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d ide l32 tot

L32 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 11138-66-2 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Xanthan gum (9CI) (CA INDEX NAME)

Search done by Noble Jarrell

## OTHER NAMES:

CN Actigum CX 9  
 CN ADM 40  
 CN B 1459  
 CN Biopolymer 9702  
 CN Biopolymer XB 23  
 CN Biozan R  
 CN Bisfect XA 200  
 CN Bistop  
 CN Chemicogel  
 CN Duovis  
 CN E 415  
 CN Echogum  
 CN Echogum F  
 CN Echogum GM  
 CN Echogum RD  
 CN Echogum SF  
 CN Echogum T  
 CN Ekogum ketorol  
 CN Enorflo X  
 CN Flocon 1035  
 CN Flocon 4800  
 CN Flocon 4800C  
 CN Flodrill S  
 CN Galaxy XB  
 CN Gumixan K  
 CN Gums, xanthomonas  
 CN Idvis  
 CN Inagel V 10  
 CN Inagel V 10K  
 CN Jungbunzlauer ST  
 CN K 5C151  
 CN K 9C57  
 CN Kelco BT  
 CN Kelflo  
 CN Keltrol  
 CN Keltrol BT  
 CN Keltrol CG  
 CN Keltrol F  
 CN Keltrol K 5C151  
 CN Keltrol RD  
 CN Keltrol SF  
 CN Keltrol T  
 CN Keltrol TF  
 CN Keltrol TF 1000  
 CN Kelzan  
 CN Kelzan 140X  
 CN Kelzan AR  
 CN Kelzan ASX  
 CN Kelzan ASXT  
 CN Kelzan D

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

DR 478314-71-5, 12673-42-6, 12771-06-1, 9088-32-8, 54511-23-8, 56592-13-3,  
98112-77-7, 51811-95-1, 37189-49-4, 37279-85-9, 37332-19-7, 37383-52-1,  
80450-59-5, 85568-76-9, 82600-55-3, 39393-27-6, 39444-54-7

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration, Polyester, Polyester formed

LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BIOBUSINESS, BIOSIS, BIOTECHNO,  
CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN,  
CSCHEM, DDFU, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT,  
ENCOMPPAT2, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS,  
NAPRALERT, NIOSHTIC, PIRA, PROMT, TOXCENTER, TULSA, USPAT2, USPATFULL,  
VTB

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

## \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

8792 REFERENCES IN FILE CA (1907 TO DATE)  
 295 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 8814 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L32 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN

RN 9000-30-0 REGISTRY

ED Entered STN: 16 Nov 1984

CN **Guar gum (9CI)** (CA INDEX NAME)

## OTHER NAMES:

CN  $\alpha$ -D-galacto- $\beta$ -D-Mannan

CN  $\alpha$ -D-Galactopyrano- $\beta$ -D-mannopyranan

CN 1212A

CN Avicel CE 15

CN Burtonite V 7E

CN C 1000

CN C 1000 (gum)

CN C 250

CN C 250 (gum)

CN Celbond 7

CN Celca-Gum D 49D

CN CP 3300

CN CSA-M 175

CN CSAA-M 80

CN Cyamopsis gum

CN Dealca TP 1

CN Dealca TP 2

CN Decorpa

CN Dycol 4500

CN E 412

CN EGMB

CN Emcogum CSAA

CN Emulgum 200

CN Emulgum 200S

CN FFH 200

CN FG-HV

CN Fine Gum G

CN Fine Gum G 17

CN Frimulsion BM

CN G 50

CN Galactasol

CN Galactasol 20H5FI

CN Galactasol 211

CN Galactasol 270

CN Galactasol 30M1F

CN Galaxy 1083

CN Gendril Thik

CN Gendriv 162

CN Guapack PF 20

CN Guapack PN

CN Guar

CN Guar 5200

CN Guar flour

CN Guar HV 7000 CPS

CN Guar Supercol U Fine

CN Guaran

CN Guarcel 302

CN Guarcol U 40

CN Guargel D 15

CN Gum cyamopsis

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
 DISPLAY

DR 9008-17-7, 9010-50-8, 9049-33-6, 9066-07-3, 53986-27-9, 57406-68-5,  
 57406-71-0, 63799-54-2, 85510-16-3

MF Unspecified

CI PMS, COM, MAN

PCT Manual registration, Polyother, Polyother only

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, ACQUIRE, BIOBUSINESS, BIOSIS,

BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,  
 CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*,  
 IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT,  
 NIOSHTIC, PHAR, PIRA, PROMT, RTECS\*, TOXCENTER, TULSA, USPAT2,  
 USPATFULL, VTB

(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


6618 REFERENCES IN FILE CA (1907 TO DATE)  
 822 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 6632 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d ide 140 tot

L40 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **827605-46-9** REGISTRY  
 ED Entered STN: 09 Feb 2005  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with ethyl  
 2-propenoate, triblock (9CI) (CA INDEX NAME)  
 MF (C5 H8 O2 . C5 H8 O2)x  
 CI PMS  
 PCT Polyacrylic  
 SR CA


CM 1

CRN 140-88-5  
 CMF C5 H8 O2



CM 2


CRN 80-62-6  
 CMF C5 H8 O2




L40 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **736998-33-7** REGISTRY  
 ED Entered STN: 01 Sep 2004  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with ethyl  
 2-propenoate, diblock (9CI) (CA INDEX NAME)  
 MF (C5 H8 O2 . C5 H8 O2)x  
 CI PMS  
 PCT Polyacrylic  
 SR CA  
 LC STN Files: CA, CAPLUS

CM 1

CRN 140-88-5  
 CMF C5 H8 O2




CM 2


CRN 80-62-6  
CMF C5 H8 O24 REFERENCES IN FILE CA (1907 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **208663-46-1** REGISTRY  
 ED Entered STN: 19 Jul 1998  
 CN Acetic acid, 2-propenyl ester, polymer with 1-methylethenyl acetate (9CI)  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1-Propen-2-ol, acetate, polymer with 2-propenyl acetate (9CI)  
 MF (C5 H8 O2 . C5 H8 O2)x  
 CI PMS  
 PCT Polyvinyl  
 SR CA  
 LC STN Files: CA, CAPLUS

CM 1

CRN 591-87-7  
CMF C5 H8 O2

CM 2


CRN 108-22-5  
CMF C5 H8 O21 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN **121917-49-5** REGISTRY  
 ED Entered STN: 04 Aug 1989  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with ethyl  
 2-propenoate, block (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 2-Propenoic acid, ethyl ester, polymer with methyl 2-methyl-2-propenoate,  
 block (9CI)  
 OTHER NAMES:  
 CN Ethyl acrylate-methyl methacrylate block copolymer  
 CN Methyl methacrylate-ethyl acrylate block copolymer

MF (C5 H8 O2 . C5 H8 O2)x  
 CI PMS, COM  
 PCT Polyacrylic  
 SR CA  
 LC STN Files: CA, CAPLUS, USPAT2, USPATFULL


CM 1

CRN 140-88-5  
 CMF C5 H8 O2



CM 2

CRN 80-62-6  
 CMF C5 H8 O2




29 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 29 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 113547-51-6 REGISTRY  
 ED Entered STN: 26 Mar 1988  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with ethyl  
 2-propenoate, graft (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 2-Propenoic acid, ethyl ester, polymer with methyl 2-methyl-2-propenoate,  
 graft (9CI)  
 OTHER NAMES:  
 CN Ethyl acrylate-methyl methacrylate graft copolymer  
 MF (C5 H8 O2 . C5 H8 O2)x  
 CI PMS  
 PCT Polyacrylic  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

CM 1


CRN 140-88-5  
 CMF C5 H8 O2



CM 2

CRN 80-62-6  
 CMF C5 H8 O2





23 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 23 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L40 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 9010-88-2 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with ethyl 2-propenoate (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 2-Propenoic acid, ethyl ester, polymer with methyl 2-methyl-2-propenoate (9CI)  
 CN Acrylic acid ethyl ester, polymer with methyl methacrylate (8CI)  
 CN Methacrylic acid methyl ester, polymer with ethyl acrylate (8CI)  
 OTHER NAMES:  
 CN 2817D  
 CN Acrilem 674  
 CN Acryloid B 44S  
 CN Acryloid B 72  
 CN Acryloid B 82  
 CN Acryloid K 120N  
 CN Acryloid K 120NL  
 CN Acryloid K 130  
 CN Acryloid K 147  
 CN Altuglas 9E  
 CN Altulite 2773  
 CN Cevian A 45000  
 CN CP 41  
 CN CP 41 (acrylate polymer)  
 CN Daitosol 5000AD  
 CN Diakon APA 1  
 CN Diakon MG 102  
 CN Dianal BR 64  
 CN Elvacite EX 2612  
 CN Ethyl acrylate-methyl methacrylate copolymer  
 CN Ethyl acrylate-methyl methacrylate polymer  
 CN Eudragit E 30D  
 CN Eudragit NE 30D  
 CN Flexbond 984  
 CN K 120N  
 CN K 130  
 CN K 147  
 CN Kollicoat EMM 30D  
 CN Lucite 30  
 CN Methyl methacrylate-ethyl acrylate copolymer  
 CN Methyl methacrylate-ethyl acrylate polymer  
 CN MG 102  
 CN NeoCryl BT 20  
 CN New Coat PV 400  
 CN New Coat PV 412  
 CN Oroglass V 825T  
 CN PA 20  
 CN PA 20 (acrylic polymer)  
 CN Paraloid B 44S  
 CN Paraloid B 72  
 CN Paraloid B 82  
 CN Paraloid K 120N  
 CN Paraloid K 120NL  
 CN Paraloid K 130  
 CN Plexiglas VS 100  
 CN Plexigum MB 319  
 CN Preparation 2817D  
 ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY

DR 9011-72-7, 9046-85-9, 9048-98-0, 53986-74-6, 54018-07-4, 54183-02-7,  
55719-51-2, 60318-38-9, 62534-36-5, 63251-48-9, 97794-17-7, 98036-92-1,  
99550-83-1, 51109-48-9, 51311-84-3, 51801-09-3, 52019-30-4, 136303-31-6,  
137087-70-8, 37199-58-9, 72394-19-5, 72626-02-9, 85897-95-6, 30174-68-6,  
39301-09-2, 39390-68-6, 107950-48-1, 181591-72-0, 211629-39-9

MF (C5 H8 O2 . C5 H8 O2)x

CI PMS, COM

PCT Polyacrylic

LC STN Files: BIOBUSINESS, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN,  
CSCHEM, DDFU, DRUGU, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS,  
PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL


Other Sources: DSL\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 140-88-5


CMF C5 H8 O2



CM 2

CRN 80-62-6

CMF C5 H8 O2



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

2711 REFERENCES IN FILE CA (1907 TO DATE)

55 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

2714 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d fcn 140 6

L40 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2005 ACS on STN

CN 2-Propenoic acid, 2-methyl-, methyl ester, polymer with ethyl 2-propenoate  
(9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Propenoic acid, ethyl ester, polymer with methyl 2-methyl-2-propenoate  
(9CI)

CN Acrylic acid ethyl ester, polymer with methyl methacrylate (8CI)

CN Methacrylic acid methyl ester, polymer with ethyl acrylate (8CI)

OTHER NAMES:

CN 2817D

CN Acrilem 674

CN Acryloid B 44S

CN Acryloid B 72

CN Acryloid B 82

CN Acryloid K 120N

CN Acryloid K 120NL

CN Acryloid K 130

CN Acryloid K 147

CN Altuglas 9E

CN Altulite 2773

CN Cevian A 45000

CN CP 41

CN CP 41 (acrylate polymer)

Search done by Noble Jarrell

CN Daitosol 5000AD  
 CN Diakon APA 1  
 CN Diakon MG 102  
 CN Dianal BR 64  
 CN Elvacite EX 2612  
 CN Ethyl acrylate-methyl methacrylate copolymer  
 CN Ethyl acrylate-methyl methacrylate polymer  
 CN Eudragit E 30D  
 CN Eudragit NE 30D  
 CN Flexbond 984  
 CN K 120N  
 CN K 130  
 CN K 147  
 CN Kollicoat EMM 30D  
 CN Lucite 30  
 CN Methyl methacrylate-ethyl acrylate copolymer  
 CN Methyl methacrylate-ethyl acrylate polymer  
 CN MG 102  
 CN NeoCryl BT 20  
 CN New Coat PV 400  
 CN New Coat PV 412  
 CN Oroglas V 825T  
 CN PA 20  
 CN PA 20 (acrylic polymer)  
 CN Paraloid B 44S  
 CN Paraloid B 72  
 CN Paraloid B 82  
 CN Paraloid K 120N  
 CN Paraloid K 120NL  
 CN Paraloid K 130  
 CN Plexiglas VS 100  
 CN Plexigum MB 319  
 CN Preparation 2817D  
 CN Primal AC 22  
 CN Primal AC 33  
 CN Primal B 52  
 CN Rhoplex AC 22  
 CN Rhoplex AC 33  
 CN Rhoplex AC 35  
 CN Rhoplex B 52  
 CN Romacril ER  
 CN Rowney Cryla  
 CN Sokrat 602  
 CN Sumipex EX  
 CN Sumipex LG 35  
 CN Ucecryl H  
 CN VS 100  
 CN Yodo Sol GH 28

=> d his

(FILE 'HOME' ENTERED AT 07:56:46 ON 19 APR 2005)

FILE 'REGISTRY' ENTERED AT 07:57:20 ON 19 APR 2005  
 ACT QAZ194CEP/A

L1 QUE ABB=ON PLU=ON (PMS OR MAN OR IDS)/CI OR UNSPECIFIE  
 L2 ( 79)SEA FILE=REGISTRY ABB=ON PLU=ON C16H16N2O6S2 AND SC4/ES AND N  
 L3 ( 43)SEA FILE=REGISTRY ABB=ON PLU=ON L2 AND NR=3  
 L4 ( 35)SEA FILE=REGISTRY ABB=ON PLU=ON L3 NOT (MXS/CI OR MIXT OR MET  
 L5 ( 29)SEA FILE=REGISTRY ABB=ON PLU=ON (1051-68-9/BI OR 117091-43-7/  
 L6 ( 1)SEA FILE=REGISTRY ABB=ON PLU=ON L5 AND 3-METHYL  
 L7 ( 28)SEA FILE=REGISTRY ABB=ON PLU=ON L5 NOT L6  
 L8 ( 32)SEA FILE=REGISTRY ABB=ON PLU=ON C18H19N3O5S AND NC3-NCSC3/ES  
 L9 ( 26)SEA FILE=REGISTRY ABB=ON PLU=ON L8 NOT L1  
 L10 ( 5)SEA FILE=REGISTRY ABB=ON PLU=ON L9 AND CEFPPOZ?  
 L11 ( 12)SEA FILE=REGISTRY ABB=ON PLU=ON C25H28N6O7S3 AND NR=4 AND NC3  
 L12 ( 11)SEA FILE=REGISTRY ABB=ON PLU=ON L11 NOT NC5/ES  
 L13 ( 7)SEA FILE=REGISTRY ABB=ON PLU=ON C16H17N3O5S AND NR=3 AND NC3-

Search done by Noble Jarrell

L14 ( 2)SEA FILE=REGISTRY ABB=ON PLU=ON C21H27N5O9S2 AND NR=3 AND NC3  
 L15 ( 2)SEA FILE=REGISTRY ABB=ON PLU=ON C20H22N4O10S AND NR=3 AND NC3  
 L16 ( 4)SEA FILE=REGISTRY ABB=ON PLU=ON C15H14CLN3O4S AND CEFAC? AND  
 L17 ( 5)SEA FILE=REGISTRY ABB=ON PLU=ON C18H18N6O5S2 AND CEFAMAND? AN  
 L18 ( 4)SEA FILE=REGISTRY ABB=ON PLU=ON L17 NOT COMPD  
 L19 ( 17)SEA FILE=REGISTRY ABB=ON PLU=ON C16H17N3O7S2 AND NR=3 AND NC3  
 L20 ( 17)SEA FILE=REGISTRY ABB=ON PLU=ON C17H17N3O6S2 AND NR=3 AND NC3  
 L21 ( 15)SEA FILE=REGISTRY ABB=ON PLU=ON (21593-22-6/BI OR 21593-23-7/  
 L22 ( 44)SEA FILE=REGISTRY ABB=ON PLU=ON C13H13N5O5S2 AND NCSC2/ES AND  
 L23 ( 35)SEA FILE=REGISTRY ABB=ON PLU=ON L22 NOT LI  
 L24 ( 28)SEA FILE=REGISTRY ABB=ON PLU=ON L23 NOT (MXS/CI OR MIXT)  
 L25 ( 18)SEA FILE=REGISTRY ABB=ON PLU=ON (102044-69-9/BI OR 109323-67-  
 L26 ( 8)SEA FILE=REGISTRY ABB=ON PLU=ON C18H18N6O8S3 AND N4C/ES AND C  
 L27 ( 6)SEA FILE=REGISTRY ABB=ON PLU=ON L26 NOT MIXT  
 L28 ( 5)SEA FILE=REGISTRY ABB=ON PLU=ON L27 NOT COMPD  
 L29 118 SEA FILE=REGISTRY ABB=ON PLU=ON L7 OR L10 OR L12 OR L13 OR L1

ACT QAZ194GAL1/A

L30 ( 1)SEA FILE=REGISTRY ABB=ON PLU=ON "XANTHAN GUM"/CN  
 L31 ( 1)SEA FILE=REGISTRY ABB=ON PLU=ON "GUAR GUM"/CN  
 L32 2 SEA FILE=REGISTRY ABB=ON PLU=ON L30 OR L31

ACT QAZ194GAL2/A

L33 ( 100)SEA FILE=REGISTRY ABB=ON PLU=ON XANTHAN (1A) GUM?  
 L34 ( 82)SEA FILE=REGISTRY ABB=ON PLU=ON L33 NOT (COMPD OR COMPOUND)  
 L35 ( 53)SEA FILE=REGISTRY ABB=ON PLU=ON L34 NOT PMS/CI  
 L36 ( 290)SEA FILE=REGISTRY ABB=ON PLU=ON GUAR (W) GUM  
 L37 ( 288)SEA FILE=REGISTRY ABB=ON PLU=ON L36 NOT (COMPD OR COMPOUND)  
 L38 338 SEA FILE=REGISTRY ABB=ON PLU=ON L35 OR L37

ACT QAZ194POL1/A

L39 ( 32)SEA FILE=REGISTRY ABB=ON PLU=ON "(C5H8O2.C5H8O2)X"/MF  
 L40 6 SEA FILE=REGISTRY ABB=ON PLU=ON (113547-51-6/BI OR 121917-49-

FILE 'HCAPLUS' ENTERED AT 08:05:34 ON 19 APR 2005

L41 11259 L29 OR CEFADROXIL OR CEFTIZOXIME OR CEFPODOXIME (1A) PROXET? OR  
 L42 521 BMY28167 OR BMY (1A) (28167 OR 28 (1A) 167) OR CEFZIL# OR PRO!E  
 L43 1813 CEFODIE OR MONOCIDUR# OR MOPNOCID# OR PRATICEF# OR CEFIZOX# OR  
 L44 286 CEFTISOMIN# OR EPOCELIN# OR DURICEF# OR CCI15641 OR CCI (1A) (1  
 L45 122 LILLY99368 OR LILLY (1A) (99368 OR 99 (1A) 368) OR PANORAL# OR  
 L46 1207 HYDROXYCEPHALIN# OR CEPHITOXIN# OR CEFADOLE OR CEFAMANDOL OR CE  
 L47 525 CEFADYL# OR CEFALOJECT# OR CEFAPRIN# OR CEFATRAXYL OR CEPHATREX  
 L48 2500 CEPHALOSPORAN? (1A) ACID OR CEPHALOSPORANATE OR ?ACETAMIDO (1A)  
 L49 92 MICROTIN# OR SEFFIN# OR ?ACETAMIDO/BI (1A) CEPH OR SYNCLOTIN# O  
 E CEPHALEXIN/CT  
 E E3+ALL  
 L50 3267 CEPHALEXIN/CT  
 E CEFPROZIL/CT  
 E CEFDITOREN/CT  
 E CEFADROXIL/CT  
 E E3+ALL  
 L51 881 CEFADROXIL/CT  
 E CEFPODOXIME/CT  
 E CEFUROXIME/CT  
 E E3+ALL  
 L52 2607 CEFUROXIME/CT  
 E CEFACLOX/CT  
 E E3+ALL  
 L53 1483 CEFACLOX/CT  
 E CEFAMANDOLE/CT  
 E E3+ALL  
 L54 1642 CEFAMANDOLE/CT  
 E CEFITOXIN/CT  
 E CEFOXITIN/CT  
 E E3+ALL  
 L55 3075 CEFOXITIN/CT

E CEPALOTHIN/CT  
 E CEPHAPIRIN/CT  
 E E3+ALL  
 L56 561 CEPHAPIRIN/CT  
 E CEFTIZOXIME/CT  
 E E3+ALL  
 L57 1070 CEFTIZOXIME/CT  
 E CEFONICID/CT  
  
 FILE 'REGISTRY' ENTERED AT 09:17:12 ON 19 APR 2005  
 E GALACTOMANNAN/CN  
 L58 75 GALACTOMANNAN OR GALACTO (1A) MANNAN?  
  
 FILE 'HCAPLUS' ENTERED AT 09:18:24 ON 19 APR 2005  
 L59 3355 L58 OR GALACTO (1A) MANNAN? OR DAIKOL? OR FAIBARON? OR GALACTOM  
 E GALCTOMANNAN/CT  
 E GALACTOMANNAN/CT  
 E E3+ALL  
 L60 2078 GALACTOMANNAN+OLD/CT  
 L61 49966 L32 OR L38 OR XANTHAN (1A) GUM OR ACTIGUM? OR ADM40 OR ADM (1A)  
 L62 893 IDVIS OR INAGEL? OR JUNGBUNZLAUER? OR K5C151 OR K9C57 OR K (1A)  
 L63 38695 GUAR (1A) GUM OR EMCOGUM? OR DEALCA? OR EMULGUM? OR FINE (1A) G  
 E XANTHAN/CT  
 E E4+ALL  
 L64 8814 XANTHAN GUM/CT  
 E GUAR GUM/CT  
 E E3+ALL  
 L65 7040 GUAR GUM+NT/CT  
 E LOCUAT/CT  
 E BEAN/CT  
 E BEAN GUM/CT  
 E E4+ALL  
 E SWELLING AGENTS/CT  
 E E3+ALL  
 L66 105 SWELLING AGENTS/CT (L) POLYMER?  
 L67 5193 (POLYMER?/CW OR POLYMERS+OLD,NT1/CT) (L) SWELL?  
 L68 7289 L40 OR PROPENOIC (1A) ACID (1A) 2 (1A) METHYL (5A) ETHYL (1A) P  
 L69 10274 ALTUGLAS? OR ALTIVITE? OR CEVIAN? OR CP41? OR CP (1A) 41 OR DAI  
 L70 2505 NEOCRYL? OR NEW (1A) COAT (1A) (PV400 OR PV412 OR PV (1A) (400  
 L71 6989 ROWNEY (1A) CRYLA OR SOKRAT? OR SUMIPEX? OR UCECRYL? OR VS100 O  
 E KSHIRSAGAR R/AU  
 L72 10 E3, E6-7  
 E BOLDHANE S/AU  
 L73 3 E4  
 E JINDAL K/AU  
 L74 34 E3-4, E10  
 L75 64 (ORCHID AND CHEM? AND PHARM?)/CS, PA  
 L76 QUE PY<=2003 OR AY<=2003 OR PRY<=2003 OR PD<20030818 OR AD<2003  
 L77 58 L41-57 AND L58-65  
 L78 5 L77 AND L72-75  
 L79 53 L77 NOT L78  
 L80 6 L79 AND L68-71  
 L81 6 L80 AND L76

=> b hcap

FILE 'HCAPLUS' ENTERED AT 09:47:58 ON 19 APR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
 held by the publishers listed in the PUBLISHER (PB) field (available  
 for records published or updated in Chemical Abstracts after December  
 26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the  
 the American Chemical Society and is provided to assist you in searching  
 databases on STN. Any dissemination, distribution, copying, or storing  
 of this information, without the prior written consent of CAS, is  
 strictly prohibited.

FILE COVERS 1907 - 19 Apr 2005 VOL 142 ISS 17  
FILE LAST UPDATED: 18 Apr 2005 (20050418/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d all 178 tot

L78 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:412577 HCAPLUS  
DN 140:395542  
ED Entered STN: 21 May 2004  
TI Sustained release pharmaceutical composition of a cephalosporin antibiotic  
IN Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao  
; Jindal, Kour Chand  
PA Orchid Chemicals & Pharmaceuticals Limited,  
India  
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 222,930.  
CODEN: USXXCO  
DT Patent  
LA English  
IC ICM A61K031-545  
ICS A61K009-20; A61K031-736  
NCL 424465000; 514200000; 514054000  
CC 63-6 (Pharmaceuticals)  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004096496	A1	20040520	US 2003-642194	20030818
	US 2004033262	A1	20040219	US 2002-222930	20020819
	WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	IN 2002-MA601	A	20020816		
	US 2002-222930	A2	20020819		
	WO 2002-IB3320	A	20020819		

# CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004096496	ICM	A61K031-545
	ICS	A61K009-20; A61K031-736
	NCL	424465000; 514200000; 514054000
US 2004096496	ECLA	A61K031/545; A61K031/546
US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736

AB Sustained release pharmaceutical compns. comprising at least a  
cephalosporin antibiotic, a mixture of polymers comprising of  
**galactomannans** and neutral swellable polymers, and other  
pharmaceutically acceptable excipients are described. The composition  
comprises about 30% to about 90% by weight of a cephalosporin antibiotic;  
about 1% to about 30% by weight of said mixture of polymers comprising from  
about 0.1% to about 15% by weight of **galactomannans**, and about 0.1%  
to about 15% of neutral swellable polymer by weight of sustained release  
composition  
ST cephalosporin antibiotic sustained release tablet  
IT Drug delivery systems  
(carriers; sustained-release pharmaceutical composition of a cephalosporin  
antibiotic)  
IT Lubricants

- (pharmaceutical; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Swelling agents  
(polymers; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Antibiotics  
Binders  
Drying  
Mixing  
Plasticizers  
Sieving  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Gelatins, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Polyesters, biological studies  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Drug delivery systems  
(sustained-release; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Polymers, biological studies  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(swellable; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Drug delivery systems  
(tablets, coated; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Drug delivery systems  
(tablets; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT Fats and Glyceridic oils, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 7631-86-9, Silicon dioxide, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(colloidal; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 9004-34-6, Cellulose, biological studies  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(microcryst.; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 9005-25-8, Starch, biological studies  
RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pregelatinized; sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 9003-39-8, Polyvinylpyrrolidone 9004-62-0, Hydroxyethylcellulose  
9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methylcellulose  
RL: MOA (Modifier or additive use); POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 57-11-4, Stearic acid, biological studies 57-50-1, Sucrose, biological studies 557-04-0, Magnesium stearate 557-05-1, Zinc stearate 1592-23-0, Calcium stearate 9000-30-0, Guar gum 11138-66-2, Xanthan gum 14807-96-6, Talc, biological studies  
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained-release pharmaceutical composition of a cephalosporin antibiotic)
- IT 153-61-7, Cephalothin 11078-30-1, Galactomannan 11111-12-9D, Cephalosporins, derivs. 15686-71-2, Cephalixin

21593-23-7, Cephapirin 34444-01-4,  
 Cefamandole 35607-66-0, Cefoxitin 50370-12-2,  
 Cefadroxil 53994-73-3, Cefaclor  
 61270-58-4, Cefonicid 64544-07-6, Cefuroxime  
 axetil 68401-81-0, Cefprozil 87239-81-4,  
 Cefpodoxime proxetil 92665-29-7,  
 Cefprozil 117467-28-4, Cefditoren  
 pivoxil

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(sustained-release pharmaceutical composition of a cephalosporin antibiotic)

IT 9004-32-4 9010-88-2, Ethyl acrylate-methyl methacrylate copolymer  
 9050-04-8, Calcium carboxymethyl cellulose 25086-89-9, Plasdone S-630  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained-release pharmaceutical composition of a cephalosporin antibiotic)

IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose 9004-53-9, Dextrin 66828-18-0, Dextrate 74811-65-7, Croscarmellose sodium

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained-release pharmaceutical composition of a cephalosporin antibiotic)

L78 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:162583 HCAPLUS

DN 140:205146

ED Entered STN: 29 Feb 2004

TI Sustained release pharmaceutical compositions of a cephalosporin

IN **Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao**  
 ; Jindal, Kour Chand

PA **Orchid Health Care, A Division of Orchid Chemicals & Pharmaceuticals Ltd., India**

SO PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-22

ICS A61K031-545; A61K031-546

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016251	A1	20040226	WO 2003-IB3340	20030818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004033262	A1	20040219	US 2002-222930	20020819
	WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	IN 2002-MA601	A	20020816		
	US 2002-222930	A	20020819		
	WO 2002-IB3320	A	20020819		



CLASS	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 2004016251	ICM	A61K009-22
		ICS	A61K031-545; A61K031-546
	US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736
AB	Sustained release pharmaceutical compns. comprising at least a cephalosporin, a mixture of polymers comprising of <b>galactomannans</b> and neutral swellable polymers, and other pharmaceutically acceptable excipients are described. The composition comprises 30-90% of a cephalosporin antibiotic, 1-30% mixture of polymers comprising 0.1-15% <b>galactomannans</b> , and 0.1-15% by weight of a neutral swellable polymer. Thus, tablets contained cephalixin monohydrate 75.73, lactose 6.27, <b>xanthan gum</b> 7.0, Eudragit NE 30D 7.0, HPMC E5 31.5, Mg stearate 1.0 and water qs to 100%.		
ST	sustained release cephalosporin polymer		
IT	Drug delivery systems (granules, sustained release; sustained release pharmaceutical compns. of cephalosporins)		
IT	Binders Dissolution Drug bioavailability Human Lubricants Plasticizers (sustained release pharmaceutical compns. of cephalosporins)		
IT	Carbohydrates, biological studies Gelatins, biological studies Polymers, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sustained release pharmaceutical compns. of cephalosporins)		
IT	Drug delivery systems (sustained-release; sustained release pharmaceutical compns. of cephalosporins)		
IT	Drug delivery systems (tablets, sustained-release; sustained release pharmaceutical compns. of cephalosporins)		
IT	Fats and Glyceridic oils, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (vegetable, hydrogenated; sustained release pharmaceutical compns. of cephalosporins)		
IT	9004-34-6, Cellulose, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (microcryst.; sustained release pharmaceutical compns. of cephalosporins)		
IT	<b>15686-71-2, Cephalixin 50370-12-2, Cefadroxil</b> RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sustained release pharmaceutical compns. of cephalosporins)		
IT	50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 57-11-4, Stearic acid, biological studies 63-42-3, Lactose 69-65-8, Mannitol 69-79-4, Maltose <b>153-61-7, Cephalothin</b> 557-04-0 557-05-1, Zinc stearate 1592-23-0, Calcium stearate 7631-86-9, Silica, biological studies <b>9000-30-0, Guar gum</b> 9000-40-2, Locust bean gum 9003-39-8, Polyvinylpyrrolidone 9004-53-9, Dextrin 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-25-8, Starch, biological studies 9010-88-2, Eudragit NE 30D 9050-04-8, Calcium carboxymethyl cellulose 9063-38-1, Sodium starch glycolate <b>11078-30-1, Galactomannan</b> 11111-12-9, Cephalosporin <b>11138-66-2, Xanthan gum</b> 14807-96-6, Talc, biological studies <b>21593-23-7, Cephapirin</b> 23325-78-2, Cephalixin monohydrate 25086-89-9, Plasdone S-630 <b>34444-01-4, Cefamandole</b> <b>35607-66-0, Cefoxitin</b> <b>53994-73-3, Cefaclor</b> <b>61270-58-4, Cefonicid</b> <b>64544-07-6, Cefuroxime</b> axetil <b>68401-81-0, Ceftizoxime</b> 74811-65-7, Croscarmellose sodium <b>87239-81-4, Cefpodoxime proxetil</b> <b>92665-29-7, Cefprozil</b> 104145-95-1,		

**Cefditoren 117467-28-4, Cefditoren pivoxil 121123-17-9, Cefprozil monohydrate**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sustained release pharmaceutical compns. of cephalosporins)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Lupin Lab Ltd; WO 0241876 A 2002 HCAPLUS  
(2) Shankar, M; WO 02067943 A 2002 HCAPLUS  
(3) Squibb Bristol Myers Co; WO 9846213 A 1998 HCAPLUS

L78 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:142610 HCAPLUS

DN 140:187392

ED Entered STN: 22 Feb 2004

TI Sustained-release pharmaceutical composition of a cephalosporin antibiotic

IN **Kshirsagar, Rajesh Suresh; Boldhane, Sanjay Parbhatrao**  
**; Jindal, Kour Chand**

PA Orchid Health Care, India

SO U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-545

ICS A61K031-736; A61K009-20; A61K009-22

NCL 424468000; 514054000; 514200000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004033262	A1	20040219	US 2002-222930	20020819
	WO 2004016250	A1	20040226	WO 2002-IB3320	20020819
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	WO 2004016251	A1	20040226	WO 2003-IB3340	20030818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004096496	A1	20040520	US 2003-642194	20030818
PRAI	IN 2002-MA601	A	20020816		
	US 2002-222930	A	20020819		
	WO 2002-IB3320	A	20020819		

**CLASS**

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004033262	ICM	A61K031-545
	ICS	A61K031-736; A61K009-20; A61K009-22
	NCL	424468000; 514054000; 514200000
US 2004033262	ECLA	A61K009/20H6B; A61K009/20H6F; A61K031/545; A61K031/546; A61K031/736
US 2004096496	ECLA	A61K031/545; A61K031/546

AB A sustained release pharmaceutical composition comprising at least a cephalosporin antibiotic and a mixture of polymers and other pharmaceutically acceptable excipients is described. Polymers are selected from mixture of **galactomannans** and neutral swellable

polymers, which releases the active ingredient in a predetd. manner. For example, a sustained-release tablet composition contained cephalexin 795.32 mg, lactose 107.68 mg, **xanthan gum** 31.5 mg, Eudragit NE 30D 52.5 mg, HPMC E5 52.5 mg, and magnesium stearate 10.5 mg. Cephalexin release from the tablets was 25.21%, 50.84%, 73.18%, and 84.17% after 1h, 6 h, 10 h and 14 h, resp.

- ST cephalosporin polymer mixt sustained release tablet  
 IT Dissolution  
 Drug bioavailability  
 Granulation  
 (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)  
 IT Polymers, biological studies  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)  
 IT Drug delivery systems  
 (sustained-release; sustained-release composition of cephalosporin antibiotic containing mixture of polymers)  
 IT Drug delivery systems  
 (tablets, sustained-release; sustained-release composition of cephalosporin antibiotic containing mixture of polymers)  
 IT **9000-30-0, Guar gum** 9000-40-2, Locust bean gum 9010-88-2, Eudragit NE 30D **11078-30-1, Galactomannan 11138-66-2, Xanthan gum**  
 RL: POF (Polymer in formulation); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)  
 IT **153-61-7, Cephalothin** 11111-12-9, Cephalosporin **15686-71-2, Cephalexin 21593-23-7, Cefaprin** **34444-01-4, Cefamandole 35607-66-0, Cefoxitin** **50370-12-2, Cefadroxil 53994-73-3, Cefaclor 61270-58-4, Cefonicid** **64544-07-6, Cefuroxime axetil 68401-81-0, Cefprozil 87239-81-4, Cefpodoxime proxetil 92665-29-7, Cefprozil** **117467-28-4, Cefditoren pivoxil**  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sustained-release composition of cephalosporin antibiotic containing mixture of polymers)

L78 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:417601 HCAPLUS  
 DN 139:12261  
 ED Entered STN: 01 Jun 2003  
 TI A pharmaceutical composition for controlled release of a  $\beta$ -lactam antibiotic  
 IN Sen, Himadri; **Kshirsagar, Rajesh Suresh**; Bhamare, Shailesh Suresh  
 PA Lupin Limited, India  
 SO PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-22  
 ICS A61K031-545; A61K031-24  
 CC 63-6 (Pharmaceuticals)  
 Section cross-reference(s): 1

FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003043607	A1	20030530	WO 2001-IN204	20011119
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,			

UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 EP 1461017 A1 20040929 EP 2001-274758 20011119  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 BR 2001017171 A 20041026 BR 2001-17171 20011119  
 US 2005031685 A1 20050210 US 2004-495961 20040518  
 PRAI WO 2001-IN204 W 20011119

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003043607	ICM	A61K009-22
	ICS	A61K031-545; A61K031-24
US 2005031685	ECLA	A61K009/20H2; A61K009/20H4B; A61K009/20H6F; A61K009/20H6F2; A61K009/20K4B; A61K031/24; A61K031/24+M; A61K031/545; A61K031/545+M; A61K033/06+M
AB		An improved stable pharmaceutical composition for controlled release of an active ingredient comprises a $\beta$ -lactam antibiotic such as cephalixin, <b>cefaclor</b> or their hydrates, salts or esters as active ingredients, a calcium salt and a mixture of hydrophilic polymers selected from the group consisting of sodium alginate and <b>xanthan gum</b> and with or without hydroxypropyl Me cellulose, the composition optionally containing probenecid. The composition may also contain a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymers and water soluble and/or water dispersible diluents are such that the active ingredient is released at a rate suitable for once or twice daily administration of the pharmaceutical composition. Thus, tablets contained cephalixin 73.87, sodium alginate 6.00, <b>xanthan gum</b> 5.00, Methocel K15M 5.00, calcium sulfate 0.72, lactose monohydrate 7.40, and Mg stearate 2.00% by weight
ST		pharmaceutical controlled release beta lactam antibiotic
IT		Drug delivery systems (controlled-release; pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		Dissolution Drug bioavailability Human Lubricants (pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		Polymers, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		Drug delivery systems (solids, controlled release; pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		Drug delivery systems (tablets, controlled-release; pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		Antibiotics ( $\beta$ -lactam; pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		9004-34-6, Cellulose, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (microcryst.; pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		<b>15686-71-2</b> , Cephalixin RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical composition for controlled release of $\beta$ -lactam antibiotics)
IT		57-66-9, Probenecid 62-33-9 63-42-3, Lactose 299-28-5, Calcium gluconate 557-04-0 814-80-2, Calcium lactate 5743-27-1, Calcium ascorbate 7693-13-2, Calcium citrate 7778-18-9, Calcium sulfate 9004-65-3, Hydroxypropyl methyl cellulose 9005-38-3, Sodium alginate 9063-38-1, Starch, carboxymethyl ether, sodium salt 10043-52-4, Calcium

chloride, biological studies 11138-66-2, **Xanthan gum** 53994-73-3, **Cefaclor** 64044-51-5, Lactose monohydrate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical composition for controlled release of  $\beta$ -lactam antibiotics)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Boots Co Plc; EP 0234670 A 1987 HCAPLUS
- (2) Katz; WO 9822091 A 1998 HCAPLUS
- (3) Staniforth, J; WO 0015198 A 2000 HCAPLUS
- (4) Toyama Chem Co Ltd; JP 52105220 A 1977 HCAPLUS

L78 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:408511 HCAPLUS

DN 136:406868

ED Entered STN: 31 May 2002

TI Pharmaceutical composition for controlled release of a  $\beta$ -lactam antibiotic

IN Sen, Himadri; **Kshirsagar, Rajesh S.**; Kandi, Chandrashekhar S.; Bhamare, Shailesh

PA Lupin Laboratories Limited, India

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-22

ICS A61K009-24; A61K031-545

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002041876	A1	20020530	WO 2000-IN112	20001122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001027030	A5	20020603	AU 2001-27030	20001122
US 2002103181	A1	20020801	US 2000-726636	20001130
PRAI WO 2000-IN112	A	20001122		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2002041876	ICM	A61K009-22
---------------	-----	------------

	ICS	A61K009-24; A61K031-545
--	-----	-------------------------

US 2002103181	ECLA	A61K009/20H6F; A61K009/20K4B; A61K031/545
---------------	------	---

AB A tablet for controlled release of a  $\beta$ -lactam antibiotic, such as cephalixin, **cefaclor** or their pharmaceutically acceptable hydrates, salts or esters, comprises a mixture of hydrophilic polymers selected from the group consisting of at least one sodium alginate and at least one **xanthan gum** as controlled release matrix; and optionally probenecid as an antibiotic adjuvant as either immediate release or controlled release part. The composition may also contain one or more of a water soluble and/or water dispersible diluent, wherein the quantities of the hydrophilic polymer matrix still provides the desired once a day profile. The resulting modified release matrix formulation not containing probenecid may be administered once or twice daily, while the formulation containing probenecid may be administered once daily. For example, cephalixin controlled-release tablets were prepared from two parts: (1) a controlled-release part containing (by weight) cephalixin 72.58%, sodium alginate 14.00%, **xanthan gum** 7.00%, mannitol 5.45%, and magnesium stearate 0.96%, and an immediate-release part containing probenecid 79.36%, microcryst. cellulose 15.15%, sodium starch glycolate 5.00%, and magnesium stearate 0.47%. Cephalixin release in simulated intestinal fluid without pancreatin was 28.0%, 61.80%, 92.70%, and 101.60%

after 1, 4, 10, and 12 h, while probenecid release was 98.80%, 102.20%, and 103.30% after 10, 20, and 30 min, resp.

ST beta lactam antibiotic controlled release tablet dissoln

IT Polymers, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrophilic; preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT Compaction  
 Compression  
 Dissolution  
 (preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT Biopolymers  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT Drug delivery systems  
 (tablets, controlled-release; preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT Lactams  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 ( $\beta$ -, antibiotics; preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT Antibiotics  
 ( $\beta$ -lactam; preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT 7631-86-9, Colloidal silicon dioxide, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (colloidal, disintegrant; preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT 63-42-3, Lactose  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (diluent; preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT 9004-34-6, Cellulose, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (microcryst., diluent; preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT 57-66-9, Probenecid  
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT **15686-71-2, Cephalexin 53994-73-3, Cefaclor**  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

IT 69-65-8, D-Mannitol 557-04-0, Magnesium stearate 9005-25-8, Starch, biological studies 9005-38-3, Sodium alginate 9063-38-1, Sodium starch glycolate **11138-66-2, Xanthan gum**  
 14807-96-6, Talc, biological studies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation and dissoln. of  $\beta$ -lactam antibiotic controlled-release tablets)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE  
 (1) The Boots Company Plc; EP 0234670 A 1987 HCAPLUS  
 (2) Toyama Chem Co Ltd; JP 52105220 A 1977 HCAPLUS  
 (3) Yissum Research Development Company; WO 9822091 A 1998 HCAPLUS

=> d all hitrn 181 tot

L81 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:818128 HCAPLUS  
 DN 139:311996  
 ED Entered STN: 17 Oct 2003  
 TI Targeted controlled delivery compositions activated by changes in pH or

Search done by Noble Jarrell

salt concentration  
 IN Shefer, Adi; Shefer, Shmuel David  
 PA USA  
 SO U.S. Pat. Appl. Publ., 20 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 IC ICM A61K007-50  
 NCL 510444000; 510130000; 510504000  
 CC 62-5 (Essential Oils and Cosmetics)  
 Section cross-reference(s): 46, 63  
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003195133	A1	20031016	US 2002-119567	20020410 <—
	CA 2482225	AA	20031023	CA 2003-2482225	20030331 <—
	WO 2003087287	A1	20031023	WO 2003-US9607	20030331 <—
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP	1495103	A1	20050112	EP 2003-746560	20030331 <—
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
PRAI	US 2002-119567	A	20020410	<—	
	WO 2003-US9607	W	20030331	<—	

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2003195133	ICM	A61K007-50
	NCL	510444000; 510130000; 510504000
US 2003195133	ECLA	A61K008/04H; A61Q013/00; C11D003/00B9; C11D003/50B2; C11D017/00D <—

AB The present invention relates to a novel controlled release carrier system for pH or salt triggered release and targeted delivery of fragrances and other active ingredients onto fabric, hair, skin, and other biol. surfaces and which provides prolonged release of fragrances and other active ingredients over an extended period of time, or yields a high impact fragrance "burst" upon treating the target surface with heat (blow drying the hair, ironing the fabric). The controlled delivery system of the present invention is substantially a free-flowing powder formed of solid hydrophobic nanospheres comprising the fragrance and other active ingredients that are encapsulated in a pH- or salt-sensitive microspheres. Also described are processes for preparing such compns. and processes for using same. Furthermore, certain components of the aforementioned compns. in combination with one another are novel, and other components have novel uses in increasing fragrance substantivity, particularly in fabric, hair, and skin care prepns. The invention further pertains to consumer and diversified products comprising the controlled release system of the present invention. For example, polyethylene was melted in an oven, then mixed with water, **Eudragit** EPO, Hi-Cap 100, and polyethyleneimine. To the mixture, Incroquat Behenyl HE and a fragrance solution were added to form a suspension. The suspension was spray-dried to produce a free flowing, dry powder, consisting of 30 % fragrance encapsulated in solid hydrophobic nanospheres. Shampoos containing the above fragrances deposited higher level of fragrances on the hair, as compared to the control samples comprising the neat fragrances.

ST controlled release pH salt sensitive microsphere; fragrance encapsulation hydrophobic polymer shampoo

IT Fats and Glyceridic oils, biological studies  
 RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (Japan wax; targeted controlled delivery microspheres activated by changes in pH or salt concentration)

- IT Phenols, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkyl, ethoxylated; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Phenols, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(alkyl; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Surfactants  
(cationic; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Polyoxyalkylenes, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(di-Me, Me hydrogen polysiloxane-; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Polysiloxanes, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(di-Me, Me hydrogen, polyoxyalkylene-; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Quaternary ammonium compounds, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(dicoco alkyl dimethyl, Me sulfates; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Quaternary ammonium compounds, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(dimethylditallow alkyl, Me sulfates; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Quaternary ammonium compounds, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(dimethylditallow alkyl, chlorides; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Fatty acids, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(esters; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Monoglycerides  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ethoxylated; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Alcohols, biological studies  
Amines, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fatty, ethoxylated; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Alcohols, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(fatty; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Gelatins, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(formalized; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Surfactants  
(ionic; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Drug delivery systems  
(microspheres; targeted controlled delivery microspheres activated by changes in pH or salt concentration)



- IT Cosmetics  
(moisturizers; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Surfactants  
(nonionic; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Polyamines  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyalkylene-; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Alcohols, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(polyhydric; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Resins  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(sandarac; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Anesthetics
- Anti-inflammatory agents
- Antibacterial agents
- Antibiotics
- Antioxidants
- Fabric softeners
- Gums and Mucilages
- Hair preparations
- Hydrocolloids
- Odor and Odorous substances
- Perfumes
- Sunscreens
- pH  
(targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Candelilla wax
- Glutens
- Keratins
- Paraffin oils
- Petroleum, biological studies
- Polyamides, biological studies
- Polyesters, biological studies
- Polyoxyalkylenes, biological studies
- Polysaccharides, biological studies
- Polysiloxanes, biological studies
- Proteins
- Salts, biological studies
- Shellac
- Soybean oil
- Tannins
- Waxes  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Amines, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tertiary; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Fats and Glyceridic oils, biological studies  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(vegetable, hydrogenated; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT Lactams  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
( $\beta$ -, antibiotics; targeted controlled delivery microspheres

- activated by changes in pH or salt concentration)
- IT Antibiotics  
( $\beta$ -lactam; targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT 78-70-6, Linalool 106-24-1, Geraniol 18479-58-8, Dihydromyrcenol 20780-48-7, Tetrahydrolinalyl acetate  
RL: COS (Cosmetic use); MSC (Miscellaneous); BIOL (Biological study); USES (Uses)  
(targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT 50-70-4, Sorbitol, biological studies 56-81-5, Glycerin, biological studies 57-48-7, Fructose, biological studies 57-55-6, Propylene glycol, biological studies 69-72-7D, Salicylic acid, benzophenyl derivs. 69-72-7D, Salicylic acid, derivs. 69-93-2, Uric acid, biological studies 79-10-7D, Acrylic acid, derivs., polymers 79-41-4D, Methacrylic acid, derivs., polymers 87-99-0, Xylitol 91-64-5D, Coumarin, derivs. 94-41-7, Benzalacetophenone 107-21-1, Ethylene glycol, biological studies 107-41-5, Hexylene glycol 107-64-2, Distearyl dimethyl ammonium chloride 107-88-0, 1,3-Butanediol 118-55-8, Salol 118-92-3D, Anthranilic acid, derivs. 119-61-9D, Benzophenone, derivs. 123-31-9, Hydroquinone, biological studies 150-13-0, p-Aminobenzoic acid 538-58-9, Dibenzalacetone 621-82-9D, Cinnamic acid, derivs. 2568-33-4, Isoprene glycol 3843-16-1, Distearyl dimethyl ammonium methylsulfate 9002-88-4, Polyethylene 9002-89-5, Polyvinyl alcohol 9003-01-4, Polyacrylic acid 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, oxidized 9004-35-7, Cellulose acetate 9005-25-8D, Starch, derivs. 9006-26-2, Ethylene-maleic anhydride copolymer 9006-65-9, Dimethicone, 9011-16-9, Methyl vinyl ether-maleic anhydride copolymer 17301-53-0, Behenyltrimethylammonium chloride 24937-49-3, Polyornithine 24938-16-7, **Eudragit** EPO 25085-34-1, Acrylic acid-styrene copolymer 25104-12-5, Polyornithine 25104-18-1, Polylysine 25300-64-5, Maleic acid-styrene copolymer 25322-68-3, Polyethylene oxide 25322-69-4, Polypropylene glycol 25609-89-6, Crotonic acid-vinyl acetate copolymer 26336-38-9, Polyvinylamine 27323-69-9D, Dihydroxycinnamic acid, derivs. 38000-06-5, Polylysine 52907-01-4, Cellulose acetate trimellitate **65497-29-2**, Guar hydroxypropyl trimonium chloride 66829-29-6, Hi-Cap 100 71138-97-1, Hydroxypropyl methyl cellulose acetate succinate 220828-91-1, Incroquat Behenyl HE 426258-09-5, Incrosoft 100  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies 50-78-2, Aspirin 53-06-5, Cortisone 53-86-1, Indomethacin 54-64-8, Thimerosal 55-56-1, Chlorhexidine 55-86-7, Chloramine 56-75-7, Chloramphenicol 59-46-1, Procaine 60-54-8, Tetracycline 60-80-0, Antipyrine 75-47-8, Iodoform 94-09-7, Benzocaine 108-95-2, Phenol, biological studies 114-07-8, Erythromycin 124-94-7, Triamcinolone 137-58-6, Lidocaine 152-97-6, Fluocortolone 378-44-9,  $\beta$ -Methasone 443-48-1, Metronidazole 1404-04-2, Neomycin 1404-26-8, Polymyxin B 1404-90-6, Vancomycin 1405-97-6, Gramicidin 1406-05-9, Penicillin 5104-49-4, Flurbiprofen 8025-81-8, Spiramycin 8063-07-8, Kanamycin 10043-35-3, Boric acid, biological studies 15687-27-1, Ibuprofen 20283-69-6 22204-53-1, Naproxen 32385-11-8, Sisomicin 32986-56-4, Tobramycin **35607-66-0**, Cefoxitin 36322-90-4, Piroxicam 37517-28-5, Amikacin 59995-64-1, Thienamycin 64221-86-9  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT **65497-29-2**, Guar hydroxypropyl trimonium chloride  
RL: COS (Cosmetic use); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(targeted controlled delivery microspheres activated by changes in pH or salt concentration)
- IT **35607-66-0**, Cefoxitin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(targeted controlled delivery microspheres activated by changes in pH or salt concentration)

L81 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2003:42092 HCAPLUS  
 DN 138:112443  
 ED Entered STN: 17 Jan 2003  
 TI Tablet compositions for poorly-compressible pharmaceuticals  
 IN Matharu, Amol Singh; Patel, Mahendra R.  
 PA Geneva Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 20 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K031-155  
 ICS A61K009-20  
 CC 63-6 (Pharmaceuticals)  
 FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003004009	A1	20030116	WO 2002-US20323	20020627 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003021841	A1	20030130	US 2002-183881	20020627 <--
PRAI US 2001-302613P	P	20010702 <--		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 2003004009	ICM	A61K031-155
	ICS	A61K009-20

US 2003021841	ECLA	A61K009/20H4; A61K009/20H6F2	<--
---------------	------	------------------------------	-----

AB The present invention relates to a process for preparing tablet dosage forms of poorly-compressible pharmaceuticals and to tablet dosage forms. The process is especially useful for preparing tablets of the poorly-compressible drug metformin-HCl. Thus, tablets contained metformin-HCl 500, HPMC 320, stearyl alc. 200, and Mg stearate mg/unit.

ST tablet poorly compressible pharmaceutical

IT Glycerides, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (C16-18, hydrophobic excipient; tablet compns. for poorly-compressible pharmaceuticals)

IT Fatty acids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esters, hydrophobic excipient; tablet compns. for poorly-compressible pharmaceuticals)

IT Alcohols, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (fatty, hydrophobic excipient; tablet compns. for poorly-compressible pharmaceuticals)

IT Polyoxyalkylenes, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrophilic excipient; tablet compns. for poorly-compressible pharmaceuticals)

IT Fatty acids, biological studies

Waxes  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrophobic excipient; tablet compns. for poorly-compressible pharmaceuticals)

IT Protamines

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (sulfates; tablet compns. for poorly-compressible pharmaceuticals)

IT Dissolution

Hypnotics and Sedatives  
 (tablet compns. for poorly-compressible pharmaceuticals)

- IT Carnauba wax  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tablet compns. for poorly-compressible pharmaceuticals)
- IT Drug delivery systems  
(tablets; tablet compns. for poorly-compressible pharmaceuticals)
- IT 63-42-3, Lactose 9000-01-5, Acacia gum **9000-30-0, Guar gum** 9000-65-1, Tragacanth gum 9003-01-4, Carboxypolymethylene 9003-39-8, Polyvinylpyrrolidone 9004-32-4, Carboxymethyl cellulose sodium salt 9004-34-6D, Cellulose, derivs. 9004-42-6, Carboxyethyl cellulose 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 9004-67-5, Methyl cellulose 9005-38-3, Sodium alginate **11138-66-2, Xanthan gum** 25322-68-3, Polyethylene glycol 37353-59-6, Hydroxymethyl cellulose 74811-65-7, Croscarmellose sodium  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrophilic excipient; tablet compns. for poorly-compressible pharmaceuticals)
- IT 57-11-4, Stearic acid, biological studies 79-41-4D, Methacrylic acid, polymers 112-85-6, Behenic acid 112-92-5, Stearyl alcohol 9004-57-3, Ethyl cellulose **9010-88-2, Eudragit NE 30D** 31566-31-1, Glyceryl monostearate 36653-82-4, Cetyl alcohol 77538-19-3, Glyceryl behenate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(hydrophobic excipient; tablet compns. for poorly-compressible pharmaceuticals)
- IT 9004-34-6, Cellulose, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(microcryst.; tablet compns. for poorly-compressible pharmaceuticals)
- IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 50-33-9, Phenylbutazone, biological studies 50-34-0, Propantheline bromide 50-47-5, Desmethylinipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4, Quinidine sulfate 50-78-2, Acetylsalicylic acid 50-81-7, Ascorbic acid, biological studies 51-06-9, Procainamide 51-34-3, Scopolamine 51-43-4, Epinephrine 51-48-9, Thyroxine, biological studies 51-52-5, Propylthiouracil 52-01-7, Spironolactone 52-28-8, Codeine phosphate 52-53-9, Verapamil 52-86-8, Haloperidol 53-03-2, Prednisone 53-86-1, Indomethacin 54-31-9, Furosemide 55-56-1, Chlorhexidine 55-63-0, Glyceryl trinitrate 57-27-2, Morphine, biological studies 57-42-1, Pethidine 57-66-9, Probenecid 57-96-5, Sulfinpyrazone 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine 58-74-2, Papaverine 58-93-5, Hydrochlorthiazide 59-02-9 59-30-3, Folic acid, biological studies 59-43-8, Thiamine, biological studies 59-67-6, Nicotinic acid, biological studies 60-13-9, Amphetamine sulfate 60-32-2,  $\epsilon$ -Aminocaproic acid 61-68-7, Mefenamic acid 61-75-6, Bretylium tosylate 64-75-5, Tetracycline hydrochloride 64-77-7, Tolbutamide 65-23-6, Pyridoxine 69-23-8, Fluphenazine 69-53-4, Ampicillin 76-42-6, Oxycodone 77-19-0, Dicyclomine 77-36-1, Chlorthalidone 78-11-5, Pentaerythritol tetranitrate 86-22-6, Brompheniramine 86-54-4, Hydralazine 87-33-2, Isosorbide dinitrate 90-82-4, Pseudoephedrine 93-14-1, Guaiphenesin 94-20-2, Diabinese 103-90-2, Acetaminophen 113-15-5, Ergotamine 113-45-1, Methylphenidate 113-92-8 117-89-5, Trifluoperazine 122-09-8, Phentermine 123-03-5, Cetylpyridinium chloride 125-71-3, Dextromethorphan 128-62-1, Noscapine 129-06-6, Warfarin sodium 134-80-5, Diethylpropion hydrochloride 146-22-5, Nitrazepam 147-20-6, Diphenylpyraline 299-28-5, Calcium gluconate 299-42-3, Ephedrine 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9, Propranolol hydrochloride 364-62-5, Metoclopramide 389-08-2, Nalidixic acid 396-01-0, Triamterene 404-82-0, Fenfluramine hydrochloride 439-14-5, Diazepam 456-59-7, Cyclandelate 480-30-8, Dichloralphenazone 554-13-2, Lithium carbonate 555-30-6, Methyldopa 561-27-3, Heroin 577-11-7, Dioctylsodium sulfosuccinate 587-23-5, Methenamine mandelate 603-50-9, Bisacodyl 630-93-3, Phenytion sodium 638-23-3, Carbocysteine 643-22-1, Erythromycin stearate 645-43-2, Guanethidine monosulfate 846-50-4, Temazepam 915-30-0, Diphenoxylate 1069-66-5, Sodium valproate 1115-70-4, Metformin hydrochloride 1309-42-8, Magnesium hydroxide 1335-30-4, Aluminum silicate 1404-88-2, Tyrothricin 1420-53-7, Codeine sulfate 1617-90-9, Vincamine 1668-19-5, Doxepin 1847-24-1, Flucloxacillin sodium 2706-50-5, Amphetamine hydrochloride

3200-06-4, Naftidrofuryl oxalate 3572-80-3, Cyclazocine 3737-09-5, Disopyramide 5104-49-4, Flurbiprofen 5714-73-8, Methenamine hippurate 5874-97-5, Orciprenaline sulfate 5965-13-9 6452-73-9, Oxprenolol hydrochloride 6893-02-3, Triiodothyronine 7054-25-3, Quinidine gluconate 7683-59-2, Isoproterenol 7720-78-7, Ferrous sulfate 8067-24-1, Codergocrine mesylate 9004-10-8, Insulin, biological studies 10238-21-8, Glyburide 10347-81-6, Maprotiline hydrochloride 10377-48-7, Lithium sulfate 14663-23-1, Dantrolene sodium 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac **15686-71-2**, Cephalixin 15687-27-1, Ibuprofen 17617-23-1, Flurazepam 17693-51-5, Promethazine theoclate 18559-94-9, Salbutamol 20594-83-6, Nalbuphine 21645-51-2, Aluminum hydroxide, biological studies 21829-25-4, Nifedipine 22204-53-1, Naproxen 23031-32-5, Terbutaline sulfate 26652-09-5, Ritodrine 29094-61-9, Glipizide 39860-99-6, Pipothiazine 42399-41-7, Diltiazem 51481-61-9, Cimetidine 52485-79-7, Buprenorphine 54767-75-8, Suloctidil 55142-85-3, Ticlopidine 58786-99-5, Butorphanol tartrate 62571-86-2, Captopril 64024-15-3, Pentazocine hydrochloride 81103-11-9, Clarithromycin 83905-01-5, Azithromycin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (tablet compns. for poorly-compressible pharmaceuticals)

RE. CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Abdallah, O; S T P PHARMA 1988, V4(1), P15 HCAPLUS
- (2) Depomed Inc; WO 9855107 A 1998 HCAPLUS
- (3) Kumar, T; WO 0228181 A 2002 HCAPLUS
- (4) Kumar, V; US 6117451 A 2000 HCAPLUS
- (5) Squibb Bristol Myers Co; WO 9947128 A 1999 HCAPLUS

IT **9000-30-0, Guar gum 11138-66-2, Xanthan gum**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrophilic excipient; tablet compns. for poorly-compressible pharmaceuticals)

IT **9010-88-2, Eudragit NE 30D**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrophobic excipient; tablet compns. for poorly-compressible pharmaceuticals)

IT **15686-71-2, Cephalixin**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (tablet compns. for poorly-compressible pharmaceuticals)

L81 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:555334 HCAPLUS

DN 137:114525

ED Entered STN: 26 Jul 2002

TI Syntactic deformable pharmaceutical foam compositions

IN Odidi, Isa; Odidi, Amina

PA Can.

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-00

CC 63-6 (Pharmaceuticals)

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002056861	A2	20020725	WO 2002-CA54	20020117 <--
	WO 2002056861	A3	20021017		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 6800668	B1	20041005	US 2001-765783	20010119 <--
	CA 2435276	AA	20020725	CA 2002-2435276	20020117 <--

PRAI US 2001-765783 A 20010119 <—  
 WO 2002-CA54 W 20020117 <—

## CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002056861	ICM	A61K009-00
US 6800668	ECLA	A61K009/20K2B; A61K009/20P <—
AB		The invention relates to methods for preparing a syntactic foam composition suitable for use as a carrier for chems. or other compds., including pharmaceuticals. Carbopol 971P, hydroxyethyl cellulose, cellulose microspheres and silica, was mixed in a high-shear mixer. The resulting admixt. was treated with 2-propanol, while simultaneously subjecting the admixt. to high-shear forces in the high-shear mixer. This mixing created a uniform stable syntactic deformable and compressible dendritic solid foam which could be shaped before drying. Metoprolol succinate was added to the above admixt. and subjected to high-shear agitation for 2 min before treatment with 2-propanol. A stable syntactic deformable and compressible dendritic solid foam which could be shaped before drying was obtained. This was dried at 40°. The dried foam was the disentangled by size reduction to obtain discrete particles. The free flowing particles were reassembled and shaped by compression in a mold. The shaped units, when subjected to an aqueous medium, released metoprolol over a period of ≤3 h.
ST		syntactic deformable foam drug delivery; polymer syntactic deformable foam drug delivery
IT		Polyesters, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (caprolactone-based; syntactic deformable pharmaceutical foam compns.)
IT		Vinyl compounds, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (carboxy-containing, polymers; syntactic deformable pharmaceutical foam compns.)
IT		Drug delivery systems (controlled-release; syntactic deformable pharmaceutical foam compns.)
IT		Drug delivery systems (foams; syntactic deformable pharmaceutical foam compns.)
IT		Polyesters, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hydroxycarboxylic acid-based; syntactic deformable pharmaceutical foam compns.)
IT		Polyesters, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lactic acid-based; syntactic deformable pharmaceutical foam compns.)
IT		Drug delivery systems (microspheres; syntactic deformable pharmaceutical foam compns.)
IT		Coating materials Human Size reduction Stabilizing agents (syntactic deformable pharmaceutical foam compns.)
IT		Metals, biological studies Polyesters, biological studies Polyoxyalkylenes, biological studies Polysaccharides, biological studies RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (syntactic deformable pharmaceutical foam compns.)
IT		39391-18-9, Cyclooxygenase RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; syntactic deformable pharmaceutical foam compns.)
IT		124-38-9, Carbon dioxide, processes 7727-37-9, Nitrogen, processes RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process) (liquid; syntactic deformable pharmaceutical foam compns.)
IT		329900-75-6, Cyclooxygenase-2 RL: BSU (Biological study, unclassified); BIOL (Biological study) (syntactic deformable pharmaceutical foam compns.)
IT		67-63-0, 2-Propanol, uses RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses) (syntactic deformable pharmaceutical foam compns.)

IT 50-02-2, Dexamethasone 50-28-2, Estradiol, biological studies 50-48-6, Amitriptyline 50-70-4, Sorbitol, biological studies 50-78-2, Aspirin 50-99-7, Glucose, biological studies 51-48-9, Levothyroxine, biological studies 53-03-2, Prednisone 54-31-9, Furosemide 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-50-1, Sucrose, biological studies 57-63-6, EthinylEstradiol 58-93-5, Hydrochlorothiazide 59-92-7, Levodopa, biological studies 60-87-7, Promethazine 63-42-3, Lactose 67-20-9, Nitrofurantoin 68-22-4, Norethindrone 69-65-8, Mannitol 76-42-6, Oxycodone 76-57-3, Codeine 78-44-4, Carisoprodol 81-81-2, Warfarin 83-43-2, Methylprednisolone 87-99-0, Xylitol 89-57-6, Mesalamine 90-82-4, Pseudoephedrine 93-14-1, Guaifenesin 99-66-1, Pentanoic acid, 2-propyl 103-90-2, Acetaminophen 114-07-8, Erythromycin 125-29-1, Hydrocodone 127-07-1, Hydroxyurea 132-98-9, Penicillin VK 155-09-9, Tranlycypromine 300-62-9D, Amphetamine, salts 303-53-7, Cyclobenzaprine 315-30-0, Allopurinol 378-44-9, Betamethasone 396-01-0, Triamterene 439-14-5, Diazepam 469-62-5, Propoxyphene 525-66-6, Propranolol 673-06-3, D-Phenylalanine 797-63-7, Levonorgestrel 846-49-1, Lorazepam 846-50-4, Temazepam 1119-34-2, L-Arginine hydrochloride 1622-61-3, Clonazepam 3056-17-5, Stavudine 3930-20-9, Sotalol 4205-90-7, Clonidine 4419-39-0, Beclomethasone 7447-40-7, Potassium Chloride, biological studies 7460-12-0, Pseudoephedrine sulfate 7481-89-2, Zalcitabine 7631-86-9, Silica, biological studies 9002-89-5, Polyvinyl alcohol 9002-96-4,  $\alpha$ -Tocopherol polyethylene glycol succinate 9003-39-8, Povidone 9004-34-6, Cellulose, biological studies 9004-54-0, Dextran, biological studies 9004-62-0, Hydroxyethyl Cellulose 9004-65-3, Hydroxypropyl Methyl cellulose 9005-25-8, Starch, biological studies 9007-12-9, Calcitonin 10238-21-8, Glyburide 10540-29-1, Tamoxifen 11138-66-2, **Xanthan gum** 12650-69-0, Mupirocin **15686-71-2**, Cephalixin 15687-27-1, Ibuprofen 16051-77-7, Isosorbide Mononitrate 18559-94-9, Albuterol 18641-57-1, Glyceryl behenate 19794-93-5, Trazodone 20830-75-5, Digoxin 21256-18-8, Oxaprozin 22204-53-1, Naproxen 23593-75-1, Clotrimazole 24980-41-4, Poly( $\epsilon$ -caprolactone) 25086-15-1, **Eudragit L100** 25248-42-4, Poly[oxy(1-oxo-1,6-hexanediyl)] 25322-68-3, Polyethylene glycol 25812-30-0, Gemfibrozil 26009-03-0, Poly(glycolic acid) 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Poly(lactic acid) 26124-68-5, Poly(glycolic acid) 26787-78-0, Amoxicillin 28860-95-9, Carbidopa 28981-97-7, Alprazolam 29122-68-7, Atenolol 30516-87-1, Zidovudine 32986-56-4, Tobramycin 34346-01-5, Glycolic acid-lactic acid copolymer 51384-51-1, Metoprolol 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine **55268-75-2**, Cefuroxime 56180-94-0, Acarbose 58001-44-8 59122-46-2, Misoprostol 59729-33-8, Citalopram 59803-98-4, Brimonidine 60205-81-4, Ipratropium 61869-08-7, Paroxetine 63590-64-7, Terazosin 63675-72-9, Nisoldipine 66357-35-5, Ranitidine 66376-36-1, Alendronate 66722-44-9, Bisoprolol 69655-05-6, Didanosine 72432-03-2, Miglitol 72509-76-3, Felodipine 72956-09-3, Carvedilol 74191-85-8, Doxazosin 75330-75-5, Lovastatin 75847-73-3, Enalapril 76547-98-3, Lisinopril 76584-70-8, Divalproex sodium 76824-35-6, Famotidine 76963-41-2, Nizatidine 78644-42-5, Poly(malic acid) 78666-19-0, Poly(malic acid), SRU 79617-96-2, Sertraline 79794-75-5, Loratadine 79902-63-9, Simvastatin 80474-14-2, Fluticasone Propionate 81093-37-0, Pravastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin 82419-36-1, Ofloxacin 82626-48-0, Zolpidem 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 83905-01-5, Azithromycin 84449-90-1, Raloxifene 85441-61-8, Quinapril 85721-33-1, Ciprofloxacin 86541-75-5, Benazepril 87333-19-5, Ramipril 88150-42-9, Amlodipine 89365-50-4, Salmeterol 91161-71-6, Terbinafine **92665-29-7**, **Cefprozil** 93413-69-5, Venlafaxine 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 97322-87-7, Troglitazone 98048-97-6, Fosinopril 98418-47-4, Metoprolol succinate 99614-02-5, Ondansetron 100986-85-4, Levofloxacin 103577-45-3, Lansoprazole 103628-46-2, Sumatriptan 104632-26-0, Pramipexole 105102-22-5, Mometasone 106133-20-4, Tamsulosin 106266-06-2, Risperidone 107753-78-6, Zafirlukast 109889-09-0, Granisetron 111974-69-7, Quetiapine 113665-84-2, Clopidogrel 114798-26-4, Losartan 120014-06-4, Donepezil 124937-51-5, Tolterodine 127779-20-8, Saquinavir 129618-40-2, Nevirapine 130209-82-4, Latanoprost 132539-06-1, Olanzapine 134523-00-5, Atorvastatin 134678-17-4, Lamivudine 135062-02-1, Repaglinide 136470-78-5, Abacavir

136817-59-9, Delavirdine 137862-53-4, Valsartan 138402-11-6,  
 Irbesartan 139755-83-2, Sildenafil 150378-17-9, Indinavir  
 151687-96-6, Carbopol 974P 154598-52-4, Efavirenz 155213-67-5,  
 Ritonavir 158966-92-8, Montelukast 159989-64-7, Nelfinavir  
 161279-68-1, Carbopol 971P 161814-49-9, Amprenavir 162011-90-7,  
 Rofecoxib 169590-42-5, Celecoxib 192725-17-0, Lopinavir  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (syntactic deformable pharmaceutical foam compns.)

IT 11138-66-2, Xanthan gum 15686-71-2,  
 Cephalixin 55268-75-2, Cefuroxime 92665-29-7,  
**Cefprozil**  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (syntactic deformable pharmaceutical foam compns.)

L81 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:581682 HCAPLUS

DN 135:142272

ED Entered STN: 10 Aug 2001

TI Shell-and-core dosage form approaching zero-order drug release

IN Berner, Bret; Louie-Helm, Jenny; Gusler, Gloria; Shell, John N.

PA Depomed, Inc., USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-00

CC 63-6 (Pharmaceuticals)

FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001056544	A2	20010809	WO 2001-US3027	20010130 <--
	WO 2001056544	A3	20020502		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2396782	AA	20010809	CA 2001-2396782	20010130 <--
	EP 1251832	A2	20021030	EP 2001-906794	20010130 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003521507	T2	20030715	JP 2001-556236	20010130 <--
	AU 767812	B2	20031127	AU 2001-34661	20010130 <--
	US 2003104062	A1	20030605	US 2002-213823	20020807 <--
PRAI	US 2000-498945	A	20000204	<--	
	WO 2001-US3027	W	20010130	<--	

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

WO 2001056544 ICM A61K009-00 <--  
 US 2003104062 ECLA A61K009/20H6B; A61K009/28H6B

AB Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also promotes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to a size that is retained in the stomach during the postprandial or fed mode. Thus, core containing Polyox-303 700 and the shell 200 mg was prepared with the drug loading in the core being 71.4% by weight (with no drug contained in the shell). The release rate approached zero order.

ST zero order controlled drug release; polymer core controlled drug release

IT Drug delivery systems

(capsules, controlled-release; shell-and-core dosage form approaching zero-order drug release)

IT Drug delivery systems

(controlled-release; shell-and-core dosage form approaching zero-order



- drug release)
- IT Diffusion  
Dissolution rate  
Molecular weight distribution  
(shell-and-core dosage form approaching zero-order drug release)
- IT Polymers, biological studies  
Polyoxyalkylenes, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(shell-and-core dosage form approaching zero-order drug release)
- IT Drug delivery systems  
(tablets, controlled-release; shell-and-core dosage form approaching zero-order drug release)
- IT 9003-01-4, Polyacrylic acid  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(crosslinked; shell-and-core dosage form approaching zero-order drug release)
- IT 1115-70-4, Metformin hydrochloride  
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
(shell-and-core dosage form approaching zero-order drug release)
- IT 50-78-2, Aspirin 59-92-7, Levodopa, biological studies 69-53-4D, Ampicillin, esters 146-17-8, Riboflavin 5'-phosphate 1134-47-0, Baclofen 1404-93-9, Vancomycin hydrochloride 3094-09-5, Doxifluridine 3847-29-8, Erythromycin lactobionate 7439-89-6D, Iron, salts, biological studies 9002-89-5, Poly(vinyl alcohol) 9003-39-8, Kollidon 90F 9004-32-4, Carboxymethyl cellulose sodium salt 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, ethers, biological studies 9004-62-0, Hydroxyethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, HPMC 11138-66-2, **Xanthan gum** 18323-44-9, Clindamycin 20830-75-5, Digoxin 25212-88-8, **Eudragit L** 100-55 25322-68-3, Polyethylene glycol 26787-78-0, Amoxicillin 27203-92-5, Tramadol 33069-62-4, Paclitaxel 37353-59-6, Hydroxymethyl cellulose 53885-35-1, Ticlopidine hydrochloride 59277-89-3, Acyclovir 62571-86-2, Captopril **64544-07-6**, Cefuroxime axetil 65277-42-1, Ketoconazole 66357-59-3, Ranitidine hydrochloride 72558-82-8, Ceftazidime 76547-98-3, Lisinopril 79217-60-0, Cyclosporin 79559-97-0, Sertraline hydrochloride 81103-11-9, Clarithromycin 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin 159989-65-8, Nelfinavir mesylate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(shell-and-core dosage form approaching zero-order drug release)
- IT **11138-66-2, Xanthan gum 64544-07-6**, Cefuroxime axetil  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(shell-and-core dosage form approaching zero-order drug release)

L81 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:900423 HCAPLUS

DN 134:61525

ED Entered STN: 22 Dec 2000

TI Taste masked compositions comprising methacrylic acid copolymer and phthalate polymer

IN Mukherji, Gour; Goel, Sandhya; Arora, Vinod Kumar

PA Ranbaxy Laboratories Limited, India

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

IC A61K009-16; A61K009-22; A61K047-30

CC 63-6 (Pharmaceuticals)

FAN. CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000076479	A1	20001221	WO 2000-IB765	20000607 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6565877	B1	20030520	US 2000-587535	20000605 <--
AU 2000049430	A5	20010102	AU 2000-49430	20000607 <--
EP 1194124	A1	20020410	EP 2000-931481	20000607 <--
EP 1194124	B1	20030903		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

BR 2000011345	A	20020423	BR 2000-11345	20000607 <--
AT 248588	E	20030915	AT 2000-931481	20000607 <--
PT 1194124	T	20040227	PT 2000-931481	20000607 <--
ES 2204605	T3	20040501	ES 2000-931481	20000607 <--
ZA 2001009547	A	20020619	ZA 2001-9547	20011120 <--

PRAI IN 1999-DE867 A 19990611 <--  
US 2000-587535 A 20000605 <--  
WO 2000-1B765 W 20000607 <--

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2000076479	IC	A61K009-16IC A61K009-22IC A61K047-30
US 6565877	ECLA	A61K009/16H6F; A61K009/16H6B <--

AB A taste masked composition which comprises a bitter tasting drug, a combination of two enteric polymers comprising, a methacrylic acid copolymer and a phthalate polymer is described. The composition of the present invention is prepared by dissolving the active ingredient, the methacrylic acid copolymer and the phthalate polymer in a solvent and recovering the composition from the solution thereof. Cefuroxime axetil 2 g were blended with 2 g **Eudragit** L100-55/hydroxypropyl Me cellulose phthalate (7:3) and dissolved in 20 mL acetone containing 5 % water. The resulting mixture was dried and sized to obtain taste-masked granules.

ST taste masked oral polymethacrylate cellulose phthalate; oral granule cefuroxime **Eudragit** cellulose phthalate

IT Drug delivery systems  
(granules, oral; taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

IT Antibiotics  
(macrolide; taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

IT Antibiotics  
(quinolone; taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

IT Drug delivery systems  
(suspensions; taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

IT Drug delivery systems  
(syrups; taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

IT Drug delivery systems  
(tablets; taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

IT 50-53-3, Chlorpromazine, biological studies 56-75-7, Chloramphenicol 63-42-3, Lactose 69-65-8, D-Mannitol 80-62-6D, Methyl methacrylate, copolymers 114-07-8, Erythromycin 7647-14-5, Sodium chloride, biological studies 9003-39-8, Crospovidone 9004-38-0, Cellulose acetate phthalate 9050-31-1, Hydroxypropyl methylcellulose phthalate 9063-38-1, Sodium starch glycolate 11111-12-9, Cephalosporin **11138-66-2, Xanthan gum** 14807-96-6, Talc, biological studies 25087-26-7, Methacrylic acid, polymer 25212-88-8, Ethyl acrylate-methacrylic acid copolymer 53237-50-6 **55268-75-2**, Cefuroxime **64544-07-6**, Cefuroxime axetil 70458-96-7, Norfloxacin 73384-59-5, Ceftriaxone 74811-65-7, Croscarmellose sodium 81103-11-9, Clarithromycin 85721-33-1, Ciprofloxacin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

RE. CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Abbott Laboratories; WO 9716174 A1 1997 HCAPLUS
- (2) Depomed Inc; WO 9811879 A1 1998 HCAPLUS
- (3) Deutsch; US 4897270 A 1990 HCAPLUS

- (4) Eastman Chemical Company; WO 9818454 A1 1998 HCAPLUS  
 (5) Goldman; US 5175003 A 1992 HCAPLUS  
 (6) Meiji Seika Kaisha Ltd; DE 2218147 A 1972 HCAPLUS  
 (7) Voigt, R; Pharmazeutische Technologie fur Studium und Beruf', chapter 10.6.2.2 -10.6.2.4, 7th edition, chapter 10.5.1 1993  
 IT 11138-66-2, Xanthan gum 55268-75-2,  
 Cefuroxime 64544-07-6, Cefuroxime axetil  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (taste masked compns. comprising methacrylic acid copolymer and phthalate polymer)

L81 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1998:268331 HCAPLUS  
 DN 128:326507  
 ED Entered STN: 11 May 1998  
 TI Pharmaceutical composition for rapid suspension in aqueous media  
 IN Calanchi, Massimo Maria; Marconi, Marco Giuseppe Raffaele; Mapelli, Luigi Giovanni  
 PA Eurand International S.P.A., Italy  
 SO PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM A61K009-00  
 ICS A61K009-20; A61K009-16  
 CC 63-6 (Pharmaceuticals)  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9817250	A1	19980430	WO 1997-EP5863	19971023 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
GB 2318511	A1	19980429	GB 1996-22090	19961023 <--
ZA 9709425	A	19990421	ZA 1997-9425	19971021 <--
CA 2268626	AA	19980430	CA 1997-2268626	19971023 <--
AU 9851887	A1	19980515	AU 1998-51887	19971023 <--
AU 725958	B2	20001026		
EP 936901	A1	19990825	EP 1997-946759	19971023 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
JP 2000508342	T2	20000704	JP 1998-518977	19971023 <--
US 6261602	B1	20010717	US 1999-297213	19990921 <--
PRAI GB 1996-22090	A	19961023	<--	
WO 1997-EP5863	W	19971023	<--	

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 9817250	ICM	A61K009-00	
	ICS	A61K009-20; A61K009-16	
WO 9817250	ECLA	A61K009/00N2	<--
GB 2318511	ECLA	A61K009/00N2	<--
US 6261602	ECLA	A61K009/00N2	<--

AB The invention provides a granular composition useful as a pharmaceutical carrier which can be used for the preparation of pharmaceutical compns. that are capable of rapid suspension in water or aqueous media including saliva. The compns. may be used by addition to a glass of water with stirring or taken directly in the mouth. The granular composition may be prepared by a process which comprises subjecting a mixture of a thickening agent and a disintegrating agent to wet granulation with an aqueous medium as wetting agent or dry granulation to make a novel granular product and preparing the pharmaceutical composition from the granular product and the drug. A water-soluble inert excipient, which may be a sugar, may be mixed with the granular product prior to mixing with the drug. Base granules were prepared containing Keltrol F, Ac-di-Sol, Avicel PH 200 and Explotab. These granules were mixed with Karion, aspartame and orange flavor and monodose

sachets were prepared from this mixture and 5-aminosalicylic acid coated with **Eudragit S**.

ST pharmaceutical granule suspension

IT Drug delivery systems  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (granules; pharmaceutical composition for rapid suspension in aqueous media)

IT Buffers  
 Lubricants  
 Sweetening agents  
 Thickening agents  
 Vitamins  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical composition for rapid suspension in aqueous media)

IT Drug delivery systems  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (suspensions; pharmaceutical composition for rapid suspension in aqueous media)

IT 9003-39-8, Pvp 9004-32-4, Sodium CM-Cellulose  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (crosslinked; pharmaceutical composition for rapid suspension in aqueous media)

IT 50-70-4, Sorbitol, biological studies 56-41-7, Alanine, biological studies 57-48-7, Fructose, biological studies 57-50-1, biological studies 63-42-3, Lactose 69-65-8, D-Mannitol 115-77-5, biological studies 1327-43-1, Magnesium aluminum silicate 7631-86-9, Silica, biological studies 9000-07-1, Carrageenan **9000-30-0**, **Guar gum** 9000-36-6, Karaya gum 9000-40-2, Carob gum 9000-65-1, Gum tragacanth 9002-18-0, Agar 9005-25-8, Starch, biological studies 9005-32-7, Alginic acid 9005-38-3, Sodium alginate 9050-04-8, Calcium carboxymethyl cellulose 9050-36-6, Maltodextrin 9063-38-1, Sodium starch glycolate **11138-66-2**, **Xanthan gum**  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (pharmaceutical composition for rapid suspension in aqueous media)

IT 50-48-6, Amitriptyline 50-78-2, Acetylsalicylic acid 51-06-9, Procainamide 52-28-8, Codeine phosphate 52-53-9, Verapamil 54-31-9, 57-27-2, Morphine, biological studies 58-08-2, Caffeine, biological studies 58-32-2, Dipyrindamole 58-55-9, Theophylline, biological studies 87-33-2, Isosorbide dinitrate 89-57-6, 5-Aminosalicylic acid 90-82-4, Pseudoephedrine 93-14-1, Guaifenesin 103-90-2, Paracetamol 114-07-8, Erythromycin 125-71-3, Dextromethorphan 364-62-5, Metoclopramide 439-14-5, Diazepam 554-13-2, Lithium carbonate 616-91-1, Acetylcysteine 638-23-3 1406-05-9, Penicillin 1812-30-2, Bromazepam 3820-67-5, Glafenine 5250-39-5, Flucloxacillin 8049-47-6, Pancreatin 11111-12-9, Cephalosporin 14838-15-4, Phenylpropanolamine 15307-86-5, Diclofenac **15686-71-2**, Cefalexin 15687-27-1, Ibuprofen 16051-77-7, Isosorbide mononitrate 18683-91-5, Ambroxol 19216-56-9, Prazosin 22071-15-4, Ketoprofen 25812-30-0, Gemfibrozil 26787-78-0, Amoxicillin 31637-97-5, Etofibrate 41340-25-4, Etodolac 42399-41-7, Diltiazem 51481-61-9, Cimetidine 54910-89-3, Fluoxetine 55985-32-5, Nicardipine 62571-86-2, Captopril 66357-35-5, Ranitidine  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical composition for rapid suspension in aqueous media)

RE. CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Kimon Ventouras; US 4886669 A 1989 HCAPLUS

IT **9000-30-0**, **Guar gum** **11138-66-2**, **Xanthan gum**  
 RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (pharmaceutical composition for rapid suspension in aqueous media)

IT **15686-71-2**, Cefalexin  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pharmaceutical composition for rapid suspension in aqueous media)

=> b home  
 FILE 'HOME' ENTERED AT 09:48:28 ON 19 APR 2005

=>